<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001829.pub4" GROUP_ID="ORAL" ID="363099072115110981" MERGED_FROM="" MODIFIED="2016-07-29 12:52:57 +0100" MODIFIED_BY="Anne-Marie Glenny" REVIEW_NO="0024" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2016-07-29 12:52:34 +0100" MODIFIED_BY="Anne-Marie Glenny">
<TITLE MODIFIED="2016-07-05 13:10:09 +0200" MODIFIED_BY="[Empty name]">Interventions for treating oral leukoplakia to prevent oral cancer</TITLE>
<CONTACT MODIFIED="2016-07-29 12:52:34 +0100" MODIFIED_BY="Anne-Marie Glenny"><PERSON ID="18367" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><LAST_NAME>Lodi</LAST_NAME><POSITION>Associated Professor</POSITION><EMAIL_1>giovanni.lodi@unimi.it</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche</DEPARTMENT><ORGANISATION>Università degli Studi di Milano</ORGANISATION><ADDRESS_1>Via Beldiletto 1/3</ADDRESS_1><CITY>Milan</CITY><ZIP>20142</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02 50319021</PHONE_1><FAX_1>+39 02 50319041</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-07-29 12:52:34 +0100" MODIFIED_BY="Anne-Marie Glenny"><PERSON ID="18367" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><LAST_NAME>Lodi</LAST_NAME><POSITION>Associated Professor</POSITION><EMAIL_1>giovanni.lodi@unimi.it</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche</DEPARTMENT><ORGANISATION>Università degli Studi di Milano</ORGANISATION><ADDRESS_1>Via Beldiletto 1/3</ADDRESS_1><CITY>Milan</CITY><ZIP>20142</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02 50319021</PHONE_1><FAX_1>+39 02 50319041</FAX_1></ADDRESS></PERSON><PERSON ID="80092310399925366469120621120517" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roberto</FIRST_NAME><LAST_NAME>Franchini</LAST_NAME><EMAIL_1>ROH2001@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche</DEPARTMENT><ORGANISATION>Università degli Studi di Milano</ORGANISATION><ADDRESS_1>Via Beldiletto 1/3</ADDRESS_1><CITY>Milan</CITY><ZIP>20142</ZIP><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="8E2408B482E26AA20024C3AAAF1AEB18" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Saman</FIRST_NAME><LAST_NAME>Warnakulasuriya</LAST_NAME><POSITION>Professor, Head of Oral Medicine</POSITION><EMAIL_1>s.warne@kcl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Clinical and Diagnostic Sciences</DEPARTMENT><ORGANISATION>King's College London</ORGANISATION><ADDRESS_1>Bessemer Road</ADDRESS_1><ADDRESS_2>Denmark Hill Campus</ADDRESS_2><CITY>London</CITY><ZIP>SE5 9RW</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7 346 3608</PHONE_1></ADDRESS></PERSON><PERSON ID="z1408111433035713467792678164726" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elena Maria</FIRST_NAME><LAST_NAME>Varoni</LAST_NAME><EMAIL_1>elena.varoni@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche</DEPARTMENT><ORGANISATION>Università degli Studi di Milano</ORGANISATION><ADDRESS_1>Via Beldiletto 1</ADDRESS_1><CITY>Milan</CITY><ZIP>20142</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02503 19017</PHONE_1><FAX_1>+39 02503 19041</FAX_1></ADDRESS></PERSON><PERSON ID="11539" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrea</FIRST_NAME><LAST_NAME>Sardella</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>andrea.sardella@unimi.it</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche</DEPARTMENT><ORGANISATION>Università degli Studi di Milano</ORGANISATION><ADDRESS_1>Via Beldiletto 1/3</ADDRESS_1><CITY>Milan</CITY><ZIP>20142</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>0039 02 50319022</PHONE_1><PHONE_2>0039 02 50319019</PHONE_2><FAX_1>0039 02 50319041</FAX_1></ADDRESS></PERSON><PERSON ID="94342899289817375097110406131745" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alexander</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Kerr</LAST_NAME><POSITION>Clinical Associate Professor</POSITION><EMAIL_1>ark3@nyu.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Oral and Maxillofacial Pathology, Radiology and Medicine</DEPARTMENT><ORGANISATION>New York University College of Dentistry</ORGANISATION><ADDRESS_1>345 East 24th Street</ADDRESS_1><ADDRESS_2>Schwartz Building</ADDRESS_2><CITY>New York</CITY><ZIP>10010</ZIP><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="6188" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Antonio</FIRST_NAME><LAST_NAME>Carrassi</LAST_NAME><EMAIL_1>antonio.carrassi@unimi.it</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche</DEPARTMENT><ORGANISATION>Università degli Studi di Milano</ORGANISATION><ADDRESS_1>Via Beldiletto 1/3</ADDRESS_1><CITY>Milan</CITY><ZIP>20142</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+ 39 02 503 19020</PHONE_1><PHONE_2>+ 39 02 503 19019</PHONE_2><FAX_1>+ 39 02 503 19041</FAX_1></ADDRESS></PERSON><PERSON ID="42211238401805437056100319112613" ROLE="AUTHOR"><FIRST_NAME>L</FIRST_NAME><MIDDLE_INITIALS>CI</MIDDLE_INITIALS><LAST_NAME>MacDonald</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>cohg@manchester.ac.uk</EMAIL_1><EMAIL_2>laura.macdonald@manchester.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Oral Health</DEPARTMENT><ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION><ADDRESS_1>J R Moore Building, Oxford Road</ADDRESS_1><CITY>Manchester</CITY><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)161 275 8601</PHONE_1></ADDRESS></PERSON><PERSON ID="8328" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Helen</FIRST_NAME><MIDDLE_INITIALS>V</MIDDLE_INITIALS><LAST_NAME>Worthington</LAST_NAME><POSITION>Professor of Evidence Based Care</POSITION><EMAIL_1>helen.worthington@manchester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Oral Health</DEPARTMENT><ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION><ADDRESS_1>JR Moore Building</ADDRESS_1><ADDRESS_2>Oxford Road</ADDRESS_2><CITY>Manchester</CITY><ZIP>M13 9PL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 306 0237</PHONE_1><PHONE_2>+44 161 275 7819</PHONE_2><FAX_1>+44 161 275 7815</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-07-29 11:43:53 +0200" MODIFIED_BY="Giovanni Lodi">
<UP_TO_DATE>
<DATE DAY="16" MONTH="5" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="5" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="1" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-07-28 10:01:36 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-07-28 10:01:36 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="6" YEAR="2016"/>
<DESCRIPTION>
<P>6 new studies included. 1 previously included study has been excluded, as it was quasi-randomised (Gaeta 2000)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-05-19 14:30:24 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>Search updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-07-14 10:24:23 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-07-13 00:59:08 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-07-14 10:24:10 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="7" YEAR="2006"/>
<DESCRIPTION>
<P>Review updated. 2 new included studies (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>), 3 new ongoing studies, 3 newly excluded studies. Conclusions remained essentially the same</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-07-14 10:24:23 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>Review updated. 1 new study (<LINK REF="STD-Gaeta-2000" TYPE="STUDY">Gaeta 2000</LINK>) has been included, but summary estimates did not change significantly, and conclusions remained essentially the same</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-07-15 11:51:08 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2016-01-28 19:37:04 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-01-28 19:37:04 +0100" MODIFIED_BY="[Empty name]">
<NAME>Università degli Studi di Milano</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-07-15 11:51:08 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-07-08 12:48:33 +0200" MODIFIED_BY="[Empty name]">
<NAME>School of Dentistry, The University of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2016-07-15 11:51:08 +0200" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Oral Health Group Global Alliance</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION>
<P>Through our Global Alliance (<A HREF="http://ohg.cochrane.org/partnerships-alliances">http://ohg.cochrane.org/partnerships-alliances</A>), the Cochrane Oral Health Group has received support from British Association for the Study of Community Dentistry, UK; British Association of Oral Surgeons, UK; British Orthodontic Society, UK; British Society of Paediatric Dentistry, UK; British Society of Periodontology, UK; Canadian Dental Hygienists Association, Canada; Mayo Clinic, USA; National Center for Dental Hygiene Research &amp; Practice, USA; New York University College of Dentistry, USA; NHS Education for Scotland (NES); and Royal College of Surgeons of Edinburgh, UK</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-07-15 11:51:01 +0200" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This project was supported by the NIHR, via Cochrane Infrastructure funding to the Cochrane Oral Health Group. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS) or the Department of Health</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-07-29 11:46:42 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-07-14 18:59:22 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-07-04 14:47:07 +0200" MODIFIED_BY="[Empty name]">Interventions for treating oral leukoplakia to prevent oral cancer</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-14 18:59:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>People with oral leukoplakia are at higher risk of developing oral cancer than those with normal oral mucosa. This review, produced through <A HREF="http://oralhealth.cochrane.org/">Cochrane Oral Health</A>, seeks to evaluate whether people affected by leukoplakia can benefit from surgical, medical or complementary treatments, either local or systemic. In particular, we conducted this review to find out which, if any, treatment is able to prevent people with leukoplakia of the mouth from getting oral cancer. This review updates our previous review published in 2006.</P>
<P>
<B>Background</B>
</P>
<P>Oral leukoplakia is a white patch formed in the mouth lining that cannot be rubbed off. It often does not hurt and may go unnoticed for years. People with leukoplakia develop oral cancer more often than people without it. Preventing this is critical because rates of oral cancer survival longer than five years after diagnosis are low. Drugs, surgery and other therapies have been tried for treatment of oral leukoplakia.</P>
<P>
<B>Objectives</B>
</P>
<P>This review aimed to evaluate whether treatments for oral leukoplakia are effective in preventing oral cancer, and safe and acceptable to patients.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The evidence on which this review is based is up-to-date as of May 2016. We found 14 randomised controlled trials (RCTs) of medical and complementary treatments, which involved 909 participants in total. Treatments included herbal extracts, anti-inflammatory drugs, vitamin A, beta carotene supplements and others. Surgical treatment has not been compared with placebo or no treatment in an RCT.</P>
<P>
<B>Key results</B>
</P>
<P>Cancer development was measured in studies of three treatments: systemic vitamin A, systemic beta carotene and topical bleomycin. None of these treatments showed effectiveness in preventing cancer development, as measured up to two years for vitamin A and beta carotene, and seven years for bleomycin.</P>
<P>Some individual studies of vitamin A and beta carotene suggested that these treatments may be effective for improving or healing oral lesions. However, some studies observed a high rate of relapse in participants whose lesions were initially resolved by treatment.</P>
<P>Most treatments caused side effects of differing severity in a high proportion of participants.</P>
<P>It seems likely that interventions were well accepted by participants because drop-out rates were similar between treatment and control groups.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The available evidence is very limited. Most interventions were assessed by only one small study. Most studies had problems in the way they were conducted, making their results unreliable. We judged the quality of evidence for the outcome of cancer development to be very low.</P>
<P>
<B>Author conclusions</B>
</P>
<P>Larger, better studies of longer duration are required. As well as further studies of drug treatment and alternative treatments like vitamins, studies are needed to evaluate the effectiveness and safety of surgery, and of stopping risk factor habits such as smoking.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-07-24 22:18:16 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-07-14 11:33:12 +0200" MODIFIED_BY="[Empty name]">
<P>Oral leukoplakia is a relatively common oral lesion that, in a small proportion of people, precedes the development of oral cancer. Most leukoplakias are asymptomatic; therefore, the primary objective of treatment should be to prevent onset of cancer. This review updates our previous review, published in 2006.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-07-14 14:52:57 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness, safety and acceptability of treatments for leukoplakia in preventing oral cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-07-18 11:03:29 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases: Cochrane Oral Health's Trials Register (to 16 May 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>the Cochrane Library</I>, 2016, Issue 4), MEDLINE Ovid (1946 to 16 May 2016), Embase Ovid (1980 to 16 May 2016) and CancerLit via PubMed (1950 to 16 May 2016). We searched the metaRegister of Controlled Trials (to 10 February 2015), ClinicalTrials.gov (to 16 May 2016) and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials (to 16 May 2016). We placed no restrictions on the language or date of publication when searching electronic databases.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-07-14 11:35:03 +0200" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) that enrolled people with a diagnosis of oral leukoplakia and compared any treatment versus placebo or no treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-07-24 22:18:16 +0200" MODIFIED_BY="[Empty name]">
<P>We collected data using a data extraction form. Oral cancer development, demonstrated by histopathological examination, was our primary outcome. Secondary outcomes were clinical resolution of the lesion, improvement of histological features and adverse events. We contacted trial authors for further details when information was unclear. When valid and relevant data were available, we conducted a meta-analysis of the data using a fixed-effect model when we identified fewer than four studies with no heterogeneity. For dichotomous outcomes, we calculated risk ratios (RRs) and 95% confidence intervals (CIs). We assessed risk of bias in studies by using the Cochrane tool. We assessed the overall quality of the evidence by using standardised criteria (Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE)).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-07-24 22:17:17 +0200" MODIFIED_BY="[Empty name]">
<P>We included 14 studies (909 participants) in this review. Surgical interventions, including laser therapy and cryotherapy, have never been studied by means of an RCT that included a no treatment or placebo arm. The included trials tested a range of medical and complementary treatments, in particular, vitamin A and retinoids (four studies); beta carotene or carotenoids (three studies); non-steroidal anti-inflammatory drugs (NSAIDs), specifically ketorolac and celecoxib (two studies); herbal extracts (four studies), including tea components, a Chinese herbal mixture and freeze-dried black raspberry gel; bleomycin (one study); and Bowman-Birk inhibitor (one study).</P>
<P>We judged one study to be at low risk of bias, seven at unclear risk and six at high risk. In general, we judged the overall quality of the evidence to be low or very low, so findings are uncertain and further research is needed.</P>
<P>Five studies recorded cancer incidence, only three of which provided useable data. None of the studies provided evidence that active treatment reduced the risk of oral cancer more than placebo: systemic vitamin A (RR 0.11, 95% CI 0.01 to 2.05; 85 participants, one study); systemic beta carotene (RR 0.71, 95% CI 0.24 to 2.09; 132 participants, two studies); and topical bleomycin (RR 3.00, 95% CI 0.32 to 27.83; 20 participants, one study). Follow-up ranged between two and seven years.</P>
<P>Some individual studies suggested effectiveness of some proposed treatments, namely, systemic vitamin A, beta carotene and lycopene, for achieving clinical resolution of lesions more often than placebo. Similarly, single studies found that systemic retinoic acid and lycopene may provide some benefit in terms of improvement in histological features. Some studies also reported a high rate of relapse.</P>
<P>Side effects of varying severity were often described; however, it seems likely that interventions were well accepted by participants because drop-out rates were similar between treatment and control groups.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-07-14 18:58:28 +0200" MODIFIED_BY="[Empty name]">
<P>Surgical treatment for oral leukoplakia has not been assessed in an RCT that included a no treatment or placebo comparison. Nor has cessation of risk factors such as smoking been assessed. The available evidence on medical and complementary interventions for treating people with leukoplakia is very limited. We do not currently have evidence of a treatment that is effective for preventing the development of oral cancer. Treatments such as vitamin A and beta carotene may be effective in healing oral lesions, but relapses and adverse effects are common. Larger trials of longer duration are required to properly evaluate the effects of leukoplakia treatments on the risk of developing oral cancer. High-quality research is particularly needed to assess surgical treatment and to assess the effects of risk factor cessation in people with leukoplakia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-28 10:13:16 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-07-15 11:53:28 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-07-15 11:53:28 +0200" MODIFIED_BY="[Empty name]">
<P>"The term leukoplakia should be used to recognize white plaques of questionable risk having excluded (other) known diseases or disorders that carry no increased risk for cancer" (<LINK REF="REF-Warnakulasuriya-2007" TYPE="REFERENCE">Warnakulasuriya 2007</LINK>). Such a definition is the result of the efforts of an international working group comprising specialists in the &#64257;elds of epidemiology, oral medicine, pathology and molecular biology with a special interest in cancer and precancer, who met in London in 2005. This meeting was co-ordinated by the World Health Organization (WHO) Collaborating Centre for Oral Cancer and Precancer in the UK, to review definitions, classifications, natural history and management of potentially malignant disorders on the basis of previously published work (<LINK REF="REF-Axell-1984" TYPE="REFERENCE">Axell 1984</LINK>; <LINK REF="REF-Axell-1996" TYPE="REFERENCE">Axell 1996</LINK>; <LINK REF="REF-Kramer-1978" TYPE="REFERENCE">Kramer 1978</LINK>) and new scientific acquisitions. Thus, 'leukoplakia' is a clinical term that is used when the clinician has excluded any other condition of the oral mucosa that can present as a white lesion (e.g. frictional keratosis, lichen planus, white sponge nevus, hairy leukoplakia). Such lesions warrant biopsy and histopathological examination to assess the possible presence of epithelial dysplasia or carcinoma. Leukoplakia is often associated with tobacco smoking or chewing, although idiopathic forms are not rare (<LINK REF="REF-Axell-1987" TYPE="REFERENCE">Axell 1987</LINK>). The role of alcohol, viruses and systemic conditions needs further investigation (<LINK REF="REF-Dietrich-2004" TYPE="REFERENCE">Dietrich 2004</LINK>; <LINK REF="REF-Syrj_x00e4_nen-2011" TYPE="REFERENCE">Syrjänen 2011</LINK>).</P>
<P>Clinical variants of leukoplakia are often classified into two groups: (1) homogeneous leukoplakia, a lesion of uniform flat appearance that may exhibit superficial irregularities, but with consistent texture throughout; and (2) non-homogeneous leukoplakia, a predominantly white or white and red lesion (erythroleukoplakia) with an irregular texture that may include ulceration and may be characterised by a speckled, nodular or verrucous topography. Histological features of both forms of leukoplakia are variable and may include ortho-keratosis or para-keratosis of various degrees, acanthosis or atrophy of the squamous epithelium, mild inflammation in the corium, dysplastic changes of various grades (i.e. mild, moderate or severe), carcinoma in situ or carcinoma. Some cases of predominantly white lesions that are difficult to diagnose, in spite of the availability of a biopsy.</P>
<P>Leukoplakia is not uncommon, and although it is highly variable among geographical areas and demographic groups, the prevalence of leukoplakia in the general population varies from less than 1% to more than 5% (<LINK REF="REF-Axell-1984" TYPE="REFERENCE">Axell 1984</LINK>; <LINK REF="REF-Axell-1987" TYPE="REFERENCE">Axell 1987</LINK>; <LINK REF="REF-Bouquot-1986" TYPE="REFERENCE">Bouquot 1986</LINK>; <LINK REF="REF-Ikeda-1991" TYPE="REFERENCE">Ikeda 1991</LINK>; <LINK REF="REF-Reichart-2000" TYPE="REFERENCE">Reichart 2000</LINK>). In a systematic review that included studies with more than 1000 individuals, the pooled prevalence was estimated to be between 1.49% and 4.27% (<LINK REF="REF-Petti-2003" TYPE="REFERENCE">Petti 2003</LINK>). Incidence data are very scarce. A study from Japan reported an age-adjusted incidence rate per 100,000 person-years of 409.2 among males and 70 among females (<LINK REF="REF-Nagao-2005" TYPE="REFERENCE">Nagao 2005</LINK>), and an Indian study, conducted in a population with distinctive risk factors for oral cancer, reported lower figures: 240 among males and 3 among females (<LINK REF="REF-Gupta-1980" TYPE="REFERENCE">Gupta 1980</LINK>).</P>
<P>Leukoplakia is one of a group of conditions defined as potentially malignant disorders (i.e. "morphological alterations amongst which some may have an increased potential for malignant transformation, [they] are also indicators of risk of likely future malignancies elsewhere in (clinically normal appearing) oral mucosa and not only site specific predictors") (<LINK REF="REF-Warnakulasuriya-2007" TYPE="REFERENCE">Warnakulasuriya 2007</LINK>). The rate of malignant transformation into squamous cell carcinoma varies from almost 0% to 36.4% (<LINK REF="REF-Arduino-2013" TYPE="REFERENCE">Arduino 2013</LINK>), and a study investigating the natural limit of malignant transformation on the basis of European epidemiological data concluded that the upper limit of the annual transformation rate of oral leukoplakia is unlikely to exceed 1% (<LINK REF="REF-Scheifele-2003" TYPE="REFERENCE">Scheifele 2003</LINK>).</P>
<P>Non-homogeneous leukoplakias carry a higher degree of risk of transformation when compared with homogeneous variants. Among patients with a histopathological diagnosis of dysplasia, about 1/10 of the total may be at higher risk. Other reported risk factors of statistical significance for cancer development in people with leukoplakia include female gender, long duration of leukoplakia, non-smoking status, location on the lateral tongue and/or floor of the mouth, size &gt; 200 mm<SUP>2</SUP> (<LINK REF="REF-Holmstrup-2006" TYPE="REFERENCE">Holmstrup 2006</LINK>) and the presence of <I>Candida albicans</I> (<LINK REF="REF-Van-der-Waal-2009" TYPE="REFERENCE">Van der Waal 2009</LINK>). Studies investigating biomarkers and histological features have suggested methods that can be used to identify which patients with leukoplakia will develop oral cancer, and which will not (<LINK REF="REF-Pitiyage-2009" TYPE="REFERENCE">Pitiyage 2009</LINK>; <LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>); however, a definitive, evidence-based and clinically useful predictor of malignant transformation for dysplastic and non-dysplastic leukoplakias is not available at the moment. Aneuploid lesions (i.e. with abnormal DNA content) are more likely to transform to cancer compared with diploid lesions (i.e. with normal DNA content) (<LINK REF="REF-Sperandio-2013" TYPE="REFERENCE">Sperandio 2013</LINK>; <LINK REF="REF-Torres_x002d_Rendon-2009" TYPE="REFERENCE">Torres-Rendon 2009</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-07-14 13:25:33 +0200" MODIFIED_BY="[Empty name]">
<P>Most leukoplakias are asymptomatic; therefore, the need for treatment is based primarily on the precancerous nature of the lesion, and the primary aim of management should be to avoid development of cancer. This is particularly important in view of the poor prognosis associated with oral squamous cell carcinoma, in which only about 50% of patients are still alive five years after diagnosis (<LINK REF="REF-Scully-2009" TYPE="REFERENCE">Scully 2009</LINK>), and of the morbidity associated with oral cancer and complications of oral cancer therapy (<LINK REF="REF-Epstein-2012" TYPE="REFERENCE">Epstein 2012</LINK>).</P>
<P>Many approaches to the treatment of leukoplakia have been proposed in an attempt to prevent cancer development and to evaluate clinical/histological resolution of oral leukoplakias (<LINK REF="REF-Lodi-2008" TYPE="REFERENCE">Lodi 2008</LINK>). These approaches include surgical excision with different techniques (scalpel, cryosurgery, photodynamic therapy, laser surgery and vaporisation), medical treatment (topical or systemic), cessation of risk activities (smoking and alcohol) and no intervention but strict surveillance.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-07-14 15:20:22 +0200" MODIFIED_BY="[Empty name]">
<P>The rationale of surgical excision is that removing the clinically altered tissue could prevent the onset of oral cancer. For medical treatments, the rationale depends on the mechanism of action of the agent employed: retinoids, vitamin A and carotenoids might influence epithelial turnover; non-steroidal anti-inflammatory drugs (NSAIDs) block cyclo-oxygenase activity, thereby modulating specific prostaglandins possibly involved in carcinogenesis; and chemotherapeutic agents act directly on early neoplastic cells. As many of these treatments have potentially serious adverse effects, the &#8220;wait and see&#8221; approach, based on strict clinical and histological surveillance, is generally employed to identify early cancer onset and to initiate cancer treatment to render the best possible prognosis. Although surgery and medical treatments aim to remove or reduce the lesion, it must be stressed that no evidence has shown a relationship between changes in size or resolution and decreased risk of oral cancer.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-07-14 19:00:40 +0200" MODIFIED_BY="[Empty name]">
<P>Cochrane Oral Health undertook an extensive prioritisation exercise in 2014 to identify a core portfolio of titles that were the most clinically important reviews to maintain in <I>The Cochrane Library</I> (<LINK REF="REF-Worthington-2015" TYPE="REFERENCE">Worthington 2015</LINK>). This review was identified as a priority title by the oral medicine expert panel (<A HREF="http://ohg.cochrane.org/priority-reviews">Cochrane OHG priority review portfolio</A>). Treatment of leukoplakia continues to be based on expert opinion, and more research is needed. This review aims to provide evidence-based support for clinicians and patients and a clinical research agenda for planning future studies.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-07-14 15:20:58 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness, safety and acceptability of treatments for leukoplakia in preventing oral cancer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-07-28 10:13:16 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-07-28 10:08:04 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-07-14 15:26:19 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing effects of surgery, medical or complementary treatments (local or systemic) or risk factor cessation versus placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-07-14 13:28:31 +0200" MODIFIED_BY="[Empty name]">
<P>Anyone with a diagnosis of oral leukoplakia (without histopathological evidence of carcinoma) as defined, at the time of the studies, by consensus conferences held in 1978, 1983, 1994 and 2005 (<LINK REF="REF-Axell-1984" TYPE="REFERENCE">Axell 1984</LINK>; <LINK REF="REF-Axell-1996" TYPE="REFERENCE">Axell 1996</LINK>; <LINK REF="REF-Kramer-1978" TYPE="REFERENCE">Kramer 1978</LINK>, <LINK REF="REF-Warnakulasuriya-2007" TYPE="REFERENCE">Warnakulasuriya 2007</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-07-14 19:00:49 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Active</HEADING>
<UL>
<LI>Surgical removal of the lesion, including surgical excision, laser surgery, cryotherapy</LI>
<LI>Systemic medical treatment</LI>
<LI>Topical medical treatment, including anti-inflammatory agents, antimycotic agents, carotenoids and retinoids, cytotoxic agents, etc.</LI>
<LI>Removal of predisposing habits (e.g. tobacco, alcohol)</LI>
<LI>Other treatment (e.g. photodynamic therapy)</LI>
<LI>Combined treatment</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<UL>
<LI>Placebo</LI>
<LI>No treatment</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-07-28 10:08:04 +0200" MODIFIED_BY="[Empty name]">
<P>In light of the pre-cancerous nature of leukoplakia, the primary objective of treatment is to prevent cancer development.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-07-24 22:18:41 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Oral cancer development, demonstrated by histopathological examination</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-07-28 10:08:04 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical resolution, in terms of the proportion of lesions that did not resolve (with relapse data when provided)</LI>
<LI>Improvement of histological features, in terms of the proportion of lesions that did not show improvement in histological features</LI>
<LI>Safety of the intervention, as measured by the incidence of adverse effects</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-07-18 11:07:20 +0200" MODIFIED_BY="[Empty name]">
<P>To identify studies included in or considered for this review, we developed detailed search strategies for each database searched. These were based on the search strategy developed for MEDLINE Ovid but revised appropriately for each database. The search strategy used a combination of controlled vocabulary and free text terms and was linked with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised controlled trials (RCTs) in MEDLINE: sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in Box 6.4.c of the <I>Cochrane Handbook for</I> <I>Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)<I>.</I> We have provided details of the MEDLINE search in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-07-18 11:04:37 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following databases.</P>
<UL>
<LI>Cochrane Oral Health's Trials Register (to 16 May 2016) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>the Cochrane Library</I>, 2016, Issue 4) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI>
<LI>MEDLINE Ovid (1946 to 16 May 2016) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>Embase Ovid (1980 to 16 May 2016) (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>);</LI>
<LI>CancerLit via PubMed (1950 to 16 May 2016) (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</LI>
</UL>
<P>We placed no restrictions on the language or date of publication when searching the electronic databases.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-07-18 11:07:20 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following databases for ongoing trials (see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for details of the search strategy).</P>
<UL>
<LI>
<A HREF="http://www.isrctn.com/page/mrct">metaRegister of Controlled Trials</A> (to 10 February 2015);</LI>
<LI>
<A HREF="http://clinicaltrials.gov">ClinicalTrials.gov</A> (to 16 May 2016);</LI>
<LI>
<A HREF="http://apps.who.int/trialsearch/default.aspx">The WHO International Clinical Trials Registry Platform</A> (to 16 May 2016).</LI>
</UL>
<P>We manually checked the reference lists of included studies and existing reviews. The metaRegister of Controlled Trials is no longer available and so was not searched in May 2016.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-07-28 10:13:16 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-07-15 10:22:47 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors (GL and RF) separately examined the title and abstract of each article identified by the different search strategies. When at least one review author considered the article relevant, it progressed in the review process and was included in a digital archive prepared by using dedicated software. We obtained full reports for all relevant studies.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-07-15 10:26:49 +0200" MODIFIED_BY="[Empty name]">
<P>All studies meeting the inclusion criteria underwent data extraction performed by at least two review authors, using a specially designed form. We present the characteristics of trial participants, interventions and outcomes for the included trials in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-07-15 10:27:27 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed the risk of bias of included trials and resolved disagreements through discussion and consensus. We used the recommended approach for assessing risk of bias in studies included in Cochrane reviews (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). This approach addresses the following seven specific domains.</P>
<UL>
<LI>Random sequence generation (selection bias)</LI>
<LI>Allocation concealment (selection bias)</LI>
<LI>Blinding of participants and personnel (performance bias)</LI>
<LI>Blinding of outcome assessment (detection bias)</LI>
<LI>Incomplete outcome data (attrition bias)</LI>
<LI>Selective reporting (reporting bias)</LI>
<LI>Other bias</LI>
</UL>
<P>Each domain in the tool includes one or more specific entries in a &#8216;Risk of bias&#8217; table. Within each entry, the first part of the tool describes what was reported to have happened in the study, in sufficient detail to support a judgement about risk of bias. The second part of the tool assigns a judgement related to the risk of bias for that entry - &#8216;low risk&#8217;, &#8216;high risk&#8217; or &#8216;unclear risk&#8217;. After taking into account the additional information provided by trial authors, we summarised the risk of bias in included studies as follows.</P>
<UL>
<LI>Low risk of bias: low risk of bias for all key domains</LI>
<LI>Unclear risk of bias: unclear risk of bias for one or more key domains</LI>
<LI>High risk of bias: high risk of bias for one or more key domains</LI>
</UL>
<P>We completed a 'Risk of bias' table for each included study (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and presented results graphically by study (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and by domain over all studies (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-07-28 10:13:16 +0200" MODIFIED_BY="[Empty name]">
<P>The primary measure of intervention effect was onset of oral cancer. Dichotomous data were reported for this outcome measure: cancer development versus absence of cancer development.</P>
<P>Secondary outcomes, clinical resolution, histological changes and adverse effects were usually reported as ordinal measures. We dichotomised data: clinical resolution vs partial or no clinical response; decreased severity vs worsening of histology or no change in histological features.</P>
<P>For each intervention, we sought and summarised data on the number of participants from both intervention and control groups who experienced the event (outcome) and the total number of participants. We analysed dichotomous data by calculating risk ratios. As we anticipated pooling data from studies in which true treatment effects were likely to differ, we planned to use a random-effects model in statistical analyses; however, we used a fixed-effect model because of the very small number of studies combined.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-07-14 15:43:06 +0200" MODIFIED_BY="[Empty name]">
<P>The individual participant was the unit of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-07-14 15:43:34 +0200" MODIFIED_BY="[Empty name]">
<P>Whenever possible, we obtained missing data from tables and graphs or through personal contact with study authors. When this was not possible, and we found no evidence that data were missing because of a specific bias, we analysed only available data (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This represents a change from the previous version of the review, in which missing data were imputed with the assumption that all were poor outcomes.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-07-14 15:44:06 +0200" MODIFIED_BY="[Empty name]">
<P>We assessed the significance of discrepancies in the estimates of treatment effects provided by different trials by using Cochran&#8217;s test for heterogeneity and the I² statistic; the latter describes the percentage total variation across studies that is due to heterogeneity rather than to chance. Heterogeneity was considered statistically significant if the P value was less than 0.1. A rough guide to the interpretation of I² given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> is as follows: 0 to 40% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, 75% to 100% represents very substantial ('considerable') heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-07-14 15:44:14 +0200" MODIFIED_BY="[Empty name]">
<P>We attempted to minimise reporting biases by conducting a thorough search of multiple sources including trial registries, and by making efforts to identify unpublished trials and non-English language publications.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-07-14 15:44:25 +0200" MODIFIED_BY="[Empty name]">
<P>When valid and relevant data were collected, we undertook a meta-analysis of the data. We grouped and analysed studies on the basis of intervention category. We conducted meta-analyses in Review Manager software, using the Mantel-Haenszel method with a fixed-effect model. We had planned to use a random-effects model, but this would not have been appropriate because of the small number of studies included. We did not pool data when substantial heterogeneity was identified.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-07-07 19:01:32 +0200" MODIFIED_BY="[Empty name]">
<P>We had planned to conduct subgroup analyses for smoking and non-smoking participants, and for lesions with or without dysplasia. Unfortunately, as such data were not available, we did not perform subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-07-15 10:29:00 +0200" MODIFIED_BY="[Empty name]">
<P>We had planned to undertake sensitivity analysis excluding studies at high risk and at unclear risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summarising findings and assessing the quality of the evidence</HEADING>
<P>We constructed 'Summary of findings' tables for each comparison to present the results for our review outcomes. We assessed the quality of the evidence using GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) criteria.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-28 10:07:31 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-07-24 22:25:39 +0200" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2016-07-15 10:29:05 +0200" MODIFIED_BY="[Empty name]">
<P>This review was originally published in 2001, and updates were published in 2004 and 2006. Since its first publication up until May 2016, we have identified a total of 3438 articles through the search strategy. We have examined titles and abstracts for eligibility and have eliminated those not matching the inclusion criteria. We identified 68 apparently eligible studies and rejected 30 because they were not pertinent. Nine of the studies are ongoing (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> for details). After we obtained the full-text version of the remaining 29 studies, we excluded 13 additional studies (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) - one because it was quasi-randomised, four because of inadequate allocation, four for problems in selection of participants and four for lack of an adequate control group. We categorised two studies as awaiting classification (<LINK REF="STD-Califano-2012" TYPE="STUDY">Califano 2012</LINK>; <LINK REF="STD-Chiba-2012" TYPE="STUDY">Chiba 2012</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>). Thus we included 14 studies in this review. See <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-07-24 22:25:39 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of trial setting and design</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Location</HEADING>
<P>Of the 15 studies included, six were conducted in the USA (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>), three in India (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>), one in Italy (<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>), two in China (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>), one in Canada (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>) and one in Japan (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>). The setting for all studies was a university hospital.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Design</HEADING>
<P>Ten trials had a two-arm parallel design (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>); three, a three-arm parallel design (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>); and one, a four-arm parallel design (<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). In three of the four studies with more than two arms, we pooled together data from the active arms: interventions differed in dosage in <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; and <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Duration</HEADING>
<P>The trials varied in length. Three studies used an open follow-up (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>); one study lasted two years (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>); and all other studies lasted less than one year.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Funding</HEADING>
<P>Two trials did not specify any funding source (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>). In two trials, some study authors worked for the company that supplied the study drug (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>); in another, the first study author had ownership interest in the patent of the drug tested (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>). One study was supported by Central Soya Company and NIH (National Institutes of Health) (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>), one by Hoffmann-La Roche and the National Cancer Institute (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>), one by the Chinese National Natural Science Foundation (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>), one by NIH (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>), one by the National Cancer Institute Specialized Programs of Reasearch Excellence (SPORE) Program (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>), one by the Butterfield Award of the Sasakawa Foundation GB and DSM Nutrition Japan (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>), one by Pfizer (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>), one by the Italian National Research Council (CNR) and the Italian Ministry of University, Research, Science and Technology (MURST) (<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>), one by Jagsonpal Pharmaceuticals Ltd., New Delhi, India (<LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>), one by the National Cancer Institute of Canada (<LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>), one by the Beijing Natural Science Foundation, the National Natural Science Foundation of China and the Tenth 5-Year Plan of National Key Technologies R&amp;D Program in China and NIH (<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>) and one by Ito En Ltd. (<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of participants</HEADING>
<P>The total number of participants randomised in the trials was 909, with a mean of 64.9 participants per study (ranged from 10 to 131 participants).</P>
<P>The reported proportion of smoking and drinking participants (the two main risk factors for oral cancer) varied from 8% (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>) to 86% (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>), and from 9% (<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>) to 71% (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>), respectively. Use of tobacco products (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>) and smoking (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>) were exclusion criteria in two studies. None of the study authors reported significant changes in these habits during the course of the trial. In two studies, all participants recruited were chewers of tobacco-containing betel quid (another well-known risk factor for oral cancer) from the same Indian village (Trivandrum, Kerala) (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>). All participants enrolled in the studies underwent a confirmatory biopsy; however, only four studies reported the histological criteria employed (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>). Seven studies reported the percentage of dysplastic lesions, which ranged from 18.75% (<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>) to 73.2% (<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>) (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). One study excluded lesions with severe dysplasia (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>), and another study included cases with at least one of the following features: at least mild dysplasia, high-risk location, significant extent of tissue involvement and presence of symptoms (<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of interventions</HEADING>
<P>We did not identify any RCTs that compared surgical treatments with placebo or no treatment, nor did we identify any RCTs of risk factor cessation. All included trials compared medical or complementary treatment versus placebo, usually a preparation similar to the treatment, without the active ingredient; in one case, the placebo contained vitamin C, which we considered an inactive ingredient (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>).</P>
<P>Four RCTs compared topical treatment versus placebo (129 participants) (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>), and nine RCTs compared systemic treatment versus placebo (716 participants) (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). One RCT compared a combination of topical and systemic treatments versus placebo (64 participants) (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>).</P>
<P>Four studies tested vitamin A or retinoids (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>); three studies tested beta carotene or carotenoids (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>); two studies tested NSAIDs: ketorolac (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>) and celecoxib (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>); and four studies tested herbal extracts, in particular, tea components (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK> - mixed; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK> - green tea extract capsules), a Chinese herbal mixture (<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>) and gel containing freeze-dried black raspberries (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>). The other interventions tested were bleomycin (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>) and Bowman-Birk inhibitor (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of outcomes</HEADING>
<P>Five studies reported data on oral cancer development (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). In Epstein's trial, although seven out of 12 participants in the control group received the active treatment at the end of the study period, we conducted an intention-to-treat (ITT) analysis for this review.</P>
<P>All studies used lesion measurement as the clinical parameter to assess change; five studies also used pictures of the lesions for clinical evaluation (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>; <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>). In 11 RCTs, a complete response was defined as complete disappearance of the lesion (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>), lasting at least four weeks in four of them (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>). For partial response, nine studies used the definition 'greater than 50% reduction', and one used a slightly different criterion - 'greater than 30% reduction' (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>). Three studies defined &#8220;stable disease&#8221; as a reduction of less than 50% of the lesion (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>); three studies adopted an otherwise non-specified "unchanged clinical aspect" (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>); and two studies defined "stable disease" as lesions not satisfying any other category (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). Eight studies gave similar definitions of "disease progression" as an increase in the size of the lesion or the appearance of new lesions (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). One study included the "no response" category, indicating stable and progressive lesions (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>). Three studies adopted different categories for clinical evaluation. <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK> used the following: remission, no change, new leukoplakia. <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK> used positive response (including complete and partial response), stable disease and progressive disease. One study reported the change in lesion measurement, expressed in mm<SUP>2 </SUP>(<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>). Clinical response was recorded immediately at the end of treatment in 10 studies (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>), two weeks after the end of treatment in <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK> and three months after the end of treatment in <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>. In two studies, it was not clear when the reported clinical assessment was recorded (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>).</P>
<P>Six studies reported assessment of histological changes (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). These studies did not use a unique histological classification, and the comparison between pre-treatment and post-treatment histological features was highly variable. One study defined histological response as an otherwise non-specified "reversal" or "improvement" of dysplastic features (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>); another adopted a graphical method for evaluating histological changes (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>). <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK> reported histological changes in the treatment group only. In one study, a control biopsy was taken only if development of cancer was suspected (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>).</P>
<P>Biomarkers evaluated included bcl-2 immunostaining (<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>), AgNOR (silver-stained nucleolar organizer region) and PCNA (proliferation cell nuclear antigen) labelling indexes (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>), biomarkers of DNA damage in exfoliated cells and peripheral blood lymphocytes (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>), Neu protein of exfoliated cells and serum (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>), epidermal growth factor receptors (EGFRs) (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>) and p53 and Ki67 (protein; cellular marker of neoplasia) (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>).</P>
<P>Most trials monitored safety of the intervention. Only <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK> and <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK> did not appear to measure adverse effects.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-07-14 15:53:41 +0200" MODIFIED_BY="[Empty name]">
<P>The primary reason for exclusion of each study is given in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Many trials were ineligible for more than one reason; however, the more common reasons for exclusion were inappropriate selection of participants, lack of random allocation and absence of a proper control arm. In particular, although we found three randomised controlled trials evaluating surgical interventions (<LINK REF="STD-Chee-2013" TYPE="STUDY">Chee 2013</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2013" TYPE="STUDY">López-Jornet 2013</LINK>; <LINK REF="STD-Schwarz-2005" TYPE="STUDY">Schwarz 2005</LINK>), we were unable to include them in the review as they did not include a no treatment or placebo group.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-07-15 10:35:13 +0200" MODIFIED_BY="[Empty name]">
<P>On the basis of criteria used in the critical appraisal of studies, one study had an overall low risk of bias (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>). We judged seven studies as having unclear risk of bias (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>; <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>; <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). We considered the remaining studies to be at high risk of bias (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>). See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2016-07-15 10:35:13 +0200" MODIFIED_BY="[Empty name]">
<P>We assessed the generation of the randomisation sequence as having low risk of bias for six trials and unclear risk for eight trials.</P>
<P>We assessed the concealment of allocation as having low risk of bias for three trials, at unclear risk for 10 trials and at high risk for one trial (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>). In <LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>, the block size was two.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-07-15 10:33:27 +0200" MODIFIED_BY="[Empty name]">
<P>We assessed blinding of participants and personnel, as well as blinding of outcome assessment, as low risk of bias for 11 trials and unclear risk for four studies in which not enough information was provided.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-07-15 10:34:43 +0200" MODIFIED_BY="[Empty name]">
<P>The reported drop-out rate ranged from 0% (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>) to 32.5% (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>). We assessed 11 trials as having low risk of bias with regard to attrition bias because they reported there were no drop-outs, or because drop-out was not likely to influence findings. We assessed three studies with high drop-out rates as having high risk of bias (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-07-14 16:00:10 +0200" MODIFIED_BY="[Empty name]">
<P>Most trials reported important outcomes and were assessed as having low risk of bias. Five studies failed to report histological results (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>); we assessed these trials as having high risk of bias for this domain.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-07-14 16:00:15 +0200" MODIFIED_BY="[Empty name]">
<P>We assessed <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>, which had discrepant published and unpublished data, along with baseline imbalance, as having unclear risk of bias for this domain. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-07-28 10:07:31 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Vitamin A and retinoids versus placebo</HEADING>
<P>Four studies (one at high, two at unclear and one at low risk of bias) compared vitamin A and retinoids versus placebo. Three of these studies evaluated systemic treatment (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>), and one evaluated topical treatment (<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Oral cancer development</HEADING>
<P>One study reported effects of systemic vitamin A on cancer incidence (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>). Investigators found no evidence of benefit compared with placebo (risk ratio (RR) 0.11, 95% confidence interval (CI) 0.01 to 2.05; 85 participants) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical resolution</HEADING>
<P>Five studies reported effects of vitamin A or retinoids on clinical features of leukoplakia, in particular, on its resolution (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). In particular, three studies tested systemic treatment (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>), but because heterogeneity was high (I<SUP>2</SUP> = 94%), it was inappropriate to combine findings in a meta-analysis. Two of the three studies at high or unclear risk of bias showed some benefit (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>: RR 0.51, 95% 0.37 to 0.71; 85 participants; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>: RR 0.44, 95% CI 0.27 to 0.73; 54 participants), but <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>, which was at low risk of bias, showed no clear evidence of benefit (RR 0.92, 95% CI 0.78 to 1.08; 40 participants).</P>
<P>
<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK> provided relapse data: nine out of 16 (56%) participants who responded to treatment (partially or completely) subsequently relapsed (no information was available regarding the two partial responders from the placebo group). <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK> reported that 14 out of 22 (64%) complete responders developed recurrent lesions (no information was available regarding the three complete responders in the placebo group).</P>
<P>One study at unclear risk of bias tested topical treatment (nine participants) and found treatment was not more likely to completely resolve the lesion than placebo: RR 0.83, 95% CI 0.48 to 1.44 (<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>).</P>
<P>In <LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>, one out of five (20%) participants responding completely or partially to the experimental treatment relapsed, and one out of four (25%) participants responding to placebo relapsed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement of histological features</HEADING>
<P>A single study recorded histological improvement and showed that improvement in histological features of lesions was more likely in participants treated with systemic retinoic acid than in those treated with placebo (RR 0.43, 95% CI 0.24 to 0.76; 39 participants; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>Topical 13-cis-retinoic acid (<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>) and 200,000 IU per week of vitamin A (<LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>) produced no adverse effects. Systemic 13-cis-retinoic acid (1 to 2 mg/kg/d) (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>) caused adverse effects of varying severity in 79% of participants (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Two participants withdrew from <LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK> because of severe conjunctivitis and hypertriglyceridaemia.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Beta carotene or carotenoids versus placebo</HEADING>
<P>Three studies compared systemic beta carotene or carotenoids versus placebo (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Oral cancer development</HEADING>
<P>Two studies reported the effects of systemic beta carotene on cancer incidence (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>). Investigators found no evidence of benefit when compared with placebo (RR 0.71, 95% CI 0.24 to 2.09; 132 participants; I<SUP>2</SUP> = 0%; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical resolution</HEADING>
<P>Three studies tested effects of systemic beta carotene and carotenoids on clinical resolution (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). Owing to high heterogeneity (I<SUP>2</SUP> = 87%), it was not appropriate to combine findings in a meta-analysis. Two of the individual studies, which were at unclear risk of bias, found that systemic beta carotene was more effective than placebo for complete resolution of the lesion (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>: RR 0.72, 95% CI 0.58 to 0.90; 89 participants; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>: RR 0.61, 95% CI 0.47 to 0.80; 58 participants). The other study, at high risk of bias, failed to show evidence of benefit (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>: RR 0.95, 95% CI 0.84 to 1.08; 43 participants).</P>
<P>
<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK> reported that eight out of 15 (54%) complete responders developed recurrent lesions (no information was available regarding the three complete responders in the placebo group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement of histological features</HEADING>
<P>Evidence of histological improvement was recorded when lycopene (a carotenoid) was compared with placebo (RR 0.24, 95% CI 0.12 to 0.46; one study; 58 participants; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) (<LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>Systemic treatment with beta-carotene produced no adverse effects in one study supplementing 10 mg/d (<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>). It caused adverse effects of varying severity in 9% of participants in another study supplementing 360 mg/wk (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>). Researchers reported no adverse effects among participants treated with systemic lycopene (<LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>). See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Non-steroidal anti-inflammatory drugs (NSAIDs) versus placebo</HEADING>
<P>Two studies at unclear risk of bias compared NSAIDs - ketorolac in <LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK> and celecoxib in <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK> - versus placebo.</P>
<SUBSECTION>
<HEADING LEVEL="4">Oral cancer development</HEADING>
<P>Cancer development was among the outcomes reported in <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008.</LINK> This did not occur in either arm, probably because of the extremely short duration of the study (12 weeks).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical resolution</HEADING>
<P>Investigators found no evidence of benefit for systemic celecoxib (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>: RR 0.94, 95% CI 0.83 to 1.08; 46 participants) nor topical ketorolac (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>: RR 0.94, 95% CI 0.81 to 1.10; 56 participants) compared with placebo in terms of clinical resolution of lesions (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement of histological features</HEADING>
<P>Histological changes were not among the outcomes in the studies testing NSAIDs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>In <LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>, which tested systemic celecoxib, trialists reported that the treatment was "safe and well tolerated". Thirty-two intervention participants reported 56 adverse effects, and 20 placebo participants reported 20 adverse effects. Minor adverse events included dizziness, diarrheoa and abdominal pain. No participants had grade 4 adverse events. Four participants (two from the placebo group and two from an intervention group) had grade 3 adverse events. Two people discontinued treatment due to an adverse event (grade 2 vision abnormality and hypertension in a participant receiving 400 mgtwice daily of celecoxib and a grade 3 ischemic cerebrovascular accident in a participant receiving 200 mg twice daily of celecoxib.</P>
<P>Ketorolac oral rinse caused adverse effects of varying severity in 29% of participants (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). One person withdrew from the trial after the first dose because of mouth pain.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Herbal extracts versus placebo</HEADING>
<P>Four studies compared herbal extracts, in particular, tea components (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>), a Chinese herbal mixture (<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>) and freeze-dried black raspberry gel (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>), versus placebo.</P>
<SUBSECTION>
<HEADING LEVEL="4">Oral cancer development</HEADING>
<P>Cancer development was among the outcomes in <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>; however, it was not possible to analyse data because trial authors reported the cumulative number of cases, without specifying the allocation arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical resolution</HEADING>
<P>The four studies testing herbal extracts included clinical resolution among outcomes (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>Systemic treatment with green tea extract showed no evidence of benefit in terms of clinical resolution of leukoplakia when compared with the control in one study at unclear risk of bias (<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>: RR 0.99, 95% CI 0.86 to 1.14; 39 participants). <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>, which was at high risk of bias, investigated a treatment integrating systemic (capsules containing 0.38 g of dried mixture of the whole water extract of green tea, green tea polyphenols and tea pigments) and topical preparations of mixed tea extract (mixed tea in glycerin at the concentration of 10%), but was not able to demonstrate benefit when compared with placebo in terms of clinical resolution (RR 1.00, 95% CI 0.94 to 1.07; 59 participants).</P>
<P>In one study investigating effects of a Chinese herbal mixture, it was not possible to extract data on clinical resolution (<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>).</P>
<P>One topical herbal treatment (freeze-dried black raspberries) showed no evidence of benefit when compared with placebo in a study that was at unclear risk of bias (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>: RR 4.13, 95% CI 0.21 to 80.91; 40 participants). Among participants who did respond to such treatment, six of 22 (32%) in the treatment arm and seven of 17 (41%) in the placebo arm had visible evidence of lesion recurrence at former treatment sites at three months post trial follow-up (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement of histological features</HEADING>
<P>In two studies reporting histological changes, neither active treatment (topical freeze-dried black raspberries and systemic green tea extract) showed benefit when compared with placebo (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>: RR 0.97, 95% CI 0.58 to 1.60; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>: RR 0.86, 95% CI 0.66 to 1.13; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>People undergoing treatment with green tea reported very high frequency (93%) of adverse effects of varying severity in one study (<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>). Adverse effects were not mentioned in <LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>. Freeze-dried black raspberry gel caused no adverse effects (<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>). <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK> stated, "drug toxicity was not monitored in the clinical trial". See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical bleomycin versus placebo</HEADING>
<P>Topical bleomycin was tested against placebo in a single small study at unclear risk of bias that included 22 participants (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>). Following post-treatment biopsy, seven participants in the placebo group were crossed over to receive the active intervention. An ITT analysis was conducted for outcomes measured after post-treatment biopsy.</P>
<P>Mean follow-up from the end of the study was 15 months for group A and 22 months for group B.</P>
<SUBSECTION>
<HEADING LEVEL="4">Oral cancer development</HEADING>
<P>The trial found no evidence of benefit of topical bleomycin compared with placebo in reducing cancer development among participants affected by leukoplakia (RR 3.00, 95% CI 0.32 to 27.83; 20 participants; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical resolution</HEADING>
<P>Topical bleomycin showed no benefit for clinical resolution when compared with placebo: RR 0.55, 95% CI 0.29 to 1.04. In addition, among participants for whom follow-up information was available, two out of four (50%) participants with a complete response relapsed and one out of two (50%) participants with a partial response relapsed (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement of histological features</HEADING>
<P>
<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK> reported histological changes, showing no benefit of topical bleomycin when compared with placebo: RR 0.49, 95% CI 0.22 to 1.10 (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>Topical bleomycin caused adverse effects of varying severity in 100% of participants (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Participants in the bleomycin group developed erythema with erosion. Erythema developed in the placebo group; 60% of the bleomycin group reported discomfort but did not require analgesics. The trial found no evidence of systemic toxicity.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bowman-Birk Inhibitor versus placebo</HEADING>
<P>A single study tested the Bowman-Birk inhibitor against placebo (<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Oral cancer development</HEADING>
<P>Cancer development was not among the outcomes of the study testing the Bowman-Birk inhibitor.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical resolution</HEADING>
<P>The topical Bowman-Birk inhibitor showed no benefit for clinical resolution when compared with placebo: RR 1.00, 95% CI 0.91 to 1.09 (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement of histological features</HEADING>
<P>Data on histological changes from <LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK> were not available for analysis, but study authors reported no statistically significant differences in histological changes between study arms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>The Bowman-Birk inhibitor caused adverse effects of varying severity in 49% of participants (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We did not undertake sensitivity analysis excluding studies at high or unclear risk of bias, as the only study at low risk of bias was not included in a meta-analysis (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-07-24 22:28:41 +0200" MODIFIED_BY="[Empty name]">
<P>Leukoplakia is the most common potentially malignant oral disorder. Although rates of oral ccancer development may vary among studies, probably as the result of differences in diagnostic criteria for leukoplakia and follow-up intervals, the morbidity and mortality associated with oral cancer suggest that leukoplakia is a relevant health issue for affected individuals. Yet, of the 14 studies included in the present review, none evaluated a surgical intervention nor the effect of habit cessation, and only three studies provided data on the effects of a medical or complementary treatment on cancer incidence.</P>
<SUMMARY_OF_RESULTS MODIFIED="2016-07-24 22:28:41 +0200" MODIFIED_BY="[Empty name]">
<P>At present, there is no evidence that any of the medical or complementary treatments studied for people with leukoplakia can reduce the likelihood of oral cancer development. It should be noted that this conclusion is based on only three studies, namely, those testing systemic vitamin A, systemic beta carotene and topical bleomycin. These studies, which were at high or unclear risk of bias, included relatively few participants and had limited follow-up. Overall, the quality of the evidence was very low.</P>
<P>Clinical change, in terms of variation in lesion size, was an outcome reported by all studies, although esearchers used different methods of measurement. Some single studies suggested effectiveness of some proposed treatments, namely, vitamin A, beta carotene and lycopene, in achieving complete clinical resolution of lesions more often than placebo (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>). Similarly, single studies showed that vitamin A and lycopene provided some benefit in terms of improvement in histological features (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>; <LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>).</P>
<P>Leukoplakias generally are not associated with significant signs and symptoms, and the risk of developing cancer is relatively low (i.e. many patients with leukoplakia receive treatment that is not necessary). Therefore, proposed treatments should have minimal propensity for adverse effects. The proportion of participants reporting adverse effects varied between 0 and 100% in the active arms of the included trials, and between 0 and 90% in the placebo arms; however adverse effects were always more common in the study group than in the control group (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). It seems likely that interventions were well accepted by participants because drop-out rates were similar between treatment and control groups (see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>); however, follow-up may not have been long enough to permit this assessment. Adverse effects caused participants to withdraw in three studies: when systemic 13-cis-retinoic acid induced severe conjunctivitis and hypertriglyceridaemia (<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>); when intolerable mouth pain followed the initial ketorolac mouthrinse (<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>); and in two participants treated with celecoxib, because of vision abnormality and hypertension in one, and ischaemic cerebrovascular accident in another (<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-07-15 10:47:33 +0200" MODIFIED_BY="[Empty name]">
<P>Less than half (33% to 42%) of people with leukoplakia who develop oral cancer do so within two years of diagnosis (<LINK REF="REF-Lind-1987" TYPE="REFERENCE">Lind 1987</LINK>; <LINK REF="REF-Silverman-1984" TYPE="REFERENCE">Silverman 1984</LINK>), and the incidence of oral cancer increases with the duration of follow-up (<LINK REF="REF-Shiu-2000" TYPE="REFERENCE">Shiu 2000</LINK>). Therefore, to properly test the effects of treatments on cancer incidence, it would be necessary to plan studies with large groups of participants and a long follow-up period - ideally, multi-centre randomised controlled trials (RCTs) assessing outcomes at 10 years. As the duration of the studies included in this review was less than 12 months in all but four studies (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>; <LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>), cancer incidence rates are likely to be underestimated. Indeed, most of the studies did not include cancer incidence as an endpoint, but rather employed outcomes that assessed clinical or histological markers or both. Although easier to perform, studies using such outcomes pose a double problem: first, there is little evidence of the predictive value of many of those outcomes; second, they are difficult to compare. In addition, widespread outcomes, such as dysplasia grade, may be affected by high inter-observer and even intra-observer variation (<LINK REF="REF-Abbey-1995" TYPE="REFERENCE">Abbey 1995</LINK>; <LINK REF="REF-Karabulut-1995" TYPE="REFERENCE">Karabulut 1995</LINK>).</P>
<P>It is noteworthy that, although surgery is the first choice in leukoplakia management for many clinicians, there is an absence of RCTs comparing the effects of surgical excision versus no treatment or placebo (<LINK REF="REF-Marley-1998" TYPE="REFERENCE">Marley 1998</LINK>). The only data available are from observational studies comparing rates of cancer incidence in people who did or did not undergo surgical treatment for oral leukoplakias. Such studies have differences in diagnostic and inclusion criteria, follow-up interval, participant characteristics and surgical techniques employed (scalpel, laser, cryotherapy). They show highly variable results and sometimes are conflicting in their conclusions (<LINK REF="REF-Saito-2001" TYPE="REFERENCE">Saito 2001</LINK>; <LINK REF="REF-Schepman-1998" TYPE="REFERENCE">Schepman 1998</LINK>). In addition, on the basis of animal and clinical studies, it has been speculated that surgery itself might act to promote carcinogenesis in pre-malignant oral lesions (<LINK REF="REF-Holmstrup-2009" TYPE="REFERENCE">Holmstrup 2009</LINK>). Trials evaluating interventions directed against risk factors (e.g. smoking) are also missing.</P>
<P>The applicability of results of two of the included studies (<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>; <LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>) should be considered in the context of their different risk factor profile as the participants were all betel quid chewers, a risk factor uncommon in individuals from geographical areas outside South Asia.</P>
<P>Leukoplakias with different histological or molecular characteristics may have different risks of transforming into cancer. However, the value of predictive factors proposed so far in the literature requires sound confirmatory data. The presence of epithelial dysplasia may be predictive of a transformation to oral cancer and the risk of cancer may increase with the severity of dysplastic changes (<LINK REF="REF-Lumerman-1995" TYPE="REFERENCE">Lumerman 1995</LINK>; <LINK REF="REF-Schepman-1998" TYPE="REFERENCE">Schepman 1998</LINK>; <LINK REF="REF-Warnakulasuriya-2011" TYPE="REFERENCE">Warnakulasuriya 2011</LINK>), although this hypothesis has been recently challenged (<LINK REF="REF-Holmstrup-2006" TYPE="REFERENCE">Holmstrup 2006</LINK>). Unfortunately, the available data did not allow us to perform a subgroup analysis of lesions with and without dysplasia, thus it is not possible to establish whether any particular treatment may be more indicated in the presence of dysplasia of different severity. Many different molecular biomarkers have been proposed, but no single marker or battery of markers seems predictive enough to be implemented during clinical care.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-07-15 10:48:07 +0200" MODIFIED_BY="[Empty name]">
<P>Of the studies included in the present review, we judged one as having low risk of bias, six asunclear risk of bias and seven ashigh risk of bias. Although these studies were randomised trials, information about randomisation methods was missing or incomplete in most studies. In particular, methods used for random sequence generation were unclear in eight out of 15 studies, and details on allocation concealment were missing in 10 out of 15 studies. The body of evidence for cancer incidence comprises three studies investigating three different treatments: vitamin A, beta carotene and topical bleomycin. We assessed these studies as having very low quality according to GRADE (Grades of Recommendation, Assessment, Development and Evaluation) assessment criteria (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). Thus, the quality and the number of included trials, often with short follow-up times, suggest cautious interpretation of results.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-07-15 10:49:06 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-07-15 10:48:41 +0200" MODIFIED_BY="[Empty name]">
<P>No randomised controlled trials (RCTs) on surgical treatment for people who have oral leukoplakia have included placebo and active treatment arms. Nor have RCTs examined risk factor cessation (e.g. smoking). Therefore, the effectiveness of these interventions cannot be reliably assessed. None of the medical and complementary treatments studied (vitamin A, beta carotene, bleomycin) has been shown to be effective in preventing cancer onset in people with leukoplakia, and, despite the findings of some studies that vitamin A or beta carotene may be effective in reducing or even resolving oral leukoplakia in the short term, the risk of subsequent relapse seems high.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-07-15 10:49:06 +0200" MODIFIED_BY="[Empty name]">
<P>Although surgery remains the treatment option favoured by most clinicians, the effectiveness of surgery compared with no treatment ("wait and see") has not been assessed in RCTs for prevention of cancer development in people with leukoplakia. Research is needed to assess surgical treatment of patients with leukoplakia and to evaluate effects of risk factor cessation in people with leukoplakia. Larger, better conducted trials of longer duration are required to properly evaluate the effects of any treatment on malignant transformation rates, which should be considered the primary outcome when effectiveness of treatments for leukoplakia is tested.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-07-29 11:46:42 +0200" MODIFIED_BY="[Empty name]">
<P>The review authors wish to thank all researchers in cited studies who have provided some of the data used in the review. We also thank members of the Cochrane Oral Health editorial team (Anne Littlewood, Marco Esposito), who assisted with this update, and external referees Isaac van der Waal and Andrew Ness, who provided clinical feedback.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-07-28 10:03:51 +0200" MODIFIED_BY="[Empty name]">
<P>Giovanni Lodi: none known<BR/>Roberto Franchini: none known<BR/>Saman Warnakulasuriya: none known<BR/>Elena Maria Varoni: none known<BR/>Andrea Sardella: none known<BR/>Alexander R Kerr: none known<BR/>Antonio Carrassi: none known<BR/>LCI MacDonald: none known. LM is a salaried member of staff with Cochrane Oral Health<BR/>Helen V Worthington: none known. HW is a Co-ordinating Editor with Cochrane Oral Health</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-07-28 10:06:57 +0200" MODIFIED_BY="[Empty name]">
<P>Giovanni Lodi: main review author, participation in all phases of review preparation<BR/>Roberto Franchini: selection of articles, data extraction, text preparation<BR/>Elena Varoni: data extraction, interpretation of studies<BR/>Saman Warnakulasuriya: interpretation of results, text preparation<BR/>Andrea Sardella: selection of articles, interpretation of results<BR/>Alexander R Kerr: interpretation of results, text preparation<BR/>Antonio Carrassi: group co-ordinator, interpretation of results<BR/>LCI MacDonald: updated text, data extraction and analysis, quality assessment<BR/>Helen V Worthington: data extraction and analysis, quality assessment<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-07-15 10:24:23 +0200" MODIFIED_BY="[Empty name]">
<P>We changed the title to specify that oral leukoplakia is treated to prevent oral cancer.</P>
<P>When it was not possible to obtain missing data from trial authors, and we found no evidence that data were missing because of a specific bias, we analysed only available data (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This represents a change from the previous version of the review, wherein missing data were imputed with the assumption that all were poor outcomes.</P>
<P>We used fixed-effect rather than random-effects meta-analysis because of the small number of included studies.</P>
<P>In accordance with the methodological recommendations of Cochrane Oral Health, we now include only randomised controlled trials to reduce risk of bias from quasi-randomised studies. Therefore, we have excluded the small, quasi-randomised study (<LINK REF="STD-Gaeta-2000" TYPE="STUDY">Gaeta 2000</LINK>) from this version of the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-07-29 12:52:57 +0100" MODIFIED_BY="Anne-Marie Glenny">
<STUDIES MODIFIED="2016-07-14 16:14:49 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-07-14 16:14:49 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Armstrong-2013" MODIFIED="2016-07-14 16:14:49 +0200" MODIFIED_BY="[Empty name]" NAME="Armstrong 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-07-14 16:14:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, et al</AU>
<TI>Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial</TI>
<SO>Cancer Prevention Research (Philadelphia, Pa.)</SO>
<YR>2013</YR>
<VL>6</VL>
<PG>410-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817635"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Epstein-1994" MODIFIED="2008-08-06 18:31:09 +0200" MODIFIED_BY="[Empty name]" NAME="Epstein 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-08-06 18:31:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Wong FL, Millner A, Le ND</AU>
<TI>Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial</TI>
<SO>Head &amp; Neck</SO>
<YR>1994</YR>
<VL>16</VL>
<NO>6</NO>
<PG>539-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817639"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817638"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-1986" MODIFIED="2008-08-06 18:31:17 +0200" MODIFIED_BY="[Empty name]" NAME="Hong 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-08-06 18:31:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al</AU>
<TI>13-cis-retinoic acid in the treatment of oral leukoplakia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>315</VL>
<NO>24</NO>
<PG>1501-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817643"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817642"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Li-1999" MODIFIED="2013-08-09 13:13:03 +0200" MODIFIED_BY="[Empty name]" NAME="Li 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-08-09 13:13:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li N, Sun Z, Han C, Chen J</AU>
<TI>The chemopreventive effects of tea on human oral precancerous mucosa lesions</TI>
<SO>Proceedings of the Society for Experimental Biology and Medicine</SO>
<YR>1999</YR>
<VL>220</VL>
<NO>4</NO>
<PG>218-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817645"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817644"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallery-2014" MODIFIED="2015-07-03 16:42:31 +0200" MODIFIED_BY="[Empty name]" NAME="Mallery 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-03 16:42:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallery SR, Tong M, Shumway BS, Curran AE, Larsen PE, Ness GM, et al</AU>
<TI>Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial</TI>
<SO>Clinical Cancer Research</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>7</NO>
<PG>1910-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817647"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817646"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulshine-2004" NAME="Mulshine 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al</AU>
<TI>Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>5</NO>
<PG>1565-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817649"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817648"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nagao-2015" MODIFIED="2016-07-14 16:14:40 +0200" MODIFIED_BY="[Empty name]" NAME="Nagao 2015" YEAR="2010">
<REFERENCE MODIFIED="2016-07-14 16:14:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagao T, Warnakulasuriya S, Fukano H, Nakamura T, Kato S, Yamamoto K, et al</AU>
<TI>A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>9 Suppl</NO>
<PG>41.e6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817651"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-14 16:14:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nagao T, Warnakulasuriya S, Fukano H, Suzuki K, Shimozato K, Hashimoto S</AU>
<TI>A randomised trial for preventing malignant transformation of oral leukoplakia</TI>
<SO>Oral Surgery</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>103&#8211;14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817654"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-14 16:14:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nagao T, Warnakulasuriya S, Nakamura T, Kato S, Yamamoto K, Fukano H, et al</AU>
<TI>Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial</TI>
<SO>International Journal of Cancer</SO>
<YR>2015</YR>
<VL>136</VL>
<PG>1708-17</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817652"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-14 16:14:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagao T, Warnakulasuriya S, Sakuma H, Suzuki K, Hashimoto S</AU>
<TI>Is response to chemoprevention in oral leukoplakia determined by p53 expression?</TI>
<SO>Oral Diseases</SO>
<YR>2010</YR>
<VL>16</VL>
<PG>518</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817653"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817650"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papadimitrakopoulou-2008" MODIFIED="2015-07-03 16:46:13 +0200" MODIFIED_BY="[Empty name]" NAME="Papadimitrakopoulou 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-07-03 16:46:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al</AU>
<TI>Pilot randomized phase II study of celecoxib in oral premalignant lesions</TI>
<SO>Clinical Cancer Research</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>2095-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817656"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817655"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Piattelli-1999" NAME="Piattelli 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piattelli A, Fioroni M, Santinelli A, Rubini C</AU>
<TI>bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study</TI>
<SO>Oral Oncology</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>3</NO>
<PG>314-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817658"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817657"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sankaranarayan-1997" MODIFIED="2008-08-06 18:31:29 +0200" MODIFIED_BY="[Empty name]" NAME="Sankaranarayan 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-08-06 18:31:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, et al</AU>
<TI>Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment</TI>
<SO>Oral Oncology</SO>
<YR>1997</YR>
<VL>33</VL>
<NO>4</NO>
<PG>231-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817660"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817659"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2004" NAME="Singh 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh M, Krishanappa R, Bagewadi A, Keluskar V</AU>
<TI>Efficacy of oral lycopene in the treatment of oral leukoplakia</TI>
<SO>Oral Oncology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>6</NO>
<PG>591-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817662"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817661"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stich-1988" MODIFIED="2008-08-06 18:31:34 +0200" MODIFIED_BY="[Empty name]" NAME="Stich 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-08-06 18:31:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK</AU>
<TI>Response of oral leukoplakias to the administration of vitamin A</TI>
<SO>Cancer Letters</SO>
<YR>1988</YR>
<VL>40</VL>
<NO>1</NO>
<PG>93-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817664"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817663"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2009" MODIFIED="2015-07-03 16:46:54 +0200" MODIFIED_BY="[Empty name]" NAME="Sun 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-03 16:46:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sun Z, Guan X, Li N, Liu X, Chen X</AU>
<TI>Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs</TI>
<SO>Oral Oncology</SO>
<YR>2010</YR>
<VL>46</VL>
<PG>105-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817666"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817665"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsao-2009" MODIFIED="2015-07-03 16:47:16 +0200" MODIFIED_BY="[Empty name]" NAME="Tsao 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-03 16:47:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, et al</AU>
<TI>Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions</TI>
<SO>Cancer Prevention Research (Philadelphia, Pa.)</SO>
<YR>2009</YR>
<VL>2</VL>
<PG>931-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817668"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817667"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-05 12:22:19 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bocharova-2004" NAME="Bocharova 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bocharova OA, Pozharitskaya MM, Chekalina TL, Lyzhenkova MA, Karpova RV, Mezentseva MV, et al</AU>
<TI>Leukoplakia of oral mucosa: pathogenesis and possible correction with phytoadaptogen</TI>
<SO>Bulletin of Experimental Biology and Medicine</SO>
<YR>2004</YR>
<VL>138</VL>
<NO>6</NO>
<PG>578-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817670"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817669"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boisnic-1994" MODIFIED="2008-08-06 18:31:40 +0200" MODIFIED_BY="[Empty name]" NAME="Boisnic 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-08-06 18:31:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boisnic S, Branchet MC, Pascal F, Ben Slama L, Rostin M, Szpirglas H</AU>
<TI>Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa. A clinical evaluation</TI>
<TO>Trétinoine topique dans le traitement des lichens plans et des leucoplasies de la muqueuse buccale. Evaluation clinique</TO>
<SO>[French]. Annals of Dermatology and Venereology</SO>
<YR>1994</YR>
<VL>121</VL>
<NO>6-7</NO>
<PG>459-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817672"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817671"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chee-2013" MODIFIED="2015-07-03 16:47:49 +0200" MODIFIED_BY="[Empty name]" NAME="Chee 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-07-03 16:47:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chee M, Sasaki C</AU>
<TI>Carbon dioxide laser fiber for the excision of oral leukoplakia</TI>
<SO>Annals of Otology, Rhinology, and Laryngology</SO>
<YR>2013</YR>
<VL>122</VL>
<PG>547-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817674"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817673"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiesa-2005" NAME="Chiesa 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, et al</AU>
<TI>Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results</TI>
<SO>International Journal of Cancer</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>4</NO>
<PG>625-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817676"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, et al</AU>
<TI>Fenretinide (4-HPR) in chemoprevention of oral leukoplakia</TI>
<SO>Journal of Cellular Biochemistry Supplement</SO>
<YR>1993</YR>
<VL>17F</VL>
<PG>255-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817677"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, et al</AU>
<TI>Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results</TI>
<SO>European Journal of Cancer. Part B, Oral Oncology</SO>
<YR>1992</YR>
<VL>28B</VL>
<NO>2</NO>
<PG>97-102</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817678"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U</AU>
<TI>Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide</TI>
<SO>Cancer Research</SO>
<YR>1994</YR>
<VL>54</VL>
<NO>7 Suppl</NO>
<PG>2032s-7s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817679"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Palo G, Veronesi U, Marubini E, Camerini T, Chiesa F, Nava M, et al</AU>
<TI>Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia</TI>
<SO>Journal of Cellular Biochemistry Supplement</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>11-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817680"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817675"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Femiano-2001" NAME="Femiano 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femiano F, Gombos F, Scully C, Battista C, Belnome G, Esposito V</AU>
<TI>Oral leukoplakia: open trial of topical therapy with calcipotriol compared with tretinoin</TI>
<SO>International Journal of Oral and Maxillofacial Surgery</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>5</NO>
<PG>402-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817682"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817681"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gaeta-2000" MODIFIED="2016-07-02 21:45:30 +0200" MODIFIED_BY="[Empty name]" NAME="Gaeta 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-07-02 21:45:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaeta GM, Gombos F, Femiano F, Battista C, Minghetti P, Montanari L, et al</AU>
<TI>Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>6</NO>
<PG>473-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817641"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817640"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garewal-1999" NAME="Garewal 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garewal H, Pitcock J, Friedman S, Alberts D, Meyskens F, Ramsey L, et al</AU>
<TI>Beta-carotene in oral leukoplakia</TI>
<SO>Proceedings, Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1992</YR>
<VL>11</VL>
<PG>141</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817684"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garewal HS, Katz RV, Meyskens F, Pitcock J, Morse D, Friedman S, et al</AU>
<TI>Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial</TI>
<SO>Archives of Otolaryngology - Head and Neck Surgery</SO>
<YR>1999</YR>
<VL>125</VL>
<NO>12</NO>
<PG>1305-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817685"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817683"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krishnaswamy-1995" MODIFIED="2008-08-06 18:31:49 +0200" MODIFIED_BY="[Empty name]" NAME="Krishnaswamy 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-08-06 18:31:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krishnaswamy K, Prasad MP, Krishna TP, Annapurna VV, Reddy GA</AU>
<TI>A case study of nutrient intervention of oral precancerous lesions in India</TI>
<SO>European Journal of Cancer. Part B: Oral Oncology</SO>
<YR>1995</YR>
<VL>31B</VL>
<NO>1</NO>
<PG>41-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817687"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817686"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lippman-1993" NAME="Lippman 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, et al</AU>
<TI>Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>1</NO>
<PG>15-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817689"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papadimitrakopoulou VA, Lippman SM, Lee JS, Toth BB, Martin JW, Lee JJ, et al</AU>
<TI>Long term follow-up of low-dose isotretinoin (13-cRA) versus beta carotene to prevent oral carcinogenesis</TI>
<SO>Proceedings, Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>A340</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817690"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817688"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00f3_pez_x002d_Jornet-2013" MODIFIED="2016-01-26 15:36:52 +0100" MODIFIED_BY="[Empty name]" NAME="López-Jornet 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-01-26 15:36:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F</AU>
<TI>Comparison of pain and swelling after removal of oral leukoplakia with CO&#8322; laser and cold knife: a randomized clinical trial</TI>
<SO>Medicina Oral, Patologia Oral y Cirugia Bucal</SO>
<YR>2013</YR>
<VL>18</VL>
<PG>38e-44e</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817692"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817691"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathew-1995" NAME="Mathew 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathew B, Sankaranarayanan R, Nair PP, Varghese C, Somanathan T, Amma BP, et al</AU>
<TI>Evaluation of chemoprevention of oral cancer with Spirulina fusiformis</TI>
<SO>Nutrition and Cancer</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>2</NO>
<PG>197-202</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817694"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817693"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwarz-2005" NAME="Schwarz 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwarz F, Maraki D, Yalcinkaya S, Bieling K, Bocking A, Becker J</AU>
<TI>Cytologic and DNA-cytometric follow-up of oral leukoplakia after CO2- and Er:YAG-laser assisted ablation: a pilot study</TI>
<SO>Lasers in Surgery and Medicine</SO>
<YR>2005</YR>
<VL>37</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817696"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817695"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaridze-1993" MODIFIED="2008-08-06 18:31:56 +0200" MODIFIED_BY="[Empty name]" NAME="Zaridze 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-08-06 18:31:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaridze D, Evstifeeva T, Boyle P</AU>
<TI>Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer</TI>
<SO>Annals of Epidemiology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>3</NO>
<PG>225-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817698"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817697"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-07-14 16:13:59 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Califano-2012" MODIFIED="2016-07-14 16:13:59 +0200" MODIFIED_BY="[Empty name]" NAME="Califano 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-07-14 16:13:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Califano JA, Ferris RL, Epstein JB, Gillespie MB, Feldman LE, Gibson MK, et al</AU>
<TI>A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>No 15_suppl (May 20 Suppl)</NO>
<PG>5528</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817700"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817699"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiba-2012" MODIFIED="2016-07-14 16:13:54 +0200" MODIFIED_BY="[Empty name]" NAME="Chiba 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-07-14 16:13:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chiba I, Takeshima M, Abiko Y, Kobayashi H, Muthumala M, Sugiura C, et al</AU>
<TI>Curcumin is an effective chemopreventive substance for betel quid chewer's oral precancer in Sri Lanka</TI>
<SO>Cancer Prevention Research</SO>
<YR>2012</YR>
<VL>5</VL>
<NO>11 Suppl 1</NO>
<PG>PR-04</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817637"/><IDENTIFIER TYPE="DOI" VALUE="10.1158/1940-6207.PREV-12-PR-04"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817636"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-06-08 13:20:24 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00004161" MODIFIED="2016-06-08 13:12:31 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00004161" YEAR="2000">
<REFERENCE MODIFIED="2016-06-08 13:12:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00004161</AU>
<TI>Fenretinide in treating patients with leukoplakia of the mouth</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00004161</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344784"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-23 14:15:20 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817701"/><IDENTIFIER MODIFIED="2013-07-23 14:15:20 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00004161"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00014404" MODIFIED="2016-06-08 13:13:28 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00014404" YEAR="2000">
<REFERENCE MODIFIED="2016-06-08 13:13:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00014404</AU>
<TI>Celecoxib in treating patients with precancerous lesions of the mouth</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00014404</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344785"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-07 17:20:53 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817702"/><IDENTIFIER MODIFIED="2013-08-07 17:20:53 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00014404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00101335" MODIFIED="2016-06-08 13:14:23 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00101335" YEAR="2011">
<REFERENCE MODIFIED="2016-06-08 13:14:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00101335</AU>
<TI>Celecoxib in preventing head and neck cancer in patients with oral leukoplakia</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00101335</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344786"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-01-26 15:35:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817704"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00155337" MODIFIED="2016-06-08 13:15:12 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00155337" YEAR="2005">
<REFERENCE MODIFIED="2016-06-08 13:15:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00155337</AU>
<TI>Photodynamic therapy for oral leukoplakia and erythroleukoplakia</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00155337</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344787"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-23 15:20:14 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817705"/><IDENTIFIER MODIFIED="2013-07-23 15:20:14 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00155337"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00176566" MODIFIED="2016-06-08 13:16:15 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00176566" YEAR="2005">
<REFERENCE MODIFIED="2016-06-08 13:16:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00176566</AU>
<TI>A phase II trial to assess the effects of green tea in oral leukoplakia</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00176566</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344788"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-23 14:19:06 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817706"/><IDENTIFIER MODIFIED="2013-07-23 14:19:06 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00176566"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00299195" MODIFIED="2016-06-08 13:17:23 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00299195" YEAR="2006">
<REFERENCE MODIFIED="2016-06-08 13:17:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00299195</AU>
<TI>A randomized study of sulindac in oral premalignant lesions</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00299195</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344789"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-23 14:28:51 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817707"/><IDENTIFIER MODIFIED="2013-07-23 14:28:51 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00299195"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00402779" MODIFIED="2016-06-08 13:18:11 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00402779" YEAR="2006">
<REFERENCE MODIFIED="2016-06-08 13:18:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00402779</AU>
<TI>Erlotinib prevention of oral cancer (EPOC)</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00402779</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344790"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-23 15:11:00 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817708"/><IDENTIFIER MODIFIED="2013-07-23 15:11:00 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00402779"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00951379" MODIFIED="2016-06-08 13:18:50 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00951379" YEAR="2010">
<REFERENCE MODIFIED="2016-06-08 13:18:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00951379</AU>
<TI>Pioglitazone for oral premalignant lesions</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00951379</SO>
<YR>(accessed 16 May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344791"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-23 14:37:41 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817709"/><IDENTIFIER MODIFIED="2013-07-23 14:37:41 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00951379"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01497951" MODIFIED="2016-06-08 13:20:24 +0200" MODIFIED_BY="[Empty name]" NAME="NCT01497951" YEAR="2011">
<REFERENCE MODIFIED="2016-06-08 13:20:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01497951</AU>
<TI>Photodynamic therapy for oral precursor lesions (PDT)</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT01497951</SO>
<YR>(accessed May 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4344792"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-23 15:07:45 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817710"/><IDENTIFIER MODIFIED="2013-07-23 15:07:45 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01497951"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-14 16:13:29 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-14 16:13:29 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abbey-1995" NAME="Abbey 1995" TYPE="JOURNAL_ARTICLE">
<AU>Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al</AU>
<TI>Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics</SO>
<YR>1995</YR>
<VL>80</VL>
<NO>2</NO>
<PG>188-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arduino-2013" MODIFIED="2015-07-03 16:50:04 +0200" MODIFIED_BY="[Empty name]" NAME="Arduino 2013" TYPE="JOURNAL_ARTICLE">
<AU>Arduino PG, Bagan J, El-Naggar AK, Carrozzo M</AU>
<TI>Urban legends series: oral leukoplakia</TI>
<SO>Oral Diseases</SO>
<YR>2013</YR>
<VL>19</VL>
<PG>642-59</PG>
<IDENTIFIERS MODIFIED="2015-06-24 16:10:03 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-06-24 16:10:03 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/odi.12065"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Axell-1984" MODIFIED="2008-08-06 18:32:13 +0200" MODIFIED_BY="[Empty name]" NAME="Axell 1984" TYPE="JOURNAL_ARTICLE">
<AU>Axell T, Holmstrup P, Kramer IRH, Pindborg JJ</AU>
<TI>International seminar on oral leukoplakia and associated lesions related to tobacco habits</TI>
<SO>Community Dentistry and Oral Epidemiology</SO>
<YR>1984</YR>
<VL>12</VL>
<PG>145-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Axell-1987" NAME="Axell 1987" TYPE="JOURNAL_ARTICLE">
<AU>Axell T</AU>
<TI>Occurrence of leukoplakia and some other oral white lesions among 20,333 adult Swedish people</TI>
<SO>Community Dentistry and Oral Epidemiology</SO>
<YR>1987</YR>
<VL>15</VL>
<NO>1</NO>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Axell-1996" MODIFIED="2016-07-14 10:16:20 +0200" MODIFIED_BY="[Empty name]" NAME="Axell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Axell T, Pindborg JJ, Smith CJ, Van der Waal I</AU>
<TI>Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21, 1994. International Collaborative Group on Oral White Lesions</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>1996</YR>
<VL>25</VL>
<NO>2</NO>
<PG>49-54</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1996237276"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bouquot-1986" NAME="Bouquot 1986" TYPE="JOURNAL_ARTICLE">
<AU>Bouquot JE, Gorlin RJ</AU>
<TI>Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years</TI>
<SO>Oral Surgery, Oral Medicine and Oral Pathology</SO>
<YR>1986</YR>
<VL>61</VL>
<NO>4</NO>
<PG>373-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dietrich-2004" NAME="Dietrich 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich T, Reichart PA, Scheifele C</AU>
<TI>Clinical risk factors of oral leukoplakia in a representative sample of the US population</TI>
<SO>Oral Oncology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>2</NO>
<PG>158-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Epstein-2012" MODIFIED="2016-07-14 16:13:29 +0200" MODIFIED_BY="[Empty name]" NAME="Epstein 2012" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al</AU>
<TI>Oral complications of cancer and cancer therapy: from cancer treatment to survivorship</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>2012</YR>
<VL>62</VL>
<PG>400-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-1980" NAME="Gupta 1980" TYPE="JOURNAL_ARTICLE">
<AU>Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, et al</AU>
<TI>Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers</TI>
<SO>Community Dentistry and Oral Epidemiology</SO>
<YR>1980</YR>
<VL>8</VL>
<NO>6</NO>
<PG>283-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-07-14 16:13:13 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Deeks JJ, Altman DG; on behalf of the Cochrane Statistical Methods Group</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<EN>Version 5.1.0 [updated March 2011]</EN>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-07-14 16:13:04 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Deeks JJ, Altman DG; on behalf of the Cochrane Statistical Methods Group</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<EN>Version 5.1.0 [updated March 2011]</EN>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmstrup-2006" NAME="Holmstrup 2006" TYPE="JOURNAL_ARTICLE">
<AU>Holmstrup P, Vedtofte P, Reibel J, Stoltze K</AU>
<TI>Long-term treatment outcome of oral premalignant lesions</TI>
<SO>Oral Oncology</SO>
<YR>2006</YR>
<VL>42</VL>
<NO>5</NO>
<PG>461-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmstrup-2009" MODIFIED="2015-07-03 16:50:45 +0200" MODIFIED_BY="[Empty name]" NAME="Holmstrup 2009" TYPE="JOURNAL_ARTICLE">
<AU>Holmstrup P</AU>
<TI>Can we prevent malignancy by treating premalignant lesions?</TI>
<SO>Oral Oncology</SO>
<YR>2009</YR>
<VL>45</VL>
<PG>549-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ikeda-1991" NAME="Ikeda 1991" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda N, Ishii T, Iida S, Kawai T</AU>
<TI>Epidemiological study of oral leukoplakia based on mass screening for oral mucosal diseases in a selected Japanese population</TI>
<SO>Community Dentistry and Oral Epidemiology</SO>
<YR>1991</YR>
<VL>19</VL>
<NO>3</NO>
<PG>160-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karabulut-1995" NAME="Karabulut 1995" TYPE="JOURNAL_ARTICLE">
<AU>Karabulut A, Reibel J, Therkildsen MH, Praetorius F, Nielesen HW, Dabelsteen E</AU>
<TI>Observer variability in the histologic assessment of oral premalignant lesions</TI>
<SO>Journal of Oral Pathology Medicine</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>5</NO>
<PG>198-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kramer-1978" MODIFIED="2008-08-06 18:32:44 +0200" MODIFIED_BY="[Empty name]" NAME="Kramer 1978" TYPE="JOURNAL_ARTICLE">
<AU>Kramer IR, Lucas RB, Pindborg JJ, Sobin LH</AU>
<TI>Definition of leukoplakia and related lesions: an aid to studies on oral precancer</TI>
<SO>Oral Surgery, Oral Medicine and Oral Pathology</SO>
<YR>1978</YR>
<VL>46</VL>
<NO>4</NO>
<PG>518-39</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1979053956"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lind-1987" NAME="Lind 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lind PO</AU>
<TI>Malignant transformation in oral leukoplakia</TI>
<SO>Scandinavian Journal of Dental Research</SO>
<YR>1987</YR>
<VL>95</VL>
<NO>6</NO>
<PG>449-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lodi-2008" MODIFIED="2016-07-14 16:12:55 +0200" MODIFIED_BY="[Empty name]" NAME="Lodi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lodi G, Porter S</AU>
<TI>Management of potentially malignant disorders: evidence and critique</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2008</YR>
<VL>37</VL>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lumerman-1995" NAME="Lumerman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lumerman H, Freedman P, Kerpel S</AU>
<TI>Oral epithelial dysplasia and the development of invasive squamous cell carcinoma</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics</SO>
<YR>1995</YR>
<VL>79</VL>
<NO>3</NO>
<PG>321-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marley-1998" NAME="Marley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Marley JJ, Cowan CG, Lamey PJ, Linden GJ, Johnson NW, Warnakulasuriya KA</AU>
<TI>Management of potentially malignant oral mucosal lesions by consultant UK oral and maxillofacial surgeons</TI>
<SO>British Journal of Oral and Maxillofacial Surgery</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>1</NO>
<PG>28-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagao-2005" NAME="Nagao 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nagao T, Ikeda N, Fukano H, Hashimoto S, Shimozato K, Warnakulasuriya S</AU>
<TI>Incidence rates for oral leukoplakia and lichen planus in a Japanese population</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>2005</YR>
<VL>34</VL>
<NO>9</NO>
<PG>532-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petti-2003" NAME="Petti 2003" TYPE="JOURNAL_ARTICLE">
<AU>Petti S</AU>
<TI>Pooled estimate of world leukoplakia prevalence: a systematic review</TI>
<SO>Oral Oncology</SO>
<YR>2003</YR>
<VL>39</VL>
<PG>770-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pitiyage-2009" MODIFIED="2015-07-03 16:51:23 +0200" MODIFIED_BY="[Empty name]" NAME="Pitiyage 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S</AU>
<TI>Molecular markers in oral epithelial dysplasia: review</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<PG>737-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reichart-2000" NAME="Reichart 2000" TYPE="JOURNAL_ARTICLE">
<AU>Reichart PA</AU>
<TI>Oral mucosal lesions in a representative cross-sectional study of aging Germans</TI>
<SO>Community Dentistry and Oral Epidemiology</SO>
<YR>2000</YR>
<VL>28</VL>
<NO>5</NO>
<PG>390-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saito-2001" NAME="Saito 2001" TYPE="JOURNAL_ARTICLE">
<AU>Saito T, Sugiura C, Hirai A, Notani K, Totsuka Y, Shindoh M, et al</AU>
<TI>Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality</TI>
<SO>International Journal of Oral and Maxillofacial Surgery</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>1</NO>
<PG>49-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scheifele-2003" NAME="Scheifele 2003" TYPE="JOURNAL_ARTICLE">
<AU>Scheifele C, Reichart PA</AU>
<TI>Is there a natural limit of the transformation rate of oral leukoplakia?</TI>
<SO>Oral Oncology</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>5</NO>
<PG>470-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schepman-1998" NAME="Schepman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Schepman KP, van der Meij EH, Smeele LE, van der Waal I</AU>
<TI>Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands</TI>
<SO>Oral Oncology</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>4</NO>
<PG>270-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scully-2009" MODIFIED="2015-07-03 16:51:50 +0200" MODIFIED_BY="[Empty name]" NAME="Scully 2009" TYPE="JOURNAL_ARTICLE">
<AU>Scully C, Bagan J</AU>
<TI>Oral squamous cell carcinoma overview</TI>
<SO>Oral Oncology</SO>
<YR>2009</YR>
<VL>45</VL>
<PG>301-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shiu-2000" NAME="Shiu 2000" TYPE="JOURNAL_ARTICLE">
<AU>Shiu MN, Chen TH, Chang SH, Hahn LJ</AU>
<TI>Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan</TI>
<SO>British Journal of Cancer</SO>
<YR>2000</YR>
<VL>82</VL>
<NO>11</NO>
<PG>1871-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverman-1984" NAME="Silverman 1984" TYPE="JOURNAL_ARTICLE">
<AU>Silverman S Jr, Gorsky M, Lozada F</AU>
<TI>Oral leukoplakia and malignant transformation. A follow-up study of 257 patients</TI>
<SO>Cancer</SO>
<YR>1984</YR>
<VL>53</VL>
<NO>3</NO>
<PG>563-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2009" MODIFIED="2013-06-11 18:38:27 +0200" MODIFIED_BY="[Empty name]" NAME="Smith 2009" TYPE="JOURNAL_ARTICLE">
<AU>Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H</AU>
<TI>Biomarkers in dysplasia of the oral cavity: a systematic review</TI>
<SO>Oral Oncology</SO>
<YR>2009</YR>
<VL>45</VL>
<PG>647-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sperandio-2013" MODIFIED="2015-07-03 16:52:19 +0200" MODIFIED_BY="[Empty name]" NAME="Sperandio 2013" TYPE="JOURNAL_ARTICLE">
<AU>Sperandio M, Brown AL, Lock C, Morgan PR, Coupland VH, Madden PB, et al</AU>
<TI>Predictive value of dysplasia grading and DNA ploidy in malignant transformation of oral potentially malignant disorders</TI>
<SO>Cancer Prevention Research (Philadelphia, Pa.)</SO>
<YR>2013</YR>
<VL>6</VL>
<PG>822-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Syrj_x00e4_nen-2011" MODIFIED="2016-01-26 14:34:03 +0100" MODIFIED_BY="[Empty name]" NAME="Syrjänen 2011" TYPE="JOURNAL_ARTICLE">
<AU>Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, et al</AU>
<TI>Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review</TI>
<SO>Oral Diseases</SO>
<YR>2011</YR>
<VL>17 Suppl 1</VL>
<PG>58-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torres_x002d_Rendon-2009" MODIFIED="2015-07-03 16:52:44 +0200" MODIFIED_BY="[Empty name]" NAME="Torres-Rendon 2009" TYPE="JOURNAL_ARTICLE">
<AU>Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM</AU>
<TI>DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression</TI>
<SO>Oral Oncology</SO>
<YR>2009</YR>
<VL>45</VL>
<PG>468-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Waal-2009" MODIFIED="2015-07-03 16:35:16 +0200" MODIFIED_BY="[Empty name]" NAME="Van der Waal 2009" TYPE="JOURNAL_ARTICLE">
<AU>Van der Waal I</AU>
<TI>Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management</TI>
<SO>Oral Oncology</SO>
<YR>2009</YR>
<VL>45</VL>
<PG>317-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warnakulasuriya-2007" MODIFIED="2016-01-26 14:33:41 +0100" MODIFIED_BY="[Empty name]" NAME="Warnakulasuriya 2007" TYPE="JOURNAL_ARTICLE">
<AU>Warnakulasuriya S, Johnson NW, Van der Waal I</AU>
<TI>Nomenclature and classification of potentially malignant disorders of the oral mucosa</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2007</YR>
<VL>36</VL>
<PG>575-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warnakulasuriya-2011" MODIFIED="2015-07-03 16:54:16 +0200" MODIFIED_BY="[Empty name]" NAME="Warnakulasuriya 2011" TYPE="JOURNAL_ARTICLE">
<AU>Warnakulasuriya S, Kovacevic T, Madden P, Coupland VH, Sperandio M, Odell E, et al</AU>
<TI>Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2011</YR>
<VL>40</VL>
<PG>677-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Worthington-2015" MODIFIED="2016-01-07 16:29:43 +0100" MODIFIED_BY="[Empty name]" NAME="Worthington 2015" TYPE="JOURNAL_ARTICLE">
<AU>Worthington H, Clarkson J, Weldon J</AU>
<TI>Priority oral health research identification for clinical decision-making</TI>
<SO>Evidence-based Dentistry</SO>
<YR>2015</YR>
<VL>16</VL>
<NO>3</NO>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-06-24 17:11:44 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Lodi-2002" NAME="Lodi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A</AU>
<TI>Systematic review of randomized trials for the treatment of oral leukoplakia</TI>
<SO>Journal of Dental Education</SO>
<YR>2002</YR>
<VL>66</VL>
<NO>8</NO>
<PG>896-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lodi-2004" MODIFIED="2015-06-04 16:35:04 +0200" MODIFIED_BY="[Empty name]" NAME="Lodi 2004" TYPE="COCHRANE_REVIEW">
<AU>Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A</AU>
<TI>Interventions for treating oral leukoplakia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-06-04 16:33:33 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-06-04 16:33:33 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001829.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lodi-2006" MODIFIED="2015-06-24 17:11:44 +0200" MODIFIED_BY="[Empty name]" NAME="Lodi 2006" TYPE="COCHRANE_REVIEW">
<AU>Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A</AU>
<TI>Interventions for treating oral leukoplakia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-06-24 17:11:44 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-06-24 17:11:44 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001829.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-07-28 10:02:43 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-07-28 10:02:43 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-07-28 10:02:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Armstrong-2013">
<CHAR_METHODS MODIFIED="2016-07-28 10:02:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group, 2 arms</P>
<P>
<B>Conducted in </B>USA</P>
<P>
<B>Number of centres:</B> 8</P>
<P>
<B>Recruitment period: </B>May 1999 to September 2009</P>
<P>
<B>Funding source:</B> Central Soya Company, NIH</P>
<P>
<B>Study duration:</B> 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 10:50:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>At least 18 years old, with histologically proven oral leukoplakia and/or erythroplakia, capable of being measured bi-dimensionally; pre-menopausal and perimenopausal women were required to agree to use adequate birth control methods and to have a negative pregnancy test. At completion of the 4-week run-in phase of the study, during which participants self administered the placebo compound, 75% compliance with administration of drug measured by counting unused drug packets was required for continuation in the study</P>
<P>If recent (within 3 months) histological analysis had not been documented with review of biopsy, 3-mm punch biopsy of representative lesions was conducted after measurement and photodocumentation of the lesion</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Use of systemic or topical oral steroids within 3 months, currently pregnant or lactating, presence of head and neck cancer (including in situ disease), history of such within 2 years, retinoid or beta carotene therapy for any reason within 2 years or beta carotene capsules of any size within 6 months (participants were allowed up to 2 multi-vitamins per day), participation in another randomised clinical trial within 6 months</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>132 people randomised: 48/132 (36%) reported use of beer, wine or liquor, whereas 56/132 (42%) did not answer questions on alcohol consumption; 28/132 (21%) reported using tobacco (viz., cigarettes, cigars, pipe, oral use), whereas 66/132 (50%) did not answer questions on tobacco use. Percentage of dysplastic lesions was not reported</P>
<P>89 people completed the study: 32/89 females, mean age 60.7 (range 29 to 82), ethnic group 69/89 white, tobacco users 20/89 (but 40/89 unknown), alcohol users 35/89 (but 34/89 unknown)</P>
<P>Group A: randomised 67; 43 completed the study. 41 available for histological analysis</P>
<P>Group B: randomised 65; 46 completed the study. 46 available for histological analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-03 23:59:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>3 grams Bowman-Birk Inhibitor concentrate twice a day for 6 months</P>
<P>
<B>Group B:</B> 3 grams placebo (corn tortilla mix) twice a day for 6 months</P>
<P>
<B>Compliance control:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 11:25:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>The primary end point was relative per cent change in total lesion area after 6 months in the study, and the percentage of participants showing a clinical response on that measure. A complete response was declared if the relative per cent change in total lesion area was minus 100%. A partial response was a relative per cent decrease in total lesion area of 50% or more, without a complete response. Disease progression was a relative per cent increase in total lesion area of at least 50%. Remaining cases were declared to be stable disease</P>
<P>A secondary clinical response measure was change in clinical impression from photographs of lesions based on blinded, comparative judgements of pairs of photographs of the same lesion at baseline and at 6 months on the study using a 7-point scale</P>
<P>
<B>Histological response</B>
</P>
<P>A single, experienced pathologist compared pre-treatment and post-treatment pairs of tissue specimens. The pathologist was blinded to study arm assignment (drug or placebo), but not to time point of the specimen. For each specimen, the pathologist marked a continuum to indicate the degree of tissue abnormality. The continuum was 140 mm long, and was anchored by the word &#8216;normal&#8217; on the left and &#8216;malignant&#8217; on the right. The distance from the left edge of the continuum to the pathologist&#8217;s mark, in millimetres, was determined. For analyses, a score was determined by subtracting the pre-treatment value from the 6-month value. The central pathologist also made a direct comparison of pre-treatment and post-treatment specimens, marking a 170-mm continuum anchored on the left by "posttreatment shows no dysplasia in comparison with pretreatment," and on the right by "posttreatment shows greater dysplasia than pretreatment". The centre of the continuum was labelled, "pretreatment and posttreatment show no difference." The reviewer&#8217;s mark was coded as the distance from the left edge, in millimetres. On this measure, low scores denote improvement over time, a score of 85 denotes no change and a value greater than 85 indicates histological worsening</P>
<P>
<B>Other outcomes</B> included changes in buccal cell and serum Neu protein, buccal cell protease activity, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 11:25:37 +0200" MODIFIED_BY="[Empty name]">
<P>Initially it was required that the total lesion area estimated at baseline be at least 100 mm<SUP>2</SUP>, but later this requirement was relaxed to facilitate accrual</P>
<P>Early in the study, participants on the drug arm who showed a partial or complete response at 6 months were allowed to continue treatment for an additional 12 months (total 18 months) with final follow-up at 21 months. However, because of the limited supply of drugs, the protocol was soon modified to limit treatment to 6 months</P>
<P>Bowman-Birk inhibitor concentrate was initially produced and supplied by Central Soya Company, but was later supplied by the NIH/National Cancer Institute/Division of Cancer Prevention pharmacy</P>
<P>Both treatment and placebo groups showed a statistically significant decrease in total lesion area</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 11:37:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Epstein-1994">
<CHAR_METHODS MODIFIED="2016-07-15 11:25:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 2 arms</P>
<P>
<B>Conducted in</B> Canada</P>
<P>
<B>Number of centres</B>: 1</P>
<P>
<B>Recruitment period: </B>unspecified</P>
<P>
<B>Funding source: </B>unspecified</P>
<P>
<B>Study duration:</B> 2 weeks for treatment plus open follow-up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 11:26:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Patients older than 18 years with clinically visible leukoplakia and pathological diagnosis of the lesion</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Pregnant women, women of childbearing age in whom contraception was not confirmed, cases of carcinoma in situ, invasive SCC and lesions identified as inflammatory in nature</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Histological diagnosis of hyperkeratosis or acanthosis with or without dysplasia. 22% of the lesions were dysplastic</P>
<P>22 participants randomised: 12/22 females, mean age 56.6 (range 25 to 79), ethnic group not reported, 14 (63%) tobacco users, 10 (45%) alcohol users. Leukoplakia was significantly larger in the placebo group (320 mm<SUP>2</SUP>) compared with the test group (76 mm<SUP>2</SUP>) at randomisation</P>
<P>Group A: randomised 10; 10 completed the study</P>
<P>Group B: randomised 12; 12 completed the study (12 analysed clinically, 11 analysed histologically)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-08 18:30:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> 1 daily topical application of 1% w/v bleomycin in dimethylsulphoxide for 14 days</P>
<P>
<B>Group B: </B>1 daily topical application of placebo (dimethylsulphoxide only) for 14 days</P>
<P>
<B>Compliance control: </B>yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 11:37:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Cancer incidence</B>
</P>
<P>
<B>Clinical response</B>
</P>
<P>Measurement of the lesion before the start of treatment and weekly during treatment: (1) complete response was defined as no clinical and histological evidence of leukoplakia, (2) partial response was defined as a greater than 50% reduction in the size of the lesion or elimination of dysplasia. Data from the first follow-up visit (2 weeks from the end of treatment) are included in the meta-analysis</P>
<P>
<B>Histological response</B>
</P>
<P>Histological grading before the start of treatment and 4 weeks after treatment</P>
<P>
<B>Other outcomes: </B>assessment of oral burning and pain during application, between applications and with eating. Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 11:37:34 +0200" MODIFIED_BY="[Empty name]">
<P>After the post-treatment biopsy (4 weeks after treatment), 7 participants in the placebo group were crossed over to receive 1% w/v bleomycin in dimethylsulphoxide. We received unpublished data on malignant transformation and based our ITT analysis on those data</P>
<P>Mean follow-up from the end of the study: 15 months (group A) and 22 months (group B)</P>
<P>Based our analyses on raw data supplied by trial authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 11:52:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hong-1986">
<CHAR_METHODS MODIFIED="2016-07-15 11:52:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group, 2 arms</P>
<P>
<B>Conducted in </B>USA</P>
<P>
<B>Number of centres:</B> unspecified</P>
<P>
<B>Recruitment period: </B>unspecified</P>
<P>
<B>Funding source:</B> supported by a grant from Hoffmann-La Roche and in part by a grant from the National Cancer Institute</P>
<P>
<B>Study duration: </B>9 months (3 months of treatment plus 6 months of follow-up)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 11:39:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Histologically confirmed oral leukoplakia</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Women with reproductive capacity, persons taking megadoses of vitamin A (&gt; 25,000 USP units/d), patients who had an oral cancer within the 2 years preceding the study</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>44 participants randomised:</P>
<UL>
<LI>13 females</LI>
<LI>9 participants &lt; 50 years old; 29 participants 50 to 69 years; 6 participants &gt; 70 years</LI>
<LI>Ethnic group not reported</LI>
<LI>9 (20%) tobacco users, 11 (25%) alcohol users, 20 (45%) tobacco + alcohol users</LI>
<LI>27% of lesions were dysplastic</LI>
</UL>
<P>Group A: randomised 24; 22 completed the study (analysed 22 clinically, 21 histologically)</P>
<P>Group B: randomised 20; 18 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 11:38:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>capsules of 13-cis-retinoic acid (1 to 2 mg/kg/d) for 3 months</P>
<P>
<B>Group B: </B>capsules of placebo for 3 months</P>
<P>
<B>Compliance control: </B>yes, pill counts at each visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 11:38:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Measurement of the lesion, colour photography performed before the start of treatment and every 2 to 3 weeks during treatment: (1) complete response was defined as no clinical evidence of leukoplakia for at least 4 weeks; (2) partial response was defined as a greater than 50% reduction in the product of the longest diameters of the lesion; (3) a response was classified as stable when the decrease in lesion size was less than 50%; (4) disease progression was defined as an unequivocal increase in the size of any lesion during treatment or as the appearance of a new lesion</P>
<P>
<B>Histological response</B>
</P>
<P>Histological grading was done before the start of treatment and upon its completion. Histological grading included (1) atypical hyperplasia; (2) mild dysplasia; (3) moderate dysplasia; (4) severe dysplasia or carcinoma in situ</P>
<P>Other outcomes included laboratory analysis, including fasting serum triglycerides and liver function testing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-05 15:52:17 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 11:39:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-1999">
<CHAR_METHODS MODIFIED="2016-07-14 02:26:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 2 arms<BR/>
</P>
<P>
<B>Conducted in</B> China</P>
<P>
<B>Number of centres: </B>1</P>
<P>
<B>Recruitment period:</B> unspecified</P>
<P>
<B>Funding source:</B> supported by a grant from the Chinese National Natural Science Foundation</P>
<P>
<B>Study duration:</B> 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 11:39:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Not specified</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Patients with severe dysplasia</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>64 participants randomised: 24 females, mean age 54.5 (range 23 to 78), ethnic group not reported, 46 (71.9%) tobacco users. 20% of lesions were dysplastic</P>
<P>Group A: randomised 32, 29 completed the study</P>
<P>Group B: randomised 32, 30 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 11:39:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>systemic (capsules) and topical (paint) mixed tea (3 grams/d and 3 paintings/d) for 6 months</P>
<P>
<B>Group B: </B>systemic (capsules) and topical (paint) placebo for 6 months</P>
<P>
<B>Compliance control:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 11:39:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Size and number of lesions of each participant were recorded at baseline and at the end of the trial: (1) complete regression was defined as complete disappearance of the lesion; (2) partial regression was defined as a 30% or greater reduction in the size of a single lesion or in the sum of sizes of multiple lesions; (3) lesions with no change in size were recorded as no change; (4) deterioration referred to the occurrence of new lesions</P>
<P>
<B>Histological response</B>
</P>
<P>Oral biopsies were conducted at the beginning and at the end of the trial. Besides routine histopathological examination, lesional tissue investigations included also silver-stained nucleolar organizer regions (AgNOR), proliferation cell nuclear antigen (PCNA) and epidermal growth factor receptor (EGFR) analysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-05 15:53:01 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 11:41:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mallery-2014">
<CHAR_METHODS MODIFIED="2016-07-15 11:40:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 2 arms<BR/>
</P>
<P>
<B>Conducted in </B>US</P>
<P>
<B>Number of centres:</B> 3</P>
<P>
<B>Recruitment period: </B>unspecified</P>
<P>
<B>Funding source: </B>supported by NIH NCI RC2 CA148099. S.R.Mallery has ownership interest (including patents) in BRB gel patent</P>
<P>
<B>Study duration: </B>6 months (12 weeks plus 3 months of follow-up)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 11:41:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Microscopically confirmed pre-malignant oral epithelial lesions, no use of tobacco products for 6 weeks before and during the 3-month study, no previous history of cancer (except for basal cell carcinoma of the skin). Participants screened before entrance into and during (10 to 12 days recall intervals) the trial for no tobacco use compliance via unannounced saliva testing for nicotine (NicAlert, JANT Pharmacal Corporation)</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Previous or current history of non-basal cell cancer, use of tobacco products, and either a microscopic diagnosis of no pre-malignant change or OSCC in the pre-trial biopsy</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>40 participants randomised: 22 females, mean age 60.15 (range 32 to 78), ethnic group not reported, 24 (60%) former smokers. 72.5% of lesions were dysplastic: 63% (14/22) in Group A and 83% (15/18) in Group B</P>
<P>Group A: randomised 22, 22 completed the study. 21 available for post-trial examination</P>
<P>Group B: randomised 18, 18 completed the study. 17 available for post-trial examination</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 11:41:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> topical application of a bioadhesive gel that contained 10% w/w freeze-dried black raspberries (0.5 g, q.i.d. for 12 weeks)</P>
<P>
<B>Group B:</B> topical application of a bioadhesive placebo gel that contained 10% w/w sucrose and food colorants (0.5 g, q.i.d. for 12 weeks)</P>
<P>
<B>Compliance control:</B> yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 11:41:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Clinical photographs of lesions were taken with a calibrated measuring device (Puritan) placed parallel to the long axis of the lesion. Acquired clinical images were analysed using ImagePro 6.2 software (Media Cybernetics). Lesional sizes were normalised to square millimetres (mm<SUP>2</SUP>) according to the following formula: lesional size mm<SUP>2</SUP> = pixels of lesional area × 100/(pixels of 1 centimetre unit on the calibration device in the same image). The remaining lesional area after the initial biopsy and before gel treatment was the pre-treatment size. Post-treatment lesional size was the residual lesional area after 3 months of gel treatment and just before the final biopsy</P>
<P>
<B>Histological response</B>
</P>
<P>Histological grading was done before the start of treatment and upon its completion. A 0 to 8 grade scale (0 = normal with or without hyperkeratosis, 1 = atypia with crisply defined clinical margins, 2 = mild dysplasia, 3 = mild-moderate dysplasia, 4 = moderate dysplasia, 5 = moderate-severe dysplasia, 6 = severe dysplasia, 7 = carcinoma in situ, 8 = invasive SCC) was used to rank light microscopic diagnoses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 11:41:19 +0200" MODIFIED_BY="[Empty name]">
<P>30 participants had OIN lesions (16 in BRB - 72.7% and 14 in placebo - 77.7%) that were recalcitrant to surgery and had recurred multiple times (2 to 8) at the same site before trial participation. 12 Group A and 3 Group B participants had a history of multiple lesions dispersed throughout the mouth, consistent with a diagnosis of proliferative verrucous leukoplakia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 11:43:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mulshine-2004">
<CHAR_METHODS MODIFIED="2016-07-15 11:42:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 2 arms<BR/>
</P>
<P>
<B>Conducted in</B> USA</P>
<P>
<B>Number of centres:</B> 3</P>
<P>
<B>Recruitment period:</B> unspecified</P>
<P>
<B>Funding source:</B> supported by a grant from the National Cancer Institute Specialized Programs of Reasearch Excellence (SPORE) Program</P>
<P>
<B>Study duration:</B> 4 months (90 days of treatment plus 1 month of follow-up)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 11:42:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Patients with bi-dimensionally measurable leukoplakia of the oral cavity or of the oropharynx. In cases of previous oral cancer diagnosis, individuals had to be free from disease for at least 3 months, excellent performance status, general good health</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Hypersensitivity to aspirin, lidocaine, NSAIDs, retinoids. Use of antibiotics, steroids, NSAIDs, aspirin, probenecid, antihistamines for &gt; 10 consecutive days, or any immunosuppressants, anticoagulants, dilantin, lithium, methotrexate, phenothiazines or drugs that could compromise test product safety during the 30 days immediately preceding the first treatment visit, debilitating oral conditions requiring extensive dental procedures or conditions interfering with compliance. Respiratory or cardiovascular problems</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>57 participants randomised: 19 females; age not reported; ethnic group: non-white participants: 6/57, white participants: 51/57; 48/56 (86%) smokers, 40/56 (71%) alcohol users. Percentage of dysplastic lesions not reported</P>
<P>Group A: randomised 38, 37 completed the study</P>
<P>Group B: randomised 19, 19 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 11:42:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> mouthwash with ketorolac 0.1%, twice a day, for 90 days</P>
<P>
<B>Group B: </B>mouthwash with placebo, twice a day, for 90 days</P>
<P>
<B>Compliance control: </B>yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 11:42:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Measurement of the lesion. (1) Complete response was defined as no clinical evidence of leukoplakia for at least 30 days from inception of treatment. (2) Partial response was defined as a greater than 50% reduction in the product of the longest diameters of a single lesion (in the sum of these figures for all lesions, in the setting of multiple lesions) for at least 30 days. (3) A response was classified as stable when the decrease in lesion size was less than 50%. (4) Disease progression was defined as an unequivocal increase in size greater than 10%, or as the appearance of a new lesion. Clinical evaluations were made at study entry, monthly during the intervention and 1 month after cessation of study drugs</P>
<P>
<B>Histological response</B>
</P>
<P>Histological grading was done before the start of treatment and upon its completion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 11:43:02 +0200" MODIFIED_BY="[Empty name]">
<P>Nine of the 56 participants who completed the study had an oropharyngeal leukoplakia (6 in Group A and 3 in Group B)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:42:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nagao-2015">
<CHAR_METHODS MODIFIED="2016-07-15 09:42:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group, 2 arms<BR/>
</P>
<P>
<B>Conducted in</B> Japan</P>
<P>
<B>Number of centres:</B> 3</P>
<P>
<B>Recruitment period:</B> not reported</P>
<P>
<B>Funding source:</B> supported by Butterfield Award of the Sasakawa Foundation GB and DSM Nutrition Japan</P>
<P>
<B>Study duration:</B> 1 year plus open follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:42:17 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Patients with leukoplakia who had never smoked or were ex-smokers</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Current smokers or ex-smokers within 3 months of cessation</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>46 participants randomised: 21 females; median age 65 (range 38 to 80 years); ethnic group: all Japanese; never smoked or ex-smokers; alcohol users not reported Percentage of dysplastic lesions not reported</P>
<P>Group A: randomised 23, 16 completed the study</P>
<P>Group B: randomised 23, 17 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:40:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>10 mg/d of beta carotene and 500 mg/d of vitamin C for 1 year</P>
<P>
<B>Group B: </B>50 mg/d of vitamin C for 1 year</P>
<P>
<B>Compliance control: </B>not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 09:41:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Cancer incidence</B>
</P>
<P>Study authors provided unpublished cancer incidence after a median follow-up of 86 months. Trial authors intended to exclude from the analysis any cases that progressed to oral cancer within 6 months of the start of the study, but there were no cancer cases within 6 months</P>
<P>
<B>Clinical response</B>
</P>
<P>Complete remission, partial remission, no change, disease progression</P>
<P>
<B>Histological response</B>
</P>
<P>Severity degree of epithelial dysplasia</P>
<P>p53 and Ki67 expression</P>
<P>Serum levels of antioxidant micronutrients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 09:42:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Follow-up since the end of treatment: </B>60 months for clinical response, 86 months for cancer incidence</P>
<P>2 participants in the experimental arm and 1 in the control arm did not receive allocated interventions. During intervention, 5 participants in the experimental arm and 5 in the control arm dropped out. Among these, 3 in the experimental arm and 4 in the control arm returned for follow-up at the close of the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 11:52:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Papadimitrakopoulou-2008">
<CHAR_METHODS MODIFIED="2016-07-14 20:09:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group, 3 arms</P>
<P>
<B>Conducted in </B>USA</P>
<P>
<B>Number of centres:</B> 8</P>
<P>
<B>Recruitment period:</B> November 2000 to January 2004</P>
<P>
<B>Funding source:</B> Pfizer (grant support)</P>
<P>
<B>Study duration:</B> 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 11:47:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Histologically confirmed early or advanced oral pre-malignant lesion; age &#8805; 18 years; Zubrod performance status 0 to 1; haemoglobin level above lower limit of normal, WBC count &gt; 3000/mm<SUP>3</SUP>, platelet count &gt; 125,000/mm<SUP>3</SUP>, total bilirubin, aspartate aminotransferase and alanine aminotransferase levels V1.5 upper limit of normal, serum creatinine V1.5 upper limit of normal; no anticipated need for treatment with oral or i.v. corticosteroids for more than 2 consecutive weeks over any 6-month period during the study; willingness to limit aspirin use to V100 mg/d and to abstain from chronic use of all other non-steroidal anti-inflammatory drugs and COX-2 inhibitors for the duration of the study</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Diagnosis of or treatment for oesophageal, gastric, pyloric channel or duodenal ulceration within 30 days before randomisation; history of head and neck cancer in the past 18 months or of another cancer in the past 3 years (patients with a history of non-melanoma skin cancer, cervical carcinoma in situ or chronic lymphocytic leukaemia stage 0 were not excluded); chronic or acute renal or hepatic disorder or significant bleeding disorder; history of or active inflammatory bowel syndrome or pancreatic disease; current use of fluconazole or lithium </P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Early oral pre-malignant lesion: atypical hyperplasia, atypical hyperkeratosis or mild dysplasia. Advanced oral pre-malignant lesion: moderate to severe dysplasia</P>
<P>50 participants randomised: 26 females; age range 34 to 84; ethnic group: 2/50 non-white participants, 48/50 white participants; 4/50 current smokers (8%), 27/50 current drinkers (54%), prior oral cancer history 10/50. Early/advanced oral pre-malignant lesion: Group A 15/2, Group B 14/1, Group C 16/2. Ten out of 32 (31%) participants in combined active arms vs 0 of 18 in the placebo arm had a history of squamous cell cancer of the oropharynx (9) or larynx (1). Percentage of participants with any degree of dysplasia not reported</P>
<P>Group A: randomised 17, 16 completed the study</P>
<P>Group B: randomised 15, 13 completed the study</P>
<P>Group C (placebo): randomised 18, 17 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 20:08:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>oral celecoxib 100 mg twice for 12 weeks</P>
<P>
<B>Group B: </B>oral celecoxib 200 mg twice for 12 weeks</P>
<P>
<B>Group C:</B> oral placebo twice daily for 12 weeks</P>
<P>Groups A and B were considered together in the present review</P>
<P>
<B>Compliance control:</B> Compliance was measured by telephone queries and remaining capsule counts at weeks 8 and 12</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:08:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Cancer incidence</B>
</P>
<P>Cancer development at 12 weeks</P>
<P>
<B>Clinical response</B>
</P>
<P>Clinical changes at 12 weeks: complete response (disappearance of all evidence of lesions), partial response (50% or greater decrease in the sum of products of diameters of all measured lesions); stable disease (any response that did not meet the criteria for the other categories), progressive disease (increase &#8805; 25% in size of lesions or appearance of new lesions or progression to invasive cancer)</P>
<P>
<B>Histological response</B>
</P>
<P>Histological changes at 12 weeks: (1) reversal of dysplasia, (2) improvement in degree of dysplasia</P>
<P>
<B>Adverse events</B> classified according to the National Cancer Institute Common Toxicity Criteria version 2.0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 11:52:04 +0200" MODIFIED_BY="[Empty name]">
<P>Follow-up from the end of treatment: 14 weeks</P>
<P>Quote: &#8220;After a protocol amendment in March 2003, only patients with early OPLs continued to be randomised as just described, whereas all patients with advanced OPLs received open-label oral celecoxib at 400 mg twice daily, based again on data of the familial adenomatous polyposis study showing significant efficacy of celecoxib only at 400 mg twice daily. Because this decision was made while the study was already accruing, the 400 mg twice daily open-label arm was included in an exploratory intent as an attempt to preserve the feasibility of the study while offering a possibly superior intervention for patients at higher cancer risk (i.e., advanced OPL). [&#8230;.] Shortly after opening the 400 mg twice daily arm for patients with developed OPLs, the first reports potentially linking use of selective COX-2 inhibitors with serious adverse cardiovascular events emerged, leading to early closure of this arm&#8221;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 20:08:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piattelli-1999">
<CHAR_METHODS MODIFIED="2016-07-14 20:08:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 2 arms<BR/>
</P>
<P>
<B>Conducted in </B>Italy</P>
<P>
<B>Number of centres: </B>1</P>
<P>
<B>Recruitment period:</B> unspecified</P>
<P>
<B>Funding source: </B>partially supported by the National Research Council (CNR) and by the Ministry of University, Research, Science and Technology (MURST), Rome, Italy</P>
<P>
<B>Study duration:</B> 4 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 20:08:20 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Histologically confirmed oral leukoplakia</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Women of childbearing age</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>10 participants randomised: 4 females, mean age 61 (range 40 to 71), ethnic group: Caucasian, 4 (40%) tobacco users. Mean duration of lesions: 5.8 years (range 0.5 to 20 years). Percentage of dysplastic lesions not reported</P>
<P>Group A: 5 randomised, 5 completed the study</P>
<P>Group B: 5 randomised, 4 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-17 18:49:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>3 times daily topical application of 0.1% isotretinoin (13-cis-retinoic acid - Roaccutane Roche) for 4 months</P>
<P>
<B>Group B:</B> 3 times daily topical application of placebo (gel only), for 4 months</P>
<P>
<B>Compliance control:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:08:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Measurement of the lesion: Photography was performed before the start of treatment and every month during treatment: Complete response was defined as complete disappearance of the lesion as assessed by visual inspection; partial response was defined as a 50% or greater reduction in the size of lesions</P>
<P>
<B>Histological response</B>
</P>
<P>Evaluation of bcl-2 immunostaining.</P>
<P>Laboratory studies (including serum cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase) were performed before the start of treatment and every month during treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-14 20:07:58 +0200" MODIFIED_BY="[Empty name]">
<P>At the end of the study period (4 months), participants who received placebo started 4-month treatment with active medication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-28 10:02:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sankaranarayan-1997">
<CHAR_METHODS MODIFIED="2016-07-28 10:02:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 3 arms</P>
<P>
<B>Conducted in</B> India</P>
<P>
<B>Number of centres:</B> 1</P>
<P>
<B>Recruitment period:</B> unspecified</P>
<P>
<B>Funding source:</B> unspecified</P>
<P>
<B>Study duration:</B> 2 years (1 year of treatment + 1 year of follow-up)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 20:07:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Not reported</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Not reported</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>Participant details were available only for those who completed the trial (131 participants: 47 female; mean age 50.7; 127 (97%) chewers, 41 (31%) smokers, 72 (55%) drinkers. Percentage of dysplastic lesions not reported</P>
<P>Group A : randomised 50, 42 completed the study</P>
<P>Group B : randomised 55, 46 completed the study</P>
<P>Group C: randomised 55, 43 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 20:07:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> capsules of vitamin A (300,000 IU/wk) for 1 year</P>
<P>
<B>Group B:</B> capsules of beta carotene (360 mg/wk) for 1 year</P>
<P>
<B>Group C:</B> capsules of placebo for 1 year</P>
<P>
<B>Compliance control:</B> yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:07:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Cancer incidence</B>
</P>
<P>
<B>Malignant transformation:</B> Biopsies were taken at baseline and during the study, whenever a malignant transformation was suspected. Malignant transformation was scored if malignancy was histologically established in the lesions during follow-up</P>
<P>
<B>Clinical response</B>
</P>
<P>Number, type and dimension of lesion(s) were recorded at baseline and at each review. (1) Complete response was defined as no clinical evidence of leukoplakia. (2) Partial response was defined as a greater than 50% reduction in the size of the single lesion or in the sum of sizes of multiple lesions. (3) Stable and progressive lesions were scored as no response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-14 20:07:14 +0200" MODIFIED_BY="[Empty name]">
<P>160 participants randomised, all with tobacco chewing habits and leukoplakia, belonging to the fisherman community of Trivandrum City, Kerala, India - a population with high incidence of leukoplakia and oral cancer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 20:06:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-2004">
<CHAR_METHODS MODIFIED="2016-07-14 20:06:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group, 3 arms</P>
<P>
<B>Conducted in</B> India</P>
<P>
<B>Number of centres:</B> unspecified</P>
<P>
<B>Recruitment period:</B> unspecified</P>
<P>
<B>Funding source:</B> supported by Jagsonpal Pharmaceuticals Ltd., New Delhi, India</P>
<P>
<B>Study duration:</B> 3 months plus 2 months of follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 20:06:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Not reported</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Not reported</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>Characteristics of 58 participants who completed the study: 14 females; age: 12 participants were between 10 and 30 years, 42 were between 31 and 60 years, 4 were between 61 and 80 years; ethnic group: not reported; smoking status: not reported; alcohol status: not reported. Percentage of dysplastic lesions: 59%</P>
<P>Group A: randomised 20, 20 completed the study</P>
<P>Group B: randomised 20, 20 completed the study</P>
<P>Group C: randomised 18, 18 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 20:05:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>capsules of lycopene at high dose (8 mg/d) divided into 2 daily doses for 3 months</P>
<P>
<B>Group B:</B> capsules of lycopene at low dose (4 mg/d) divided into 2 daily doses for 3 months</P>
<P>
<B>Group C:</B> capsules of placebo in 2 daily doses for 3 months</P>
<P>Groups A and B were considered together in the present review</P>
<P>
<B>Compliance control:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:05:53 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Clinical assessment was made at the third month of the study. (1) Complete response was defined as no clinical evidence of leukoplakia for at least 4 weeks. (2) Partial response was defined as a greater than 50% reduction in the product of the longest diameters of the lesion. (3) Stable response was defined to occur when the decrease in lesion size was &lt; 50%. (4) Disease progression was defined as an unequivocal increase in the size of any lesion during treatment, or as the appearance of a new lesion</P>
<P>
<B>Histological response</B>
</P>
<P>Histological grading was done before the start of treatment and upon its completion. For histological evaluation, 5 stages were taken as normal, atypical hyperplasia, mild dysplasia, moderate dysplasia and severe dysplasia. They were ranked as 0, 1, 2, 3 and 4, respectively, so that change could be quantified in terms of these ranks. For example, a case from stage moderate dysplasia comes to stage mild dysplasia post treatment; improvement was considered as 32¼ for 1 unit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-05 16:00:52 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 20:05:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stich-1988">
<CHAR_METHODS MODIFIED="2016-07-14 20:05:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 2 arms</P>
<P>
<B>Conducted in </B>India</P>
<P>
<B>Number of centres:</B> unspecified</P>
<P>
<B>Recruitment period:</B> unspecified</P>
<P>
<B>Funding source: </B>supported by a grant from National Cancer Institute of Canada</P>
<P>
<B>Study duration: </B>6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 20:05:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Betel quid chewers</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Not reported</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>WHO 1978</P>
<P>The 65 participants had tobacco chewing habits and leukoplakia, belonging to the fisherman community of Trivandrum City, Kerala, India - a population with high incidence of leukoplakia and oral cancer. 2% tobacco users, 37% alcohol users, 28% tobacco + alcohol users. Percentage of dysplastic lesions not reported</P>
<P>Group A: randomised 30, 21 completed the study</P>
<P>Group B: randomised 35, 33 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 20:05:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> systemic capsules of vitamin A (200,000 IU/wk) for 6 months</P>
<P>
<B>Group B:</B> systemic capsules of placebo for 6 months</P>
<P>
<B>Compliance control:</B> yes, capsules were administered twice weekly under strict supervision of a local nurse</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:05:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Leukoplakias were evaluated before the start of treatment and at the end of the study (6 months): (1) remission of leukoplakia, (2) no change, (3) development of new leukoplakia</P>
<P>
<B>Histological response</B>
</P>
<P>Biopsies were taken before the start of treatment and at the end of the study (6 months). Histological markers evaluated were (1) loss of polarity of basal cells, (2) lymphocytic infiltration, (3) nuclei with condensed chromatin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-14 20:05:22 +0200" MODIFIED_BY="[Empty name]">
<P>Questionnaires completed during the trial demonstrated that habits such as chewing, smoking and drinking did not change during the course of the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-28 10:02:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2009">
<CHAR_METHODS MODIFIED="2016-07-28 10:02:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group, 2 arms</P>
<P>
<B>Conducted in</B> China</P>
<P>
<B>Number of centres:</B> 1</P>
<P>
<B>Recruitment period:</B> 1998 to 2001</P>
<P>
<B>Funding source:</B> Beijing Natural Science Foundation, National Natural Science Foundation of China, Tenth 5-Year Plan of National Key Technologies R&amp;D Program in China (No. 2004BA720A28), NIH grants</P>
<P>
<B>Study duration: </B>8 to 12 months plus 3 months of follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 20:05:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Oral leukoplakia was defined as a white patch or plaque that cannot be characterised clinically or pathologically as any other disease. All participating patients had general good health without other uncontrolled medical conditions. Patients underwent a baseline biopsy to confirm the absence of invasive cancer </P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Those with a previous diagnosis of head and neck or oral cancer; those currently treated by other drugs or having drug hypersensitivity; those requiring extensive dental procedures; those with a history of social or psychiatric situations interfering with study compliance</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>Characteristics of the 112 participants who completed the study: 43 females; age: Group A 52.9 ± 10.4, Group B 44.4 ±11.8; ethnic group: not reported; smokers: 53/112 (47%); alcohol drinkers: 10/112 (9%). Percentage of participants with any dysplasia: 18.75% (11.61% mild dysplasia, 3.57% moderate dysplasia, 3.57% severe dysplasia)</P>
<P>Group A: randomised 60, 59 completed the study</P>
<P>Group B: randomised 60, 53 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 20:04:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> ZengShengPing - a mixture of 6 medical herbs (0.3 g per tablet) - 4 tablets each time, 3 times a day, for 8 to 12 months (not better specified: length of the study)</P>
<P>
<B>Group B: </B>placebo 4 tablets each time, 3 times a day, for 8 to 12 months (not better specified: length of the study)</P>
<P>
<B>Compliance control:</B> self report during monthly visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:04:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Measurement of the lesion: (1) positive response defined as disappearance or reduction in size by more than 50% at final checkup (3 months after cessation of treatment), (2) stable disease defined as insignificant change in the size of the lesion, (3) progressive disease defined as increase in size of the lesion by &gt; 50%, or development of new lesions</P>
<P>
<B>Histological evaluation</B>
</P>
<P>AgNOR and PCNA labelling index in tissues were evaluated in tissue samples before and after treatment. Histological assessment was available for pre-treatment samples only</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-03 01:34:27 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 20:06:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsao-2009">
<CHAR_METHODS MODIFIED="2016-07-14 20:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group, 4 arms</P>
<P>
<B>Conducted in </B>Texas (USA)</P>
<P>
<B>Number of centres:</B> 1</P>
<P>
<B>Recruitment period: </B>August 2002 to March 2008</P>
<P>
<B>Funding source: </B>supported by Ito En Ltd.</P>
<P>
<B>Study duration:</B> 12 weeks and open follow-up (median 27.5 months)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 20:04:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Presence of 1 or more histologically confirmed, bi-dimensionally measurable OPLs that could be sampled by biopsy and had at least 1 of the following high-risk features of malignant transformation: harbouring at least mild dysplasia, located in a high-risk area (i.e. floor of mouth, ventrolateral tongue, and soft palate), significant extent of OPL tissue involvement, and presence of symptoms (pain or substantial discomfort). Additional inclusion criteria included age between &#8805; 18 and &#8804; 75 years; Zubrod performance status &lt; 2; adequate haematological, liver and renal function; adequate cardiac function (defined as no clinically significant electrocardiogram abnormality, unstable atrial or ventricular arrhythmias requiring medical control or ischaemic event experienced within the prior 6 months); negative pregnancy test in females of childbearing potential within 7 days before first dose of study medication; use of effective contraceptive method while in the trial; written informed consent for participation</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Known hypersensitivity to oral green tea extract (GTE) or its analogous, use of prior investigational agents within 30 days, any serious intercurrent illness, history of prior malignancy with less than a 1-year disease-free interval before study entry, lactating females, patients who were not able to abstain from consumption of methylxanthine-containing products (including coffee, tea, chocolate, caffeinated soft drinks and theophylline) and decaffeinated tea</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>41 participants randomised: 22 females; mean age 57 (range 33 to 76); ethnic group: Caucasian 37/41, Hispanic 2/41, Asian 2/41; smoking status: never smoked 15/41, former smoker 22/41, current smoker 4/41; alcohol status: never 8/41, former 9/41, current 24/41. Mean duration of lesions: 5.8 years (range 0.5 to 20 years). Percentage of participants with any dysplasia: 73.2% (56.1% mild dysplasia, 17.1% moderate/carcinoma in situ). 34.1 % of participants had prior HNSCC, 12.2 % had prior radiotherapy (not specified whether head and neck radiotherapy), 90.2% had prior surgery (not specified which type of surgical therapy)</P>
<P>Group A: randomised 11, 11 completed the study</P>
<P>Group B: randomised 9, 8 completed the study</P>
<P>Group C: randomised 10, 9 completed the study</P>
<P>Group D: randomised 11, 11 completed the study</P>
<P>Groups A, B and C were considered together in the present review</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 20:06:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>GTE capsules (500 mg/m<SUP>2</SUP> daily), given orally thrice a day after meals for 12 weeks</P>
<P>
<B>Group B:</B> GTE capsules (750 mg/m<SUP>2</SUP> daily) given orally thrice a day after meals for 12 weeks</P>
<P>
<B>Group C:</B> GTE capsules (1000 mg/m<SUP>2</SUP> daily) given orally thrice a day after meals for 12 weeks</P>
<P>
<B>Group D: </B>placebo capsules given orally thrice a day after meals for 12 weeks</P>
<P>Each capsule contained 350 mg of GTE. GTE dosage calculations were based on participant's body surface area according to the following formula: body surface area (m<SUP>2</SUP>) = weight (kg) 0.425 × height (cm) 0.725 × 0.007184. Calculated dose was adjusted downward to the closest dose that could be administered by using 1 or more 350-mg capsules</P>
<P>Groups A, B and C were considered together in the present review</P>
<P>
<B>Compliance control:</B> yes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:03:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Cancer incidence</B>
</P>
<P>Cancer incidence was recorded during an open follow-up period</P>
<P>
<B>Clinical response</B>
</P>
<P>Bi-dimensional measurement of the lesion: (1) Disappearance of all lesions was considered a complete response. (2) 50% or greater decrease in the sum of products of diameters of all measured lesions was considered a partial response. (3) Increase of 25% or greater in size of lesions or appearance of new lesions or progression to invasive cancer was considered progressive disease. (4) Any response that did not meet criteria for CR, PR or PD was considered stable disease</P>
<P>
<B>Histological response</B>
</P>
<P>(1) Complete response was defined as a complete reversal of pre-malignancy to normal epithelium with no new lesions. (2) Partial response was defined as improvement in degree of maturation of epithelium with no new lesions and no progression of any lesion. (3) Stable disease was defined as no change in histology and no appearance of new lesions or progression of any lesion. (4) Progression of disease was defined as progression from hyperplasia and/or hyperkeratosis to dysplasia, or from a lower to a higher degree of dysplasia or invasive carcinoma, or appearance of any new lesions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-14 20:03:10 +0200" MODIFIED_BY="[Empty name]">
<P>Quote: "With a median follow-up time of 27.5 months, 15 patients subsequently developed oral cancer with a median time to oral cancer development of 46.4 months." It is not specified how they were distributed in the 3 arms, but (quote): "There was no difference in oral cancer&#8211;free survival between the GTE and placebo arms"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AgNOR = silver-stained nucleolar organizer region<BR/>CNR = National Research Council<BR/>COX = cyclo-oxygenase<BR/>CR = complete response<BR/>EGFR = epidermal growth factor receptor<BR/>FU = follow-up<BR/>HNSCC = head and neck squamous cell carcinoma<BR/>ITT = intention-to-treat<BR/>MURST = Ministry of University, Research, Science and Technology<BR/>NIH = National Institutes of Health<BR/>OIN = oral intraepithelial neoplasia<BR/>OPL = oral pre-malignant lesion<BR/>OSCC = oral squamous cell carcinoma<BR/>PCNA = proliferation cell nuclear antigen<BR/>PD = progressive disease<BR/>PR = partial response<BR/>RCT = randomised controlled trial<BR/>SCC = squamous cell carcinoma<BR/>WHO = World Health Organization</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-07-14 20:02:31 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-07-14 20:02:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bocharova-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 20:02:31 +0200" MODIFIED_BY="[Empty name]">
<P>The study was not randomised, and both arms of the study employed active treatments, i.e. no placebo (or no treatment) group was included in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 19:02:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boisnic-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 19:02:07 +0200" MODIFIED_BY="[Empty name]">
<P>The study included participants with traumatic lesions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 19:02:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chee-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 19:02:10 +0200" MODIFIED_BY="[Empty name]">
<P>Both arms of the study employed active treatments, i.e. no placebo (or no treatment) group was included in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 19:02:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiesa-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 19:02:04 +0200" MODIFIED_BY="[Empty name]">
<P>All participants underwent active treatment. The aim of the treatment tested was to prevent recurrence of leukoplakia; all participants were randomised after surgical removal (active treatment) of the oral lesion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 19:01:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Femiano-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 19:01:55 +0200" MODIFIED_BY="[Empty name]">
<P>The study was not randomised, and participants were allocated to study arms by researchers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-08 10:44:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaeta-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-08 10:44:43 +0200" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 16:45:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garewal-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 16:45:22 +0200" MODIFIED_BY="[Empty name]">
<P>Participants randomised were a selected group who responded to the drug tested in the randomised phase (beta carotene)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 16:45:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krishnaswamy-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 16:45:28 +0200" MODIFIED_BY="[Empty name]">
<P>The study used an inadequate method of allocation, and only 66% of participants had lesions, none with a histological diagnosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 16:45:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lippman-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 16:45:01 +0200" MODIFIED_BY="[Empty name]">
<P>Participants randomised were a selected group who responded to 1 of the 2 drugs tested during the randomised phase (isotretinoin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 16:45:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 16:45:31 +0200" MODIFIED_BY="[Empty name]">
<P>Both arms of the study employed active treatments, i.e. no placebo (or no treatment) group was included in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 16:45:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mathew-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 16:45:35 +0200" MODIFIED_BY="[Empty name]">
<P>The study was not randomised, as controls were taken from another study control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 16:45:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwarz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 16:45:43 +0200" MODIFIED_BY="[Empty name]">
<P>Both arms of the study employed active treatments, i.e. no placebo (or no treatment) group was included in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 16:45:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zaridze-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 16:45:46 +0200" MODIFIED_BY="[Empty name]">
<P>The oral lesions diagnosed as leukoplakia were not biopsied for histological examination. Data, as presented in the paper, do not allow analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-07-15 11:47:38 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-07-14 16:46:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Califano-2012">
<CHAR_METHODS MODIFIED="2014-08-05 14:56:10 +0200" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 16:45:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>(1) Presence of 3p, 9p21 or 17p LOH, and/or (2) surgically unresectable high-grade pre-malignant lesions and/or (3) high-grade pre-malignancy after curative therapy for HNSCC</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 16:46:22 +0200" MODIFIED_BY="[Empty name]">
<P>Participants received cetuximab 400 mg/m<SUP>2 </SUP>week 1 followed by 250 mg/m<SUP>2</SUP> weeks 2 to 8 or observation, with the option for cross-over to cetuximab for participants originally randomised to the observation arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 16:46:18 +0200" MODIFIED_BY="[Empty name]">
<P>Histological grade (1 = benign, 2 = mild dysplasia, 3 = moderate dysplasia, 4 = severe dysplasia/carcinoma in situ, 5 = invasive cancer) and change in grade of dysplasia were evaluated. Malignant transformation was evaluated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-05 14:56:10 +0200" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-15 11:47:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiba-2012">
<CHAR_METHODS MODIFIED="2016-07-14 16:53:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group, 2 arms</P>
<P>
<B>Conducted in </B>Sri Lanka</P>
<P>
<B>Number of centres:</B> 15</P>
<P>
<B>Recruitment period:</B> unspecified</P>
<P>
<B>Funding source:</B> unspecified</P>
<P>
<B>Study duration:</B> unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 11:47:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Betel quid chewers with pathological diagnosis of oral pre-cancer</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Lesion not measurable</P>
<P>
<B>Histological criteria for leukoplakia</B>
</P>
<P>Not reported</P>
<P>72 participants randomised: mean age 53.9, 90.2% male, ethnic 98.6% Sinhala. Percentage of dysplastic lesions not reported</P>
<P>Group A: unspecified</P>
<P>Group B: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-07 17:58:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> curcumin-coated chewing gum</P>
<P>
<B>Group B: </B>placebo chewing gum</P>
<P>
<B>Compliance control:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 19:02:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical response</B>
</P>
<P>Lesions were measured every 6 months. Participants were followed up every month by oral and maxillofacial surgeons at each hospital</P>
<P>
<B>Histological response</B>
</P>
<P>Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-07 17:58:44 +0200" MODIFIED_BY="[Empty name]">
<P>The only available report of this study is an abstract</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>HNSCC = head and neck squamous cell carcinoma<BR/>LOH = loss of heterozygosity<BR/>RCT = randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-07-15 11:48:55 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-07-14 19:02:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00004161">
<CHAR_STUDY_NAME MODIFIED="2013-05-28 14:52:17 +0200" MODIFIED_BY="[Empty name]">
<P>Fenretinide in treating patients with leukoplakia of the mouth</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 04:06:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 19:02:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria:</B> histologically proven dysplastic leukoplakia &gt; 1 cm in diameter, age 18 and older</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 19:02:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> oral fenretinide daily (except days 1 to 3 each month) for 6 months</P>
<P>
<B>Group B:</B> oral placebo daily (except days 1 to 3 each month) for 6 months, then oral fenretinide daily (except days 1 to 3 each month) for 6 months. Participants are followed up every 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 19:02:53 +0200" MODIFIED_BY="[Empty name]">
<P>Regression of oral dysplastic leukoplakia</P>
<P>Intermediate endpoint markers</P>
<P>Surrogate endpoint biomarkers</P>
<P>Recurrence rate of oral dysplastic leukoplakia after administration of fenretinide, both at the same site and at new sites</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-07-07 16:30:01 +0200" MODIFIED_BY="[Empty name]">
<P>February 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-24 12:24:54 +0200" MODIFIED_BY="[Empty name]">
<P>Samuel W. Beenken; University of Alabama at Birmingham</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 04:08:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status:</B> completed (the study has ended normally, and participants are no longer being examined or treated)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 19:03:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00014404">
<CHAR_STUDY_NAME MODIFIED="2015-07-08 12:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Celecoxib in treating patients with precancerous lesions of the mouth</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 19:03:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 19:03:08 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria:</B> histologically confirmed index oral pre-malignant lesion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 19:03:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> lower-dose oral celecoxib twice daily</P>
<P>
<B>Group B:</B> higher-dose oral celecoxib twice daily</P>
<P>
<B>Group C:</B> oral placebo twice daily</P>
<P>Treatment continues in all 3 arms for 12 weeks in the absence of disease progression or unacceptable toxicity. Participants are followed at 18, 24 and 26 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE MODIFIED="2016-07-07 16:30:07 +0200" MODIFIED_BY="[Empty name]">
<P>October 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-07-14 19:03:02 +0200" MODIFIED_BY="[Empty name]">
<P>Jay O Boyle, Study Chair; Memorial Sloan-Kettering Cancer Center</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 19:03:00 +0200" MODIFIED_BY="[Empty name]">
<P>This study is no longer recruiting participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 19:03:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00101335">
<CHAR_STUDY_NAME MODIFIED="2016-06-08 16:47:41 +0200" MODIFIED_BY="[Empty name]">
<P>Celecoxib in preventing head and neck cancer in patients with oral leukoplakia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 04:10:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> cross-over RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 04:10:17 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria:</B> diagnosis of oral leukoplakia with hyperplasia or dysplasia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 19:03:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>oral celecoxib twice daily for 3 months</P>
<P>
<B>Group B:</B> oral placebo twice daily for 3 months</P>
<P>All participants undergo biopsy. Participants then cross over to the opposite treatment arm for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 19:03:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary:</B> regression of oral leukoplakia lesions in participants with hyperplastic or dysplastic oral leukoplakia</P>
<P>
<B>Secondary:</B> multiple intermediate biomarkers (e.g. COX-2, PPAR&#947;, PPAR&#948;) in normal and hyperplastic or dysplastic oral epithelia of participants; safety; cost-effectiveness</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-28 12:27:42 +0200" MODIFIED_BY="[Empty name]">
<P>2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-07-14 04:13:24 +0200" MODIFIED_BY="[Empty name]">
<P>Paul F. Engstrom; Fox Chase Cancer Center</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 04:11:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status:</B> completed (the study has ended normally, and participants are no longer being examined or treated)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 19:03:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00155337">
<CHAR_STUDY_NAME MODIFIED="2013-07-23 15:20:50 +0200" MODIFIED_BY="[Empty name]">
<P>Photodynamic therapy for oral leukoplakia and erythroleukoplakia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 19:03:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 19:03:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria:</B> patients with leukoplakia or erythroleukoplakia, age 20 to 80 years<BR/>
<B>Exclusion criteria:</B> oral cancers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 04:13:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> photodynamic therapy</P>
<P>
<B>Group B:</B> unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-23 15:24:31 +0200" MODIFIED_BY="[Empty name]">
<P>Regression of lesions</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-23 15:24:35 +0200" MODIFIED_BY="[Empty name]">
<P>2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-23 15:25:04 +0200" MODIFIED_BY="[Empty name]">
<P>Chun-Pin Chiang; National Taiwan University Hospital</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 04:12:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status: </B>completed (the study has ended normally, and participants are no longer being examined or treated)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 17:00:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00176566">
<CHAR_STUDY_NAME MODIFIED="2016-07-14 04:13:52 +0200" MODIFIED_BY="[Empty name]">
<P>A phase II trial to assess the effects of green tea in oral leukoplakia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 17:00:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 17:00:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria:</B> patients with oral leukoplakia without evidence of active infection</P>
<P>
<B>Exclusion criteria:</B> allergy to caffeine, GI ulcers, pregnancy, previous invasive mouth cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 04:14:32 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> green tea lozenge</P>
<P>
<B>Group B: </B>placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 17:00:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes: </B>prevalence, size, histological severity of oral leukoplakia</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-28 15:15:13 +0200" MODIFIED_BY="[Empty name]">
<P>2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-07-14 17:00:07 +0200" MODIFIED_BY="[Empty name]">
<P>Susan Goodin, PharmD; University of Medicine and Dentistry New Jersey</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 04:14:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status:</B> terminated (the study has stopped recruiting or enrolling participants early and will not start again; participants are no longer being examined or treated)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 19:51:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00299195">
<CHAR_STUDY_NAME MODIFIED="2016-06-08 16:49:28 +0200" MODIFIED_BY="[Empty name]">
<P>A randomized study of sulindac in oral premalignant lesions</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 17:00:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 17:09:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria:</B> oral pre-malignant lesion (OPL) defined as a lesion that can include atypical hyperplasia, atypical hyperkeratosis, leukoplakia and erythroplakia/erythro-leukoplakia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 17:09:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drug:</B> sulindac 150 mg p.o. b.i.d. × 24 weeks</P>
<P>
<B>Drug:</B> placebo b.i.d. × 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 17:09:54 +0200" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy of sulindac in participants with early or advanced oral pre-malignant lesion (OPL) by both clinical response (reduction in size of all lesions) and histological response (change in histological grade)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-28 12:41:09 +0200" MODIFIED_BY="[Empty name]">
<P>2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-23 14:31:04 +0200" MODIFIED_BY="[Empty name]">
<P>Jay O. Boyle; Memorial Sloan-Kettering Cancer Center</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 19:51:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status: </B>This study is ongoing but is not recruiting participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 19:51:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00402779">
<CHAR_STUDY_NAME MODIFIED="2016-06-08 16:49:12 +0200" MODIFIED_BY="[Empty name]">
<P>Erlotinib prevention of oral cancer (EPOC)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 17:10:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>RCT, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 17:10:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Male or female patients with 1 of the following: (1) loss of heterozygosity (LOH) at 3p14 and/or 9p21 in the oral Intraepithelial neoplasia (IEN) of patients with a history of curatively treated oral cancer, or (2) LOH at 3p14 and/or 9p21 plus at 1 other chromosomal region in the IEN of participants with no oral cancer history; participants must have confirmed diagnosis of oral IEN lesion with LOH; age &#8805; 18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 04:18:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> erlotinib 150 mg for 1 year</P>
<P>
<B>Group B: </B>placebo for 1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 17:10:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome:</B> oral cancer-free survival</P>
<P>
<B>Secondary outcomes:</B> Size, number and appearance of oral IEN will be assessed and correlated with cancer risk; a panel of molecular markers will be used for correlation with oral cancer development in our participants with oral IEN</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-28 14:22:02 +0200" MODIFIED_BY="[Empty name]">
<P>2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-23 15:12:26 +0200" MODIFIED_BY="[Empty name]">
<P>Vassiliki Papadimitrakopoulou; M.D. Anderson Cancer Center</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 19:51:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status:</B> This study is ongoing but is not recruiting participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 19:51:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00951379">
<CHAR_STUDY_NAME MODIFIED="2016-07-14 04:20:11 +0200" MODIFIED_BY="[Empty name]">
<P>Pioglitazone for oral premalignant lesions</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-24 14:40:40 +0200" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 17:11:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>
<B>STAGE I:</B> males or females with suspected or histologically confirmed oral premalignant lesion(s)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 17:11:17 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A: </B>pioglitazone hydrochloride p.o. q.d. for 24 weeks</P>
<P>
<B>Group B:</B> placebo p.o. q.d. for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 19:51:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome measures</B>
<BR/>Clinical and histological response defined as 50% or greater reduction in the sum of measured products of perpendicular dimensions of target lesion(s), or improvement in the degree of dysplasia or hyperplasia<BR/>
<B>Secondary outcome measures</B>
<BR/>Tissue levels of PPAR gamma, cyclin D1 and p21 as indirect measures of pharmacological effect, TUNEL for apoptosis and Ki-67 for proliferation, transglutaminase and involucrin as markers of squamous differentiation, 15-PGDH and loss of heterozygosity. Level of C-reactive protein in plasma. Tobacco and alcohol use. Adverse events and clinical laboratory toxicity assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-24 14:50:21 +0200" MODIFIED_BY="[Empty name]">
<P>2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-07-14 17:11:51 +0200" MODIFIED_BY="[Empty name]">
<P>Jay Boyle; M.D. Anderson Cancer Center</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 19:51:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status:</B> This study is currently recruiting participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-14 20:02:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01497951">
<CHAR_STUDY_NAME MODIFIED="2016-06-08 16:50:02 +0200" MODIFIED_BY="[Empty name]">
<P>Photodynamic therapy for oral precursor lesions (PDT)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-14 17:11:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> RCT, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 20:02:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<P>Existing leukoplakia simplex SIN III (diagnostics by biopsy); leukoplakia verrucosa without indications of malignant changes (diagnostics by biopsy); oral lichen planus SIN III (diagnostics by biopsy)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 04:24:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B> aminolaevulinic acid</P>
<P>
<B>Group B:</B> placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 20:02:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome:</B> changes in per cent (%) of initial area in mm<SUP>2</SUP>
</P>
<P>
<B>Secondary outcomes:</B> pain due to treatment, assessed by visual analogue scale (VAS)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-28 14:13:12 +0200" MODIFIED_BY="[Empty name]">
<P>2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-23 15:08:04 +0200" MODIFIED_BY="[Empty name]">
<P>Georg Watzek; Medical University of Vienna</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-14 19:51:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Status:</B> This study is currently recruiting participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>COX = cyclo-oxygenase<BR/>CTCAE = Common Terminology Criteria for Adverse Events<BR/>EPOC = excess post-exercise oxygen consumption<BR/>IEN = intraepithelial neoplasia<BR/>Ki-67 = protein; cellular marker of neoplasia<BR/>NCI = National Cancer Institute<BR/>OPL = oral pre-malignant lesion<BR/>PDT = photodynamic therapy<BR/>PGDH = 15-hydroxyprostaglandin dehydrogenase<BR/>PPAR = peroxisome proliferator-activated receptor<BR/>RCT = randomised controlled trial<BR/>SIN = squamous intraepithelial neoplasia<BR/>TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labeling<BR/>VAS = visual analogue scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-07-15 11:43:36 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-15 11:43:36 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:25:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2013">
<DESCRIPTION>
<P>Quote: "Independent randomisation schedules were created for each performance centre (so study-arm assignment would not be confounded with geography). For those centres expected to accrue at a faster rate, the randomisation schedule incorporated a block size of 4. A block size of 2 was used for centres with lighter accrual goals"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-05 16:34:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomised to the drug or placebo arm by the department of Pharmacy, with the use of a table of random numbers&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:39:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-1986">
<DESCRIPTION>
<P>Quote: &#8220;the randomisation code was computer-generated&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:40:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Personal communication: random sequence based on random number table. Randomisation stratified for presence of dysplasia</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 02:39:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mallery-2014">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 02:44:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mulshine-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:09:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nagao-2015">
<DESCRIPTION>
<P>Quote: "random allocation was performed [...] with stratification by blocking randomisation according to presence or absence of dysplasia"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:43:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Papadimitrakopoulou-2008">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 03:00:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piattelli-1999">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:07:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sankaranarayan-1997">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:05:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:05:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stich-1988">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-12 15:58:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2009">
<DESCRIPTION>
<P>Quote: &#8220;randomly assigned to two groups&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-05 16:40:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsao-2009">
<DESCRIPTION>
<P>Quote: &#8220;The randomisation was done with the Pocock-Simon dynamic allocation scheme to balance three prognostic factors in each of the four arms. The prognostic factors were tobacco use (current, stopped, never), alcohol use (current, stopped, never), and tea use (zero to four 8-oz cups daily or five or more 8-oz cups daily)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-15 11:43:35 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-09 11:41:42 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Armstrong-2013">
<DESCRIPTION>
<P>Comment: block size 2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 02:17:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomised to the drug or placebo arm by the department of Pharmacy&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:39:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-1986">
<DESCRIPTION>
<P>Quote: &#8220;randomisation was performed by the pharmacy&#8221; and &#8220;The code for treatment assignment was broken after the patients had completed the full nine months of study&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 02:30:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 02:39:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mallery-2014">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 02:44:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mulshine-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:09:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nagao-2015">
<DESCRIPTION>
<P>Quote: "a trial coordinator not involved in the routine care of patients generated the allocation sequence and enrolled participants. The central randomisation by numbered containers was used for allocation concealment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:43:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Papadimitrakopoulou-2008">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 03:01:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piattelli-1999">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:07:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sankaranarayan-1997">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:05:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:05:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stich-1988">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 03:31:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:03:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsao-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-07-09 16:42:56 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-07-15 11:42:28 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-17 17:28:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2013">
<DESCRIPTION>
<P>Quote: "double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-09 16:35:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-15 11:39:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-1986">
<DESCRIPTION>
<P>Quote: &#8220;neither the patient nor the physician was aware of which treatment was assigned&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-15 11:40:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-15 11:42:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallery-2014">
<DESCRIPTION>
<P>Quote: "All participating oral pathologists, surgeons, and patients were blinded to the patients&#8217; gel assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-09 16:37:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mulshine-2004">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-06-08 18:57:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nagao-2015">
<DESCRIPTION>
<P>Quote: "double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-09 16:37:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Papadimitrakopoulou-2008">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-09 16:37:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piattelli-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 03:03:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sankaranarayan-1997">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221; and &#8220;subjects were examined every 2 months during visits by dentists and physician, both of whom were blinded to the treatment group&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 20:05:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 20:05:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stich-1988">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 03:31:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 20:03:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsao-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-07-15 11:42:31 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-17 17:28:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2013">
<DESCRIPTION>
<P>Quote: "double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-09 16:35:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-15 11:39:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-1986">
<DESCRIPTION>
<P>Quote: &#8220;neither the patient nor the physician was aware of which treatment was assigned&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-15 11:40:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-15 11:42:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallery-2014">
<DESCRIPTION>
<P>Quote: "All participating oral pathologists, surgeons, and patients were blinded to the patients&#8217; gel assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-09 16:37:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mulshine-2004">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-06-08 18:57:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nagao-2015">
<DESCRIPTION>
<P>Quote: "double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-09 16:37:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Papadimitrakopoulou-2008">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-09 16:37:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piattelli-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 03:03:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sankaranarayan-1997">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221; and &#8220;subjects were examined every 2 months during visits by dentists and physician, both of whom were blinded to the treatment group&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 20:05:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-2004">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 20:05:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stich-1988">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 03:31:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 20:03:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsao-2009">
<DESCRIPTION>
<P>Comment: insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-07-15 11:42:33 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-08 17:20:42 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Armstrong-2013">
<DESCRIPTION>
<P>Comment: high number of lost participants: 43/132 (32.5%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-01-26 16:23:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>No missing data with the exception of 1/12 (8.3%) histological outcome in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-15 11:39:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-1986">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups and not likely to have a clinically relevant impact on the intervention effect estimate: 4/44 (9%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-15 11:40:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups and not likely to have a clinically relevant impact on the intervention effect estimate: 5/64 (7.8%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-15 11:42:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallery-2014">
<DESCRIPTION>
<P>No missing data. All randomised participants included in analysis of results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-15 09:42:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mulshine-2004">
<DESCRIPTION>
<P>Missing outcome data are balanced in numbers across intervention groups and are not likely to have a clinically relevant impact on the intervention effect estimate 1/57 (1.7%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-07 16:28:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nagao-2015">
<DESCRIPTION>
<P>High number of drop-outs (stopping treatment) 13/46 (28.2%), although not lost to follow-up and included in ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 20:08:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Papadimitrakopoulou-2008">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups and not likely to have a clinically relevant impact on the intervention effect estimate 4/50 (8%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 20:07:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piattelli-1999">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups and not likey to have a clinically relevant impact on the intervention effect estimate 1/10 (10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 20:07:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sankaranarayan-1997">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups and not likely to have a clinically relevant impact on the intervention effect estimate 29/160 (16.9%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 20:05:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singh-2004">
<DESCRIPTION>
<P>No missing data. All randomised participants included in analysis of results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-17 18:52:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stich-1988">
<DESCRIPTION>
<P>Proportion of lost participants (11/65) with imbalance across intervention groups (30% vs 5.7%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 20:04:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sun-2009">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups and not likely to have a clinically relevant impact on the intervention effect estimate 8/120 (6.6%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 20:04:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsao-2009">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups and not likely to have a clinically relevant impact on the intervention effect estimate 2/41 (5%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-07-15 11:40:20 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-03 23:54:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2013">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-26 16:23:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:39:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-1986">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:40:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Comment: missing histological assessment of lesions at the end of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-07 16:27:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallery-2014">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 09:42:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mulshine-2004">
<DESCRIPTION>
<P>Comment: data on histological modifications reported only partially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:09:24 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nagao-2015">
<DESCRIPTION>
<P>Comment: data on histological outcomes not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 18:04:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Papadimitrakopoulou-2008">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 18:49:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piattelli-1999">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:06:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sankaranarayan-1997">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-31 13:49:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singh-2004">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:05:11 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stich-1988">
<DESCRIPTION>
<P>Histological data available for only 18 participants in the study group and for none in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:04:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sun-2009">
<DESCRIPTION>
<P>Comment: information about histological features of lesions not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-27 16:33:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsao-2009">
<DESCRIPTION>
<P>Comment: important outcomes and adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-07-15 11:42:37 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-04 14:31:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2013">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:38:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Some areas of concern: discrepancies between published and raw data; baseline imbalance in lesion size; cross-over to intervention of more than half of participants in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:39:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-1986">
<DESCRIPTION>
<P> Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:40:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P> Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 11:42:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallery-2014">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 09:42:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mulshine-2004">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 18:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nagao-2015">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 18:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Papadimitrakopoulou-2008">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 18:49:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piattelli-1999">
<DESCRIPTION>
<P> Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:06:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sankaranarayan-1997">
<DESCRIPTION>
<P> Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 20:06:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singh-2004">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 18:52:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stich-1988">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 03:31:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sun-2009">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-27 16:33:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsao-2009">
<DESCRIPTION>
<P>Comment: no other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-07-15 11:49:51 +0200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-07-14 19:55:24 +0200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-07-14 19:55:24 +0200" MODIFIED_BY="[Empty name]">Vitamin A or retinoids versus placebo for treating oral leukoplakia</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Systemic or topical vitamin A vs placebo for treating leukoplakia</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>people with oral leukoplakia<BR/>
<B>Intervention: </B>vitamin A or retinoids<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with vitamin A or retinoids</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Cancer development at 24 months from start of treatment (treatment lasted 12 months)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>93 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>10 per 1000<BR/>(1 to 191)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.11<BR/>(0.01 to 2.05)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>85<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>This study evaluated systemic treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical resolution (not completely resolved) at 4 to 12 months</P>
</TD>
<TD COLSPAN="6">
<P>Studies could not be combined in meta-analysis</P>
<P>One study evaluated topical treatment and did not find evidence of benefit</P>
<P>3 studies of systemic vitamin A - 2 showed benefit in terms of clinical resolution, and 1 did not</P>
</TD>
</TR>
<TR>
<TD>
<P>Histological changes (not improved) at 3 months</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>889 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>382 per 1000 (213 to 676)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.43 (0.24 to 0.76)</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>This study evaluated systemic treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Safety of the intervention at 4 to 12 months</P>
</TD>
<TD COLSPAN="6">
<P>3 studies (1 each evaluating topical acitretin, topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13-cis-retinoic acid (1 to 2 mg/kg/d) caused adverse effects of varying severity in 79% of participants</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI = confidence interval; RR = risk ratio; vs = versus; d = day</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect but may be substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>*</SUP>From event rate in control group<BR/>
<SUP>a</SUP>Downgraded 3 levels as single small study at unclear risk of bias with very imprecise result<BR/>
<SUP>b</SUP>Downgraded as single small study</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-07-14 19:56:48 +0200" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2016-07-14 19:55:15 +0200" MODIFIED_BY="[Empty name]">Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>people with oral leukoplakia<BR/>
<B>Intervention: </B>systemic beta carotene<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with beta carotene or carotenoids</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Cancer development at</P>
<P>24 months from start of treatment (treatment lasted 12 months)</P>
</TD>
<TD VALIGN="TOP">
<P>108 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>79 per 1000<BR/>(26 to 238)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.73<BR/>(0.24 to 2.20)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>132<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Clinical resolution (not completely resolved) at</P>
<P>5 to 12 months</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>The 3 studies could not be combined in meta-analysis. 2 found benefit for systemic beta carotene, and 1 did not</P>
</TD>
</TR>
<TR>
<TD>
<P>Histological changes (not improved)</P>
<P>at 5 months (treatment lasted 3 months)</P>
</TD>
<TD VALIGN="TOP">
<P>833 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>200 per 1000</P>
<P>(100 to 383)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.24 (0.12 to 0.46)</P>
</TD>
<TD VALIGN="TOP">
<P>58</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Safety of the intervention at 5 to 12 months</P>
</TD>
<TD COLSPAN="6">
<P>Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d, and caused adverse effects of varying severity in 9% of participants in another study supplementing 360 mg/wk</P>
<P>No adverse effects were reported by participants treated with systemic lycopene in one study</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI = confidence interval; RR = risk ratio; vs = versus; d = day; wk = week</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but may be substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>*</SUP> From event rate in control group<BR/>
<SUP>a</SUP>Downgraded 3 levels for unclear or high risk of bias and serious imprecision<BR/>
<SUP>b</SUP>Downgraded 2 levels as single small study at unclear risk of bias</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-07-15 11:49:45 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-07-14 19:57:14 +0200" MODIFIED_BY="[Empty name]">Non-steroidal anti-inflammatory drugs (NSAIDs) vs placebo for treating oral leukoplakia</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>NSAIDs vs placebo for treating oral leukoplakia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people with oral leukoplakia</P>
<P>
<B>Intervention: </B>NSAIDs</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH VALIGN="TOP">
<P>Risk with NSAIDs</P>
</TH>
</TR>
<TR>
<TD>
<P>Cancer development</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Clinical resolution (not completely resolved) at 3 months</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<BR/>
</P>
<P>1 study evaluated systemic treatment and 1 evaluated topical treatment. Neither found benefit for NSAIDs</P>
</TD>
</TR>
<TR>
<TD>
<P>Histological changes (not improved)</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Safety of the intervention</P>
<P>over 3 months</P>
<P/>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Systemic celecoxib (1 study) - 32 intervention participants reported 56 adverse effects and 20 placebo participants in the placebo group reported 20 adverse effects. Minor adverse events included dizziness, diarrheoa and abdominal pain. 4 participants (2 from the placebo group and 2 from an intervention group) had grade 3 adverse events. 2 participants permanently discontinued treatment owing to an adverse event (grade 2 vision abnormality and hypertension in a participant receiving 400 mg twice daily of celecoxib and a grade 3 ischaemic cerebrovascular accident in a participant receiving 200 mg twice daily of celecoxib)</P>
<P>Ketorolac oral rinse (1 study) caused adverse effects of varying severity in 29% of participants</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI = confidence interval; RR = risk ratio; vs = versus</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2016-07-15 11:49:51 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-07-14 19:58:20 +0200" MODIFIED_BY="[Empty name]">Herbal extracts vs placebo for treating oral leukoplakia</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Herbal extracts vs placebo for treating oral leukoplakia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people with oral leukoplakia</P>
<P>
<B>Intervention: </B>herbal extracts - tea components; a Chinese herbal mixture; curcumin chewing gum; freeze-dried black raspberry gel</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH VALIGN="TOP">
<P>Risk with herbal extracts</P>
</TH>
</TR>
<TR>
<TD>
<P>Cancer development</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Clinical resolution (not completely resolved) at 3 to 6 months</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>3 studies (1 of freeze-dried black raspberry gel, 1 of green tea extract capsules and 1 of mixed tea treatment) did not find evidence of benefit for the intervention</P>
</TD>
</TR>
<TR>
<TD>
<P>Histological changes (not improved) at 3 months</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>2 studies (1 of green tea extract capsules and 1 of freeze-dried raspberry gel) did not find evidence of benefit from these interventions</P>
</TD>
</TR>
<TR>
<TD>
<P>Safety of the intervention up to 3 months</P>
</TD>
<TD COLSPAN="6">
<P>3 studies measured adverse effects: green tea extract capsules caused high frequency (93%) of adverse effects of varying severity in 1 study; the mixed tea treatment study did not mention adverse effects; freeze-dried black raspberry gel did not cause any adverse effects</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI = confidence interval; RR = risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2016-07-14 20:01:49 +0200" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2016-07-14 20:01:45 +0200" MODIFIED_BY="[Empty name]">Topical bleomycin vs placebo for treating oral leukoplakia</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Topical bleomycin vs placebo for treating oral leukoplakia</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>people with oral leukoplakia<BR/>
<B>Intervention: </B>topical bleomycin<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with topical bleomycin</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Cancer development up to 7 years</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>83 per 1000</P>
<P/>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>250 per 1000</P>
<P>(27 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 3.00<BR/>(0.32 to 27.83)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>20<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Clinical resolution (not completely resolved)</P>
<P>at 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>917 per 1000</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>504 per 1000 (266 to 954)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.55 (0.29 to 1.04)</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>a</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Histological changes (not improved) at 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>818 per 1000</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>401 per 1000 (180 to 900)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.49 (0.22 to 1.10)</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>a</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Safety of the intervention up to 3 months</P>
</TD>
<TD COLSPAN="6">
<P>"All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was reported by 60% of the bleomycin group, but analgesics were not required. Taste of the topical application as well-tolerated. There was no observed systemic toxicity in the patient groups"</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI = confidence interval; RR = risk ratio; vs = versus</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but may be substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>*</SUP> From event rate in control group<BR/>
<SUP>a</SUP>Downgraded 3 levels as a single small study at unclear risk of bias with imprecise result<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2016-07-14 20:01:56 +0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2016-07-14 16:23:20 +0200" MODIFIED_BY="[Empty name]">Bowman-Birk inhibitor versus placebo for oral leukoplakia</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Bowman-Birk inhibitor vs placebo for treating oral leukoplakia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people with oral leukoplakia</P>
<P>
<B>Intervention: </B>Bowman-Birk inhibitor</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH VALIGN="TOP">
<P>Risk with Bowman-Birk inhibitor</P>
</TH>
</TR>
<TR>
<TD>
<P>Cancer development</P>
</TD>
<TD COLSPAN="6">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Clinical resolution (not completely resolved) at 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>957 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>957 per 1000</P>
<P>(871 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.00 (0.91 to 1.09)</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>a</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Histological changes (not improved) at 6 months</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD>
<P>Safety of the intervention up to 6 months</P>
</TD>
<TD COLSPAN="6">
<P>Trial authors reported that there were no significant adverse effects. 33 participants in the intervention group reported 75 adverse effects. 25 participants in the placebo group reported 63 adverse effects</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>CI = confidence interval; RR = risk ratio; vs = versus</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>*</SUP> From event rate in control group<BR/>
<SUP>a</SUP>Downgraded 2 levels as a single small study at high risk of bias</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-07-15 12:42:48 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-07-08 12:55:26 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-01-26 15:37:52 +0100" MODIFIED_BY="[Empty name]">Participants with dysplastic leukoplakia</TITLE>
<TABLE COLS="2" ROWS="15">
<TR>
<TH>
<P>
<B>Study</B>
</P>
</TH>
<TH>
<P>
<B>Participants with dysplastic leukoplakia (any grade)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>
</P>
</TD>
<TD>
<P>22%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>
</P>
</TD>
<TD>
<P>27%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>
</P>
</TD>
<TD>
<P>20%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>
</P>
</TD>
<TD>
<P>72.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>
</P>
</TD>
<TD>
<P>59%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>
</P>
</TD>
<TD>
<P>18.75%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>
</P>
</TD>
<TD>
<P>73.2%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-07-15 12:42:48 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-01-26 14:20:17 +0100" MODIFIED_BY="[Empty name]">Participants reporting adverse effects</TITLE>
<TABLE COLS="5" ROWS="16">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Arms</P>
</TH>
<TH>
<P>Active treatment</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Adverse effects</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>
</P>
</TD>
<TD>
<P>Bowman Birk inhibitor concentrate vs placebo</P>
</TD>
<TD>
<P>75 reported from 33 of 67 participants</P>
</TD>
<TD>
<P>63 reported from 25 of 65 participants</P>
</TD>
<TD>
<P>Minor adverse effects</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>
</P>
</TD>
<TD>
<P>Topical bleomycin vs placebo</P>
</TD>
<TD>
<P>10/10</P>
</TD>
<TD>
<P>0/12</P>
</TD>
<TD>
<P>Bleomycin group - erythema and erosion (100%), discomfort (60%)</P>
<P>Placebo group - erythema only</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>
</P>
</TD>
<TD>
<P>Systemic 13-cis-retinoic acid (from 1 to 2 mg/kg per day) vs placebo</P>
</TD>
<TD>
<P>19/24</P>
</TD>
<TD>
<P>4/20</P>
</TD>
<TD>
<P>Cheilitis, facial erythema, dryness and peeling of skin, conjunctivitis, hypertriglyceridaemia</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>
</P>
</TD>
<TD>
<P>Systemic and topical tea vs placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Not measured or reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>
</P>
</TD>
<TD>
<P>Freeze-dried black raspberry gel vs placebo gel</P>
</TD>
<TD>
<P>0/22</P>
</TD>
<TD>
<P>0/18</P>
</TD>
<TD>
<P>"No participant experienced any treatment-associated complications"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>
</P>
</TD>
<TD>
<P>Ketorolac oral rinse vs placebo</P>
</TD>
<TD>
<P>11/38</P>
</TD>
<TD>
<P>3/19</P>
</TD>
<TD>
<P>Pain, toxicity grade 1 and 2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>
</P>
</TD>
<TD>
<P>Beta carotene and vitamin C vs placebo</P>
</TD>
<TD>
<P>0/23</P>
</TD>
<TD>
<P>0/23</P>
</TD>
<TD>
<P>No untoward side effects were noted</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>
</P>
</TD>
<TD>
<P>Celecoxib vs placebo</P>
</TD>
<TD>
<P>56 reported from 32 participants</P>
</TD>
<TD>
<P>20 reported from 18 participants</P>
</TD>
<TD>
<P>4 participants presented grade 3 adverse events: 2 in placebo arm and 2 in active treatment arm. 2 participants from intervention groups discontinued treatment owing to adverse effects (1 grade 2 and 1 grade 3).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>
</P>
</TD>
<TD>
<P>Topical 13-cis-retinoic acid vs placebo</P>
</TD>
<TD>
<P>0/5</P>
</TD>
<TD>
<P>0/5</P>
</TD>
<TD>
<P>"No side effects from the use of the gel<BR/>were ever observed"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>
</P>
</TD>
<TD>
<P>Vitamin A (300,000 IU per week) vs placebo</P>
</TD>
<TD>
<P>13/50</P>
</TD>
<TD>
<P>1/55</P>
</TD>
<TD>
<P>Headache, muscular pain, dry mouth</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>
</P>
</TD>
<TD>
<P>Beta carotene (360 mg per week) vs placebo</P>
</TD>
<TD>
<P>5/55</P>
</TD>
<TD>
<P>1/55</P>
</TD>
<TD>
<P>Headache, muscular pain</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>
</P>
</TD>
<TD>
<P>Lycopene (8 mg or 4 mg) vs placebo</P>
</TD>
<TD>
<P>0/40</P>
</TD>
<TD>
<P>0/18</P>
</TD>
<TD>
<P>"No side effects, toxicity of any sort were encountered in the complete duration of the therapy"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>
</P>
</TD>
<TD>
<P>Vitamin A (200,000 IU per week) vs placebo</P>
</TD>
<TD>
<P>0/30</P>
</TD>
<TD>
<P>0/35</P>
</TD>
<TD>
<P>"The administered doses of vitamin A did not produce any detectable adverse<BR/>effects during the trial period"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>
</P>
</TD>
<TD>
<P>Chinese herbal mixture vs placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Not measured or reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tsao-2009" TYPE="STUDY">Tsao 2009</LINK>
</P>
</TD>
<TD>
<P>Green tea extract at different doses (500, 750 or 1000 mg/m<SUP>2</SUP> daily) vs placebo</P>
</TD>
<TD>
<P>28/30</P>
</TD>
<TD>
<P>8/11</P>
</TD>
<TD>
<P>Grade 1 to 2 adverse events including insomnia, headache, nausea and nervousness</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>vs = versus</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-07-14 20:01:16 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-07-05 11:02:08 +0200" MODIFIED_BY="[Empty name]">Participants leaving the studies</TITLE>
<TABLE COLS="4" ROWS="15">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Arms</P>
</TH>
<TH>
<P>Active treatment</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Armstrong-2013" TYPE="STUDY">Armstrong 2013</LINK>
</P>
</TD>
<TD>
<P>Bowman Birk inhibitor concentrate vs placebo</P>
</TD>
<TD>
<P>24/67</P>
</TD>
<TD>
<P>19/65</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>
</P>
</TD>
<TD>
<P>Topical bleomycin vs placebo</P>
</TD>
<TD>
<P>0/10</P>
</TD>
<TD>
<P>1/12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hong-1986" TYPE="STUDY">Hong 1986</LINK>
</P>
</TD>
<TD>
<P>Systemic 13-cis-retinoic acid (from 1 to 2 mg/kg per day) vs placebo</P>
</TD>
<TD>
<P>2/24</P>
</TD>
<TD>
<P>2/20</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>
</P>
</TD>
<TD>
<P>Systemic and topical tea vs placebo</P>
</TD>
<TD>
<P>3/32</P>
</TD>
<TD>
<P>2/32</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mallery-2014" TYPE="STUDY">Mallery 2014</LINK>
</P>
</TD>
<TD>
<P>Freeze-dried black raspberry gel vs placebo gel</P>
</TD>
<TD>
<P>0/22</P>
</TD>
<TD>
<P>0/18</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mulshine-2004" TYPE="STUDY">Mulshine 2004</LINK>
</P>
</TD>
<TD>
<P>Ketorolac oral rinse vs placebo</P>
</TD>
<TD>
<P>1/38</P>
</TD>
<TD>
<P>0/19</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nagao-2015" TYPE="STUDY">Nagao 2015</LINK>
</P>
</TD>
<TD>
<P>Beta carotene and vitamin C vs placebo</P>
</TD>
<TD>
<P>5/23</P>
</TD>
<TD>
<P>5/23</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Papadimitrakopoulou-2008" TYPE="STUDY">Papadimitrakopoulou 2008</LINK>
</P>
</TD>
<TD>
<P>Celecoxib vs placebo</P>
</TD>
<TD>
<P>3/32</P>
</TD>
<TD>
<P>1/18</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Piattelli-1999" TYPE="STUDY">Piattelli 1999</LINK>
</P>
</TD>
<TD>
<P>Topical 13-cis-retinoic acid vs placebo</P>
</TD>
<TD>
<P>0/5</P>
</TD>
<TD>
<P>1/5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>
</P>
</TD>
<TD>
<P>Vitamin A (300,000 IU per week) vs placebo</P>
</TD>
<TD>
<P>8/50</P>
</TD>
<TD>
<P>12/55</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sankaranarayan-1997" TYPE="STUDY">Sankaranarayan 1997</LINK>
</P>
</TD>
<TD>
<P>Beta carotene (360 mg per week) vs placebo</P>
</TD>
<TD>
<P>9/55</P>
</TD>
<TD>
<P>12/55</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Singh-2004" TYPE="STUDY">Singh 2004</LINK>
</P>
</TD>
<TD>
<P>Lycopene (8 mg or 4 mg) vs placebo</P>
</TD>
<TD>
<P>0/40</P>
</TD>
<TD>
<P>0/18</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stich-1988" TYPE="STUDY">Stich 1988</LINK>
</P>
</TD>
<TD>
<P>Vitamin A (200,000 IU per week) vs placebo</P>
</TD>
<TD>
<P>9/30</P>
</TD>
<TD>
<P>2/35</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>
</P>
</TD>
<TD>
<P>Chinese herbal mixture vs placebo</P>
</TD>
<TD>
<P>1/60</P>
</TD>
<TD>
<P>7/60</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>vs = versus</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-07-24 22:24:55 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-07-24 22:24:32 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Vitamin A or retinoids versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:23:06 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="341.21" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Oral cancer development</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 18:43:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="2.0485245813473267" CI_START="0.006310187198970968" EFFECT_SIZE="0.11369509043927649" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.311441179653306" LOG_CI_START="-2.199957756718754" LOG_EFFECT_SIZE="-0.944258288532724" MODIFIED="2013-09-12 16:51:57 +0200" MODIFIED_BY="[Empty name]" ORDER="4821" O_E="0.0" SE="1.4752081668501775" STUDY_ID="STD-Sankaranarayan-1997" TOTAL_1="42" TOTAL_2="43" VAR="2.176239135541461" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="53" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:22:29 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.42" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="90" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Clinical resolution</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="90" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 18:46:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="85" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="0.7268810798538866" CI_START="0.26872680450865954" EFFECT_SIZE="0.4419642857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="32" LOG_CI_END="-0.13853663534147334" LOG_CI_START="-0.5706890121317525" LOG_EFFECT_SIZE="-0.3546128237366129" MODIFIED="2013-09-12 16:27:39 +0200" MODIFIED_BY="[Empty name]" ORDER="4829" O_E="0.0" SE="0.2538484453153755" STUDY_ID="STD-Stich-1988" TOTAL_1="21" TOTAL_2="33" VAR="0.06443903318903318" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7103234465171768" CI_START="0.3689114959468457" EFFECT_SIZE="0.5119047619047619" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="40" LOG_CI_END="-0.14854384980074295" LOG_CI_START="-0.43307781116384736" LOG_EFFECT_SIZE="-0.29081083048229517" MODIFIED="2013-09-12 16:54:00 +0200" MODIFIED_BY="[Empty name]" ORDER="4828" O_E="0.0" SE="0.16713665737051173" STUDY_ID="STD-Sankaranarayan-1997" TOTAL_1="42" TOTAL_2="43" VAR="0.02793466223698783" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0750039692673476" CI_START="0.7794813476959127" EFFECT_SIZE="0.9153936545240893" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.031410067812297444" LOG_CI_START="-0.10819427263634433" LOG_EFFECT_SIZE="-0.038392102412023434" MODIFIED="2015-06-03 13:09:26 +0200" MODIFIED_BY="[Empty name]" ORDER="4826" O_E="0.0" SE="0.08200428063216257" STUDY_ID="STD-Hong-1986" TOTAL_1="22" TOTAL_2="18" VAR="0.006724702041998473" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-02 21:45:30 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Topical treatment</NAME>
<DICH_DATA CI_END="1.439486255584769" CI_START="0.48242519978930765" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.15820752252970433" LOG_CI_START="-0.31657001462495393" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2016-01-19 18:48:06 +0100" MODIFIED_BY="[Empty name]" ORDER="4827" O_E="0.0" SE="0.27888667551135854" STUDY_ID="STD-Piattelli-1999" TOTAL_1="5" TOTAL_2="4" VAR="0.07777777777777778" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:24:32 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Improvement of histological features</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="16" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 18:48:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="0.7571853990127514" CI_START="0.24257397148338558" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.12079776923192122" LOG_CI_START="-0.6151558013572676" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2013-09-12 16:40:34 +0200" MODIFIED_BY="[Empty name]" ORDER="4834" O_E="0.0" SE="0.290388355182154" STUDY_ID="STD-Hong-1986" TOTAL_1="21" TOTAL_2="18" VAR="0.08432539682539683" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-07-24 22:24:38 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Beta carotene or carotenoids versus placebo</NAME>
<DICH_OUTCOME CHI2="0.5122713808915279" CI_END="2.091473013891273" CI_START="0.23969776164535803" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7080405355425697" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.32045226528589676" LOG_CI_START="-0.6203360214924555" LOG_EFFECT_SIZE="-0.14994187810327936" METHOD="MH" MODIFIED="2016-07-24 22:23:13 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4741573035847184" P_Q="1.0" P_Z="0.5321324480473162" Q="0.0" RANDOM="NO" SCALE="538.86" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="67" TOTAL_2="65" WEIGHT="100.0" Z="0.6247541237212707">
<NAME>Oral cancer development</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5122713808915279" CI_END="2.091473013891273" CI_START="0.23969776164535803" DF="1" EFFECT_SIZE="0.7080405355425697" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.32045226528589676" LOG_CI_START="-0.6203360214924555" LOG_EFFECT_SIZE="-0.14994187810327936" MODIFIED="2016-01-26 13:36:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4741573035847184" P_Z="0.5321324480473162" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="65" WEIGHT="100.0" Z="0.6247541237212707">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="2.423195322074764" CI_START="0.09015147453855232" EFFECT_SIZE="0.4673913043478261" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3843884219296699" LOG_CI_START="-1.0450271654616075" LOG_EFFECT_SIZE="-0.3303193717659687" MODIFIED="2016-01-19 18:44:51 +0100" MODIFIED_BY="[Empty name]" ORDER="4822" O_E="0.0" SE="0.8396457917549096" STUDY_ID="STD-Sankaranarayan-1997" TOTAL_1="46" TOTAL_2="43" VAR="0.705005055611729" WEIGHT="58.5250388342333"/>
<DICH_DATA CI_END="4.622413266599331" CI_START="0.2374313168544676" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.664868770952747" LOG_CI_START="-0.624461998776173" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2016-01-19 18:44:51 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.75735927642901" STUDY_ID="STD-Nagao-2015" TOTAL_1="21" TOTAL_2="22" VAR="0.5735930735930737" WEIGHT="41.47496116576669"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:23:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.42" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="107" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Clinical resolution</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="80" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-26 13:36:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="107" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="1.0830347390472816" CI_START="0.8377426170987173" EFFECT_SIZE="0.9525252525252526" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.0346423871281607" LOG_CI_START="-0.07688939084860377" LOG_EFFECT_SIZE="-0.02112350186022153" MODIFIED="2016-01-19 18:46:12 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.06551431847475647" STUDY_ID="STD-Nagao-2015" TOTAL_1="21" TOTAL_2="22" VAR="0.004292125925211818" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9000642477862885" CI_START="0.5831108758971356" EFFECT_SIZE="0.7244565217391304" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="40" LOG_CI_END="-0.04572648893492122" LOG_CI_START="-0.2342488582564333" LOG_EFFECT_SIZE="-0.13998767359567726" MODIFIED="2016-01-19 18:46:12 +0100" MODIFIED_BY="[Empty name]" ORDER="4830" O_E="0.0" SE="0.11073897294023478" STUDY_ID="STD-Sankaranarayan-1997" TOTAL_1="46" TOTAL_2="43" VAR="0.012263120127858053" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7974130611906556" CI_START="0.4723292657405217" EFFECT_SIZE="0.6137112722478576" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="-0.09831665510882237" LOG_CI_START="-0.3257551445019533" LOG_EFFECT_SIZE="-0.21203589980538787" MODIFIED="2016-01-19 18:46:12 +0100" MODIFIED_BY="[Empty name]" ORDER="4831" O_E="0.0" SE="0.1335984945082049" STUDY_ID="STD-Singh-2004" TOTAL_1="40" TOTAL_2="18" VAR="0.017848557734858855" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:24:38 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Improvement of histological features</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="15" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-26 13:36:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="0.4612592509999239" CI_START="0.12487554423056872" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="-0.3360549105501087" LOG_CI_START="-0.9035226060266793" LOG_EFFECT_SIZE="-0.619788758288394" MODIFIED="2016-01-19 18:48:35 +0100" MODIFIED_BY="[Empty name]" ORDER="4835" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Singh-2004" TOTAL_1="40" TOTAL_2="18" VAR="0.1111111111111111" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-07-24 22:23:47 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>NSAIDs versus placebo</NAME>
<DICH_OUTCOME CHI2="2.1624300091989716E-4" CI_END="1.0439443062631724" CI_START="0.8502268464738585" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9421196714900273" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.01867732996149007" LOG_CI_START="-0.07046518601747429" LOG_EFFECT_SIZE="-0.025893928027992116" METHOD="MH" MODIFIED="2016-07-24 22:23:47 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9882673682975966" P_Q="0.9884731185622444" P_Z="0.2548482156139813" Q="2.0872465285783434E-4" RANDOM="NO" SCALE="4.42" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="36" WEIGHT="200.0" Z="1.138652320854685">
<NAME>Clinical resolution</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0771782084935684" CI_START="0.8252855329110036" DF="0" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.032287558973855046" LOG_CI_START="-0.08339576791863135" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2016-01-26 13:13:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.38654474621573853" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="17" WEIGHT="100.0" Z="0.8659004848572995">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="1.0771782084935684" CI_START="0.8252855329110035" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" LOG_CI_END="0.032287558973855046" LOG_CI_START="-0.0833957679186314" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2016-01-19 18:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.06795295885835012" STUDY_ID="STD-Papadimitrakopoulou-2008" TOTAL_1="29" TOTAL_2="17" VAR="0.0046176046176046245" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0985425406352411" CI_START="0.8068071602860477" DF="0" EFFECT_SIZE="0.9414414414414415" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.04081687946810444" LOG_CI_START="-0.09323025614727366" LOG_EFFECT_SIZE="-0.026206688339584606" MODIFIED="2016-01-26 13:13:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4434622759741831" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="19" WEIGHT="100.0" Z="0.7663597594062883">
<NAME>Topical treatment</NAME>
<DICH_DATA CI_END="1.0985425406352411" CI_START="0.8068071602860478" EFFECT_SIZE="0.9414414414414415" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" LOG_CI_END="0.04081687946810444" LOG_CI_START="-0.0932302561472736" LOG_EFFECT_SIZE="-0.026206688339584606" MODIFIED="2016-01-19 18:58:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4832" O_E="0.0" SE="0.07873995100449586" STUDY_ID="STD-Mulshine-2004" TOTAL_1="37" TOTAL_2="19" VAR="0.00619997988419041" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-07-24 22:24:46 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Herbal extracts versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="58" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:23:55 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="420.34" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="79" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Clinical resolution</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="11" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 19:04:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="1.144374648096298" CI_START="0.8555944822913134" EFFECT_SIZE="0.9895052473763118" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.05856822809701411" LOG_CI_START="-0.06773202484637474" LOG_EFFECT_SIZE="-0.004581898374680291" MODIFIED="2016-01-19 19:00:37 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.07418939377528172" STUDY_ID="STD-Tsao-2009" TOTAL_1="28" TOTAL_2="11" VAR="0.005504066148743811" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 19:04:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Topical treatment</NAME>
<DICH_DATA CI_END="80.90923049331938" CI_START="0.2108596434468923" EFFECT_SIZE="4.130434782608695" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.907998070730156" LOG_CI_START="-0.6760065321876462" LOG_EFFECT_SIZE="0.6159957692712549" MODIFIED="2016-01-19 19:01:31 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="1.5178570947829924" STUDY_ID="STD-Mallery-2014" TOTAL_1="22" TOTAL_2="18" VAR="2.303890160183066" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="30" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 19:04:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Systemic plus topical treatment</NAME>
<DICH_DATA CI_END="1.066967993133507" CI_START="0.9372352370788245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.02815139167002681" LOG_CI_START="-0.028151391670026803" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-01-19 19:04:14 +0100" MODIFIED_BY="[Empty name]" ORDER="4824" O_E="0.0" SE="0.03307253363721986" STUDY_ID="STD-Li-1999" TOTAL_1="29" TOTAL_2="30" VAR="0.0010937924811850394" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:24:46 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="50" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Improvement of histological features</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="10" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-19 19:03:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Systemic treatment</NAME>
<DICH_DATA CI_END="1.1310060251586853" CI_START="0.6604649129199479" EFFECT_SIZE="0.8642857142857143" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" LOG_CI_END="0.05346491852952224" LOG_CI_START="-0.18015024925309803" LOG_EFFECT_SIZE="-0.06334266536178793" MODIFIED="2016-01-19 19:02:20 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.13722670596924208" STUDY_ID="STD-Tsao-2009" TOTAL_1="28" TOTAL_2="11" VAR="0.018831168831168824" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-01-26 13:36:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Topical treatment</NAME>
<DICH_DATA CI_END="1.604854959796577" CI_START="0.5825929086873732" EFFECT_SIZE="0.9669421487603306" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.20543578876188093" LOG_CI_START="-0.23463480590245778" LOG_EFFECT_SIZE="-0.014599508570288439" MODIFIED="2016-01-19 19:03:12 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.2584996456904087" STUDY_ID="STD-Mallery-2014" TOTAL_1="22" TOTAL_2="18" VAR="0.06682206682206683" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-07-24 22:24:55 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Topical bleomycin versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:24:19 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="938.74" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Oral cancer development</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.830736341144103" CI_START="0.32338346674265595" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.444524696979576" LOG_CI_START="-0.49028218754025105" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2016-06-08 12:01:32 +0200" MODIFIED_BY="[Empty name]" ORDER="4820" O_E="0.0" SE="1.136515141415488" STUDY_ID="STD-Epstein-1994" TOTAL_1="8" TOTAL_2="12" VAR="1.2916666666666667" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:24:03 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="239.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Clinical resolution</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0373898061936877" CI_START="0.28679736332542644" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.015941976127604517" LOG_CI_START="-0.5424248456767674" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2016-01-19 19:06:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4823" O_E="0.0" SE="0.3279874350882325" STUDY_ID="STD-Epstein-1994" TOTAL_1="10" TOTAL_2="12" VAR="0.10757575757575756" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:24:55 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Improvement of histological features</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0974330225389408" CI_START="0.217792193938224" EFFECT_SIZE="0.4888888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.04037802428603573" LOG_CI_START="-0.6619576901923107" LOG_EFFECT_SIZE="-0.31078983295313745" MODIFIED="2016-01-19 19:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4833" O_E="0.0" SE="0.4125554753024375" STUDY_ID="STD-Epstein-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.17020202020202016" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2016-07-24 22:24:09 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Bowman-Birk inhibitor versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-24 22:24:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Clinical resolution</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0910297369328275" CI_START="0.9107612088453934" EFFECT_SIZE="0.9968287526427061" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="44" LOG_CI_END="0.03783658781092221" LOG_CI_START="-0.04059547513985098" LOG_EFFECT_SIZE="-0.0013794436644644047" MODIFIED="2016-01-19 19:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.0460713820222573" STUDY_ID="STD-Armstrong-2013" TOTAL_1="43" TOTAL_2="46" VAR="0.0021225722414407733" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-07-24 22:23:38 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-07-15 11:51:26 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYAAAAL5CAIAAAA2YGR8AAAuoElEQVR42u3dv04dSfrG8SMhIQcO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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-07-15 11:51:24 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAc0klEQVR42u1da3Ab13U+fOwLgEjskqxFqdWYopp2Rv2ROpViyaJr
g1EStUmcZJqZjOO8PFO5idNkOsk0qTvjOv1RO07s1vU4SWXPKH6lzdjjqZ2HZUuCY0PKg+qo02mU
ZhxSVOWIoCtyl5QILoAFwd7XvvAgQRCAQPl8egB77zn3nl18uPfuYr89AAhE09ABOh4ERJNgdeIx
QDQPSC8E0guB9EIgkF4IpBcC6YVAIL0QVwzdeAgaCwsPQeBKPdJrg88HbTj9FHByRODaC4H0QiCQ
XgikFwLptWFgttwR0SR6JQjkSLpi1ZXat61V+tZjq0RYxTFR2XrZQBo1ffRKJpPT0nBb7dseElWl
scn+3/oc3T0t2S7YONq1YnI0JgsAA5qskK9zIq7K5GUsotBLuE5Ujjq0UJEP26qUYua2pKgpWifF
HGqp6gk+NJB/ZkSJmsxBsUmdSpsUZcBajRMjJ8Zb7T0g2147iV5VxJBgf2g5t3L7fcbuA1tWNNa3
TH3Aa8tRR33HiBLxY2D9aqwlgH5NVsl+pWRZ7QdpcRh51Iq113YJ4HI0H82Q98WpGHlJqOklstH3
fF7uo4Xp458dnLo0yqx7Yrmj7yJ14w6tS7w0FRgEts3njujMYa4X4GbtnO2XAeyS00XaqpVXaKvw
9PEerx3omoKFaH4uQ0YZNs70Pc/Lwe33r06wvl+mfc/xuFhb9F1c+69F11FXcuo2LwbW74Vxbp0x
85FFgNFY/ugCwIk88qjZ9KJrr8IcQHYGzBvI9jmDvhTGjVmykbsOJrLkddYY2XPW0PYxD8VJ7cyR
ukEwyYuz0wj8mFCQYERjrVDjwsSg7ZcBaGd5qxLzhEljZMRrB8YNsGdAu8Ft6qOi70m336WdpO88
71u0wN5ZOdrTTNaLYQLGC14MFJYxyK1tje2klOvfScx3FpBHVdAopVAiCbZxiYxes9sLxT1Juk3/
yXn2QrfIW1HI/hFCxT/2eM9FNh2S77/keJb0hRe6W0l3Sc0HioOHPCP5SAWX2e1LSzwG4azkAv3S
mGjfm2YCPgFvCDgGgoZAS+bQUmFvEma3OR3nBnk8Liz8zbGgN+NgaMoXyf+3wcylAHtNoGubk2aF
k30pc1/kMvlQyUkB+cBv5JbissBJXihwkjn7ZU9wW+p5xDM64bvcBhf9k8MTpO/lYL8jJu97Idik
8O4IhEmDHglF7ID5SXFqKb9GZ9TMtHYbCfhxHKZaQP65x8hq+fhRu88vyg5DP50Hd8CwWmqupowX
yMJMHQA9CnBKY5YnbZNyn4xlhzXPsntHWmNlNm/E3g59ZAGlOnAs4jfH26E4PmPnPFaqpX3/7Awp
tFnfStr1IW3ppK2fDQ+ojJE0Bg12/DwUcS9o/8beFH81/i6+B98nu3wGbztpydg6v9+E+RsHA22e
yqsddM2Vk/Ozpdab9stsJrPlLCHPuX6FWs71bv4OPfnvlT/jD4Jzi0PkA0/GZf0yH3NzCu1jNi49
EPWMRDssjk0shu7NUKlvmaykNhm87991fUhb15O2XrEvEZLJ17ALEH2yHb4IMa8O8JYit7MOYvuV
0XmAfTLyqMlrr0Yt4Gq+CGLb9fZifuypvkZG7XzgaQPXXpXXXl2gtU9cU0u12X3pP7qWXn203l6+
Npv5SSOj7k1/NbCV7Wj1+NB2KGqBg4HPmGgo8GbowM3QFq5Km3VoEYA35CCQXgikFwKB9EK0Eri0
xzPHJp7eIL3aZT7YqPNI+bXKZZwcEbj2QiC9EAikFwLphUB6NRnmlW8ahWUbl15Ggt6plagqr926
PuHtSr538xf7oVV87l6TjDZmI43ah175sf4V61fWsK4Lv+Rjk75ndbs1yGjP6zjatQ29TMcqeB+H
yZWqjkZ1sGlNVo+5GlYzImump8YFJs+1fT1uryanXD9RNqApCjdN6MpB21YlO6C0pfYJPvCcVnaD
ociazfS4ER6MGZXpu7Sm2L7+Vha6XJnrb2EgwmLy+rJlSUuBIaOMthpafrfqPbEl9W8lGJqkfx9R
FjZ9Iw+98lxvAX55unPTE4XJoSStuW9TpofUDF1449sZdl24k9noUiaq5WAoff5Aoij8dAs2ff4n
UIxdXuhcYg1f+M1nu+Pn/+R7S/DloxAjddyeNk3w3I8OQzGS6dk/Dv/6yrcvPdDB+luE5O91wDdi
kY4lEQLpK8L6eoP2RTD0xvlDdzNr0Vc0snj5mQIce9zx96/uu1U7NiiDlsuL/LtVWz56HZJB9mSB
zjiMk48mf1bKAryogbXXrVEnWI1Q4xLcymxyE3DWV85yP6qFfZjpd12566wxs+esMUK2HpbAetiz
57h1J0C3aY+/SPrfDRpXEWlco3vH2Ys51y7cF7B3F7m16OvrBdumMloHh6mq35nW3l5pfoSw/WTa
KFOqkqprP3Vob3IlDSuUFIfktU5/4cZcMiDFrSbHpTJa87eXlnsvlshoU87qMlpeIPoau6kAyX1M
W+vBwt8cl5sio60J2k+TyWTXGbFFlaodriBxa+dTlz07UQPBAuCa2LIyroDthZkXyro7EZLj+tcd
jMV07FJQRkvfOa7CUfiWaX/73ZhEX7sXp6OjeB2jjb4zVKUK6mmxdf8Z2CEBSNsdUlyUxun9G6kx
WkM1rFLQkduoO2C7WlrG1bSFkH7XnWMdT1tLCcNmMZlMggcMdhYgjYEhpjuu25WHHcW1+3yoL3ZF
A97Gn0Ah+tIMY4oMxhredtIu9CqMk//Gvyy+8B9/j5I9D/DrXOwoQHThK/QzV9gC6nwfq/HBbSZz
B53ZkrLZuPR+QqH5JwafK+tuNn4w6wu5JfZogH+/BuCULWXmSC83K7cKZW6vQnW7ln3nnGt3b05y
wtrfcc3mt3OJvl625TgxveZ55FGbrL3aAOZgancj23Ni6UbIaK/KtddbUedo5DKNbO6hrwYXX0iv
tzq9mgq8GRpltK04tAjAG3IQSC8E0guBQHohWglc2uOZYxNPb5BeOB80OnDMRovA7xoC6YVAIL0Q
SC8E0qtmmA2yQVwd9KJJzdSBChLXxIrqVFv+UsXyoB62mvvWlaNbh55WuOoVhCyQknvW0WSZjBZ/
xa5t9EompzV+82aZinQFWWnP/Dcqlgf1sNXc9zR598xspWR4o8cvraPN0n2xsjgG1zg5GlbRG690
pmA1NZZPNuHlc3WiLBUsuHleEyN/yjwMpkhNaRLN00psXTEqyyRL3VNM0dqvKjxbrSIEq0LRCkFf
3o8Q0ELCZp5jUTkyxuJyfcxQvljXjytnOYYliUamjQVz1yb2/V0gRy1zFzlyUxFZjfP8timm3D0c
as9RRTZaYZeSFK0fJAlltLWuvQxfVcvzyX5PS7v3Iy6zfK59Uvpevs3zvIrcrTCbVr8H8G7ToXla
oWtKlH9TO7fIzfdNP98HsHA0N/dnwHK8xpnvQiRv8unF9eX9dMvT7p3uA9M0U+yuufwszUMGU5Dh
PtuUnPqk25bnZ+Vf9DQdeZpNqpBWd/nlXU/TXt0ctV1T1P2YyJH77pfynOpPHyft2t/v/Uyovcem
NP5O2D0Zy738YQD5HuRRLfQii6+33+9tTTIF67M8nywFT8uaO2u8g29nRZ5XjoIx/qyXp5XmhOV4
YWJQ2JwyenLEaQS0cd4Y18dKDtOigu/L+1EnjFPudGTQflQJNCoonDCgm/u8cwLGX/DbEn4S3Ojp
Dq9/nRLfmFD9ch6ZGzvd8nPk2iNg3cB2fYTEmL/uYjbU3jsMkatW2H3XsXceAnj9r5FHVRC8GZrK
RAcu5QIq0lA+WVFANaOl2VnB05iaQ3Pa3mRAtxoUplIDZ+CrX9kTNBi7aQkWmOYs7FveD3hK17E/
LlKfclFtaV5ZkeOWvpYragM5asW/sf1uGttKSXB9H2HnxPOdm2a4MNdbieFvjitko71YeqbVWSYm
9QrCOWYdpjHd2tH3Wsj6pGcyxgx6i9eF19W7F9ORO/lpZNjXb930MtSKRdBuOx2JVdDaUoSUs50m
d+8qVdSeLM1Ry3BjhxwI7oRZ0t6AG5GwkzJv0py2ZgcOUzVSVu8qvewwDNeGCpTtoJ/gk+MvYFjx
yvthB5k5iv/D8rT6n073cPoA334XnCbWt83u7At9gpptdHyHL/Z8X9rPaa9jnfWTdbyVIfUhL/eX
am0pVAde86SN3VQPPgTDckk5i70sPy4scyWvgHx6QA35ZeCMErSjOW0/AXDmfuRRbWsvOftqicGp
vBJWp8467iNICgeCeV475BxZK0Vv95LR/gVLBvuKfa3IGPx1+YPEes+mYLZaYhP9sJSZZxvR2zcH
qmZvUdzHvBmsH6tXWRRjC/WZI231ydmySx6zceleT5j9INXkdij5cyXlJbG7iP7R5kDWde2BS1bI
78fqe2eDdpt0efTj5JwFl/a1rL1qhp4vFwqumkk2UfdD4er3BHPrJSmRbO4hdHouXMFstO299lo7
vWLOcnf0YlmxnF/FT6r7MUWrNr3SN8FZCD6/phlY7muIjBbphVgdeDM0ymhbcWgRgDfkIJBeCKQX
AoH0QrQSuLTHM8cmnt4gvXA+aHTgKKNF4HcNgfRCIJBeCKQXAunVBJhXuB/zCsWD9KoOKrqNpNcs
ujWUh8rKtrRoZ0U/RtSNs0r/W9aUjfYhA2nUhNErmZyWb+fvyqqqey1Ev1BWtrdFO8v7MRffWKX/
vWvKRrtnEUe7pkyOxtxxb7w6xnK2OtGDrug2zvSzpqYc4193rnlN7Hs73SB2QpEqcr9yta0Z5bpY
XVFeSzG5rfmQHOWfXr+m0LYNmSloUwdltZ9Uf5G1Y8vv/VwKXHVt4pii2DaLR9Qn4gcO2l42Wtlw
4+T90XLRj6MdNNxstLMixrh6UGTLTmsRno3WjYX1t1s+jTxqytpL97URR6bmmfb1Pld0W5yKZojF
P6U/LGyVnKq7otvu5w/J3f5wkIS41rNIbOTcI/RjX0rP3fu+NPPfk5/hvzEsvJzbQ0wy0bxJWhzd
kz+6QKrvOzTTB9AbPfKO/cDUtbS3I+ljxiCLR9RD8ek9vW7ft7zpxanP5R65lpWLfuLKI4uunSHx
GJenPt7LA33gQmSbF0vG6+/NDyKPGk8vsvj6Q1/LdRfTod4xYZwTBTyPrPYRV4WrTcC4p8254zqY
UIKNFSaoZJXY3KIxXy3HVbzqbtC4PCg7Ap++geaRNewXAeS/7N9JHO6QQPsogHRP6pasV0dicXWx
op40+Ol9bleO7cWpSfBpfqe16Mdh+W1FjGd5jJMsry3FvcaM48Wyz+vPxmy01VD/zdBUIZHan62o
sS1T4YKvZi1V4JaobV2bsCiWsmKgQKWrIo+sULDS6pM5cPR8B9kytxah52Kp+8lcWBdLY3TjBFeZ
GxLf+iEFlLahbLQDhcLepNsfymjDKDQqG+1IsfwcP7zO7QyJbr3e6MYngxcBuNo2ZMPLPRFrz/KL
Z4HlkY1+iClYtQVeTZgiLUz/kGwZdjryoTL3UiXHJ00oV+aKfnaEc92KGF2k3eh6li9Ogtcfruyr
ostP275GDJEDHF926Cv/S/9F/zn7rS3BAufR7LcmGAm1u6RHL3ewckLwx+xDJzrgwsLlf0hPwlS2
S/1mrFgI2oh/hVOPGvwn+M75f7yf2B747wcjp5ZAfeX3LbkI0YUuvdMB9fKDf/74klsXcBf1Yov0
Qxr61TdtN85CoevwywVaLvq54fbLUbZNu+Yxuq2R/7/svO8QK+iczwRieRQCo1d2w0q2GxZ40aNU
dl1rL9mZKCmbLSjhW3ysnPIc7+O8oWRPeeNnTs4T0hzvGXwMWPbXucXLEW4TvmHKukkW2tnjm5jt
XQZT0Mb2yz2XqMZVzk5QPasyepzXRcPx8HoBnmX2+YIX5ymeg5aUi37+huW35XYkRif8dLCI9h6r
NBbSX0HCYarha6+acfjOxbbaZXPL5YbyYezGKZTRVll7NZtePR99vGu+zb7d9qEvNLK52MXg+gLp
hTLaJgJvhkYZbSsOLQLwhhwE0guB9EIgkF6IVgKX9njm2MTTG6QXzgdVsbxuN5wcEfhdQyC9EAik
FwLphUB6tQRmXVVrdTGDVXj7aaPQ4jsmak5h4Buq2apGIg/kWloLu+heOiBSHll0bclGpUBFWWnV
1fJc+xWvMKzJTd9AB2MFjW0duWxDLoFctaT8ev4uGc6jW47SqoKNo137TI4id+wY0806Ip/sv8ij
RornlLVHac5ZYLrbKNe4ijy04NuDK78dOCDbLHMtV7wq8uEU1/N6OWRJ3WFgqWUVrpCl+XD594vm
qvXKWXtxRbRLehgL5bqlGNOE9rdfk0d1mpObanmlRcxG20Zrr2J6rhfgZu2czbW1VJl6cPoHufex
crjmGWUXs9s2nzvCdbe73hB5aD17MYwkwf5pJk7z4uZZbtli+vhn3z91nObMtfIKz7zWJ09/CujD
B/JzGZ7+9mhujudEorlqvXImnn02Ldql/BV98Xgpdl2Y4W1mzPx/kuhHY0zLO5BHHrUPvXjS2MLE
oE3/h3E6yJwytHdOsnKROxaYQmKE32asGqDxj9C19+CclXJ+blmeV5aqXnMSmFyBlpsw6O+A9gyI
9Lc0Hy7XxRZeD5ZTXBe4a97ti8fLlhKGxtukeXPJpC3lUlTL+3oBedQ2S/twqtdQPlm3XCpRtgq1
a5l9qJlwbllffisUs7PbC0WeaFbkwwWeRcsvT5Qk0S2JLdiLObREZbSz25yOc4PhbFy4tG+Lpb2v
mx0JVzgsdywEFbQdvtrVs+drMTdjbFlu2UAOWZPZ/g7MxPh2T7FHpIWkuWr98goRlsTmuJcstoJM
8+b2Zaa126BU+Ytog+te3TvSZOaTNNjx83BFH8sdy8eWw8TkhAPHxtw8tML+hGG+i7NK3u4oZPbc
UZpbViVe/PkqymmgtoUZO8c5szR7i8iHS3PV+uUp7wSQc/b+sth6QeMPxij+apyuD7WU8X1yGnEG
bztpO3rNLQ6RDzHZJ9slJ/qdLHcsXWH3yp95VWhcFZsPOMI+lhmkI5y8Gaxs7BiZ4XKluWVn49ID
XFE7+0GF2s7zLLjSZqqBFXst7wuWK5tdZ5m9K891O68O8NCitw/SCSC6XxmdB9gnI4/aY+1V0+qs
ZTC3XOhbfyuzW68OGW0z1l5tR69m544NwcgvrL+RmBS8QxXpFaRX2y0bWsmuxvy4WMLQIk6JgRU2
HoLGAmW0bbG0RyC9EAikFwLphcClPWK9QBktymhxPlhuTds4OSJw7YVAeiEQSC8E0guB9GotzBZ4
rM8P0c70ciLKwR7/tvXSrK9bVsxyWwl3V/HQY3X5VclGG7ORRhuBXj1K+j74m6rVK+eIrYRfVvYw
r7fq8hMorTqv42i3EehVnDCMSw/THLFyhH9iVEk7xiSwthC3ag44mltOh5Je1bVP2Ew5S7PejjH1
q5DDJuKqbFANrBLnA8/wSakuPxiIaFzDO6CxVLmGLGkpMJTtyKMNQK/uoWMOvZ1Qn8u/xH9X2Pbj
3MwuAFvJuHlspd+CpyS3nKJryrMfmJb6iI+aUxgd0kIOC8WpWAZgl5oWd/rlf1ifH+R+E+NxXY7m
5hYAFiKOuR/gB5gudCPQ642//0BUS7McsUI/6+wGTSV88HPE/vAe+JzillOMG579eeMsIaczDhP0
8z7r3QDP8+KqE8Yk3y7srM8PJo2LvNfsDFPifr1g2ySwnUivamize+3Nob0vrpgj1tySVbMBkSwT
uXr2ruy1TGkbyotLVa/1+AWy0fYXbswlYeymAiT3hfUBFv7m2KZPyFFMMOaPV8gRe9JfOxtd8a8F
FbaulcOuJ5if4urXSpkv/by4nWZ9fjDgWvTCzAvkZffidHQUr2NskMkxO+SYvRJ55fpZOs5w/ay0
3VFdksnX9Xjlrp+wvxa207ozsENk+DsRnLXsYbg2xdd4Z+rzg0V4G5fRFo7aVMGmGcYUGQY0vO1k
I9DLui+2uXCevPIcsXRVdLNyawzg1yxH7P2DtOj/Ttzilbt+wr7rYOEuUvceJXueV0jB61t+Xlz5
F/X5wbhmn2Nv5p8YfI4u02w5TkyveR55tDHWXuvB6gJckRfX/NgLUj1+VbAhs9G2aO1Vf6r2tsOF
pRWre5a7f/Tqo/Td12ZzHfX4VcEfPPNgcIbvgLc8tMDBQGFeY2d4PASYjbYFhxYBeEMOAumFQHoh
EEgvRCuBS3s8c2zi6Q3SC+eDRu9vASdHBH7XEEgvBALphUB6IZBebwngHahIrybAOCCzhLXVNLtV
pLQIpFcNSC/elTf1/hVz4FIk8VAhvdaOzdoIaFqW62h1RfLz2iZ6DzALRxUZaVMRWYkD2JKipfDA
Ib1qgTpB/pvIc81uMX2J57V9keo2up5mFo9NHeF5iN79Uj5CptEvxHIvP4kHrgrwbtXw0orNejwn
aOJZg75QESMteJbdUJ+4b7erhuTmMbhoB261v6pyCtU5QBX0t+zBWAUsk6N71shZc0MikVj2tmA3
/Uqyc8veGL2n3FruGezHA4eTYy3IDZP/hqUQ40KSXSql5W+2dMhUxSZl3ows4IFDetWCaTsFKfvX
ACc9JW3OgdcivkUGznAp7bI0Tm83UW3jhU/ggauCq0iI1gg8cHnm/NPWQ4Q13UtDkwDkXyHecWFm
kb6jGHrqye9aXXRrYfTOb52ZBL2z84kHDvstvOWEaOX7W0QhWtOAS3tc2iNaBLxbtdEo4v4ivZoG
XGvgmSMC6YVAeiEQSC8E0guB9EIgkF4IpBcC6YVYE6wr7N9eDSC9EDh6IZBeCEQJ8H6vNlt7XQ3A
B4+34NjWSc/1ft3boAGcHBG49kIgvRAIXNojrsR5Di7tm3HuqLMXvfZlsufDXtfk6i+n9fr69pfj
es0R8Co/6mqdIr0azi5+kNnfmtnlfjC62KrdNXTCWk/fvrsFtUZglexp1U5x7dVGFzPqvyRg6Q37
XjS0Nxy9mjyQ1TOv1uFqlV5wW3vfes0R6DXvMNKrWQOSRf9aNZ85uXMjeV2rK3iedfZd1k5dEVTy
QXo1c8ITK5M1zpF1uOrr7nu9EVT2wbVXe8yN1jqntvXPy/r6V3PlPkivNmJi/T+HN+qH9Eb/II+X
VRtPleBVgtoOb+Cq01pdw52uowF9LcFXuu5VwcdCeiGa+E3DyRHRRCC9EEgvBNILgUB6IZBeiKsC
gR+FUOOCaBD0CvTCK2CIxsDCyRGBay8E0guBQHohkF6IqwvdK6/8N945Jcbe9vQqHdOKG3iPChsp
9pLkdcs4OSIQSC9Em9PLqrG2zM6y/NIr9MOTVbFza0Psjxd7tZDa+dA3Soi22uMINtpatQ33R9+A
h37tk6NliW+S982w2B9RE/zGcUur5JskzHzrlg5jbufBvXFfrLbeH94XhOJv90O/5tGr0pMILD1c
E9x2n2rhCSzDD75oOb90/295MH6s7bk/tJ9Q5+1+6OucHHVL/CkZd/WyMblsbNav6HitV+xbD7+2
1/5YJUe+PMD2PfQNfAiAHnhI1eqHS7faYiW2wrq3XfanBoVt2x767sYeB/rtWeXRBFbgIWVXnl96
KKYNuz/tGmq917109hwVvZ4rF4GTgpYdfats4rBWuWrRrvtjreeiUcsPffcad0yvPrL6NZx3YUvd
8ip5TUsnx5LegsHQdyKmtt+finG286EPPATA/3aXareLG+ln4dLfHDdS7KW/OeqrXcxq0/3Qq3wY
iPb+3GCD3UWB9NpI2HA36FSmV3EDfwSFDRz78tX2fei+Kr4kGHubAm/IQSC9EEgvBALphUB6IZBe
CMTKCF6YwCcwIZpHL3z+EgInRwTSC4FAeiGQXgikFwKB9EIgvRAIBGJ1/D/uexkr+sbwjAAAAABJ
RU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-07-15 11:51:21 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAgsAAAL/CAYAAADoXITBAABjwklEQVR42uydD2SX3f//P9xuSZLI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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-07-24 22:23:07 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.1 Cancer development</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA+AAAACACAMAAAC85fOIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-07-24 22:22:30 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.2 Oral lesion not completely resolved</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtIAAADQCAMAAAAd43a6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-07-24 22:23:14 +0200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.1 Cancer development</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAADQCAMAAACOYlZ0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-07-24 22:23:38 +0200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.2 Oral lesion not completely resolved</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtIAAACgCAMAAAAWwXt7AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-07-18 11:09:13 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-07-18 11:09:13 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-07-18 11:09:13 +0200" MODIFIED_BY="[Empty name]">MEDLINE Ovid search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-24 16:09:18 +0200" MODIFIED_BY="[Empty name]">
<P>1. exp Leukoplakia, Oral/<BR/>2. (erythroplak$ or erythroleukoplak$).ti,ab.<BR/>3. (leukoplak$ adj (oral or mucosa$ or mouth$)).ti,ab.<BR/>4. (keratosis adj (oral or mucosa$ or mouth$)).ti,ab.<BR/>5. (leukokeratosis adj (oral or mucosa$ or mouth$)).ti,ab.<BR/>6. ((precancer$ or pre-cancer$ or preneoplas$ or pre-neoplas$) adj6 (oral or mouth$ or mucosa$)).ti,ab.<BR/>7. ((white adj (spot$ or lesion$ or patch$)) and (mouth$ or oral or mucosa$)).ti,ab.<BR/>8. "oral dysplasia".ti,ab.<BR/>9. or/1-8</P>
<P>The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of <I>The Cochrane Handbook for Systematic Reviews of Interventions, </I>Version 5.1.0 [updated March 2011] (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. or/1-8<BR/>10. exp animals/ not humans.sh.<BR/>11. 9 not 10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-07-18 11:09:05 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-07-18 11:09:05 +0200" MODIFIED_BY="[Empty name]">Cochrane Oral Health's Trials Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-24 16:07:11 +0200" MODIFIED_BY="[Empty name]">
<P>(leukoplak* or erthroplak* or erythroleukoplak* or keratosis or leukokeratosis or precancer or pre-cancer or preneoplas* or pre-neoplas* or "white spot*" or "white lesion*" or "white patch*" or "oral dysplasia")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-08-13 12:39:01 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-07-24 16:07:59 +0200" MODIFIED_BY="[Empty name]">The Cochrane Central Register of Controlled Trials (CENTRAL) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-24 16:07:42 +0200" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor Leukoplakia, Oral this term only<BR/>#2 (erythroplak* in All Text or erythroleukoplak* in All Text)<BR/>#3 (oral next leukoplak* in All Text or mucosa* next leukoplak* in All Text or mouth* next leukoplak* in All Text)<BR/>#4 (oral next keratosis in All Text or muscoa* next keratosis in All Text or mouth* next keratosis in All Text)<BR/>#5 (oral next leukokeratosis in All Text or muscoa* next leukokeratosis in All Text or mouth* next leukokeratosis in All Text)<BR/>#6 ( (precancer* in All Text near/6 oral in All Text) or (pre-cancer in All Text near/6 oral in All Text) or (preneoplas* in All Text near/6 oral in All Text) or (pre-neoplas* in All Text near/6 oral in All Text) )<BR/>#7 ( (precancer* in All Text near/6 mouth* in All Text) or (pre-cancer in All Text near/6 mouth* in All Text) or (preneoplas* in All Text near/6 mouth* in All Text) or (pre-neoplas* in All Text near/6 mouth* in All Text) )<BR/>#8 ( (precancer* in All Text near/6 mucosa* in All Text) or (pre-cancer in All Text near/6 mucosa* in All Text) or (preneoplas* in All Text near/6 mucosa* in All Text) or (pre-neoplas* in All Text near/6 mucosa* in All Text) )<BR/>#9 ( ("white spot*" in All Text near/6 mouth* in All Text) or ("white lesion*" in All Text near/6 mouth* in All Text) or ("white patch*" in All Text near/6 mouth* in All Text) )<BR/>#10 ( ("white spot*" in All Text near/6 oral in All Text) or ("white lesion*" in All Text near/6 oral in All Text) or ("white patch*" in All Text near/6 oral in All Text) )<BR/>#11 ( ("white spot*" in All Text near/6 mucosa* in All Text) or ("white lesion*" in All Text near/6 mucosa* in All Text) or ("white patch*" in All Text near/6 mucosa* in All Text) )<BR/>#12 "oral dysplasia" in All Text<BR/>#13 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-07-18 11:08:46 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-07-18 11:08:46 +0200" MODIFIED_BY="[Empty name]">Embase Ovid search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-24 16:10:16 +0200" MODIFIED_BY="[Empty name]">
<P>1. Leukoplakia/<BR/>2. (erythroplak$ or erythroleukoplak$).ti,ab.<BR/>3. (leukoplak$ adj (oral or mucosa$ or mouth$)).ti,ab.<BR/>4. (keratosis adj (oral or mucosa$ or mouth$)).ti,ab.<BR/>5. (leukokeratosis adj (oral or mucosa$ or mouth$)).ti,ab.<BR/>6. ((precancer$ or pre-cancer$ or preneoplas$ or pre-neoplas$) adj6 (oral or mouth$ or mucosa$)).ti,ab.<BR/>7. ((white adj (spot$ or lesion$ or patch$)) and (mouth$ or oral or mucosa$)).ti,ab.<BR/>8. "oral dysplasia".ti,ab.<BR/>9. or/1-8</P>
<P>The above subject search was linked to the Cochrane Oral Health Group filter for identifying RCTs in EMBASE via OVID:</P>
<P>1. random$.ti,ab.<BR/>2. factorial$.ti,ab.<BR/>3. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>4. placebo$.ti,ab.<BR/>5. (doubl$ adj blind$).ti,ab.<BR/>6. (singl$ adj blind$).ti,ab.<BR/>7. assign$.ti,ab.<BR/>8. allocat$.ti,ab.<BR/>9. volunteer$.ti,ab.<BR/>10. CROSSOVER PROCEDURE.sh.<BR/>11. DOUBLE-BLIND PROCEDURE.sh.<BR/>12. RANDOMIZED CONTROLLED TRIAL.sh.<BR/>13. SINGLE BLIND PROCEDURE.sh.<BR/>14. or/1-13<BR/>15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)<BR/>16. 14 NOT 15</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-01-26 14:21:11 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2015-07-24 16:10:44 +0200" MODIFIED_BY="[Empty name]">CancerLit (PubMed) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-26 14:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>#1 Oral leukoplakia [mh:exp]<BR/>#2 oral AND leukoplak*[Title/Abstract]<BR/>#3 mucosa* AND leukoplak*[Title/Abstract]<BR/>#4 mouth* AND leukoplak*[Title/Abstract]<BR/>#5 erthroplak* or erythroleukoplak*[Title/Abstract]<BR/>#6 oral AND keratosis[Title/Abstract]<BR/>#7 mouth* AND keratosis [tiab]<BR/>#8 oral AND leukokeratosis [tiab]<BR/>#9 mucosa* AND leukokeratosis [tiab]<BR/>#10 mouth* AND leukokeratosis [tiab]<BR/>#11 precancer* AND oral [tiab]<BR/>#12 pre-cancer* AND oral [tiab]<BR/>#13 preneoplas* AND oral [tiab]<BR/>#14 pre-neoplas* AND oral [tiab]<BR/>#15 precancer* AND mouth*<BR/>#16 pre-cancer* AND mouth* [tiab]<BR/>#17 preneoplas* AND mouth* [tiab]<BR/>#18 pre-neoplas* AND mouth* [tiab]<BR/>#19 precancer* AND mucosa* [tiab]<BR/>#20 pre-cancer* AND mucosa* [tiab]<BR/>#21 preneoplas* AND mucosa* [tiab]<BR/>#22 pre-neoplas* AND mucosa* [tiab]<BR/>#23 "white spot*" AND mouth* [tiab]<BR/>#24 "white spot*" AND oral [tiab]<BR/>#25 "white spot*" AND mucosa* [tiab]<BR/>#26 "white lesion*" AND mouth* [tiab]<BR/>#27 "white lesion*" AND oral [tiab]<BR/>#28 "white lesion*" AND mucosa* [tiab]<BR/>#29 "white patch*" AND mouth* [tiab]<BR/>#30 "white patch*" AND oral [tiab]<BR/>#31 "white patch*" AND mucosa* [tiab]<BR/>#32 oral AND dysplasia [tiab]<BR/>#33 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32</P>
<P>The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.a of <I>The Cochrane Handbook for Systematic Reviews of Interventions, </I>Version 5.1.0 [updated March 2011] (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>#1 randomized controlled trial [pt]<BR/>#2 controlled clinical trial [pt]<BR/>#3 randomized [tiab]<BR/>#4 placebo [tiab]<BR/>#5 drug therapy [sh]<BR/>#6 randomly [tiab]<BR/>#7 trial [tiab]<BR/>#8 groups [tiab]<BR/>#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8<BR/>#10 animals [mh] not humans [mh]<BR/>#11 #9 NOT #10</P>
<P>[limits: Cancer]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-07-18 11:08:25 +0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2015-07-24 16:12:29 +0200" MODIFIED_BY="[Empty name]">Trials registries search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-18 11:08:25 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">metaRegister of Controlled Trials search strategy</HEADING>
<P>leukoplakia</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ClinicalTrials.gov search strategy</HEADING>
<P>"oral leukoplakia"</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">WHO International Clinical Trials Registry Platform search strategy</HEADING>
<P>"oral leukoplakia"</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_3" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="3">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;14 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;29 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;68 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2898 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3438 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;2830 records excluded following title and abstract analysis&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;30 records excluded&lt;/p&gt;&lt;p&gt;9 ongoing studies&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;13 articles excluded, with reasons; 2 awaiting classification&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>